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Abstract 
In Australia each year, more than one in four pregnant women will undergo an induction of 
labour (IOL).  PGE2 vaginal gel is the most commonly used IOL method in Australia and is 
an effective cervical priming agent, although there are no evidence-based 
recommendations regarding the optimal dosage and frequency of PGE2 vaginal gel that 
will deliver the safest, most effective, least costly and more positive healthcare 
experiences for women.    
 
The aim of this thesis was to compare two policies of PGE2 vaginal gel for induction of 
labour at term: a policy of amniotomy once technically possible (regardless of modified 
Bishop’s score (MBS)), versus a policy of giving more PGE2 vaginal gel (repeat 
administration and amniotomy only when MBS ≥ 7).  Four key objectives were addressed 
across the domains of clinical outcomes, healthcare experience and healthcare costs.  A 
randomised controlled trial was undertaken to determine which policy of PGE2 vaginal gel 
IOL results in the shorter IOL-to-birth time and is associated with lower rates of obstetric 
intervention and morbidity.  The data from this trial were then used to develop predictive 
models to help identify those women who might specifically benefit from one policy versus 
the other.  A healthcare experience tool was developed de novo, validated, and the 
experiences of women who were induced according to a policy of early amniotomy and 
repeat PGE2, were compared.  And finally, the healthcare costs of women in the two arms 
of the trial were analysed.   A decision-analytic model, specifically a Markov chain, was 
developed to further investigate costs, and a Monte Carlo simulation was performed to 
confirm the robustness of these findings. 
 
This thesis finds that in women being induced with PGE2 vaginal gel, performing an 
amniotomy (even if the cervix is deemed unfavourable) is likely to result in similar clinical 
outcomes, but a shorter labour, a more positive healthcare experience, and lower 
healthcare costs, when compared to giving more PGE2. 
 
. 
  
3 
 
Declaration by author 
This thesis is composed of my original work, and contains no material previously published 
or written by another person except where due reference has been made in the text. I 
have clearly stated the contribution by others to jointly-authored works that I have included 
in my thesis. 
 
I have clearly stated the contribution of others to my thesis as a whole, including statistical 
assistance, survey design, data analysis, significant technical procedures, professional 
editorial advice, and any other original research work used or reported in my thesis. The 
content of my thesis is the result of work I have carried out since the commencement of 
my research higher degree candidature and does not include a substantial part of work 
that has been submitted to qualify for the award of any other degree or diploma in any 
university or other tertiary institution. I have clearly stated which parts of my thesis, if any, 
have been submitted to qualify for another award. 
 
I acknowledge that an electronic copy of my thesis must be lodged with the University 
Library and, subject to the policy and procedures of The University of Queensland, the 
thesis be made available for research and study in accordance with the Copyright Act 
1968 unless a period of embargo has been approved by the Dean of the Graduate School.  
 
I acknowledge that copyright of all material contained in my thesis resides with the 
copyright holder(s) of that material. Where appropriate I have obtained copyright 
permission from the copyright holder to reproduce material in this thesis. 
 
4 
 
Publications during candidature 
 
A) Peer reviewed papers 
1. Beckmann M, Gibbons K, Kumar S, Flenady V.  Predictors of mode of birth and 
duration of labour following induction using prostaglandin vaginal gel.  ANZJOG, 2017. 
57(2): 168-75  
2. Beckmann M, Thompson R, Miller Y, Prosser S, Flenady V, Kumar S.  Measuring 
women’s experience of induction of labor using prostaglandin vaginal gel. Eur J Obset 
Gyn, 2016. 210:189-95 
3. Brown J, Beckmann M.  Induction of labour using balloon catheter and prostaglandin 
gel.  ANZJOG, 2017. 57(1):68-73 
4. Dunn L, Beckmann M, Kumar S. Maternal age is a risk factor for caesarean section 
following induction of labour.  ANZJOG, 2017. (epub) 
5. Christensen K, Janssens S, Beckmann M.  Evaluation of a standardized ward round in 
a prenatal inpatient setting.  Int J Gyn Obs, 2016. 136(3):357-361 
6. Wilson E, Beckmann M, Janssens S, Jolly B, Hewett D.  Simulation training in 
Obstetrics and Gynaecology: What’s happening on the frontline?  ANZJOG, 2016. 
56(5):496-502 
7. Wilkinson S, Donaldson E, Beckmann M, Stapleton H.  Service-wide management of 
healthy gestational weight gain following an implementation science approach. 
Maternal Child Nutr, 2016. (epub) 
8. Safa H, Beckmann M.  Comparison of maternal and neonatal outcomes from full-
dilatation cesarean deliveries using the Fetal Pillow or hand-push method.  Int J Gyn 
Obs, 2016. 135(3):281-284 
9. Whilte L, Lee N, Beckmann M.   First stage of labour management practices:  A survey 
of Australian obstetric providers.  ANZJOG, 2016. (epub) 
10. Jenkinson R, Stapleton H, Beckmann M, Reynolds M, Kruske S, Kildea S.  Women's, 
midwives' and obstetricians' experiences of a structured process to document refusal of 
recommended maternity care.  Women Birth, 2016. 29(6):531-541 
5 
 
11. Hasted T, Beckmann M, Stapleton H, Wilkinson S.  Clinician’s attitudes to the 
introduction of routine weighing in pregnancy.  J Preg, 2016. (epub) 
12. Lowe B, Beckmann M.  Involving the consultant before fetal blood sampling.  ANZJOG, 
2016. 56(4):387-90 
13. Hanlon A, Beckmann M.  Mode of birth and early postnatal psychological morbidity.  
ANZJOG, 2015. 55(6): 578-83 
14. Beckmann M, Kumar S, Flenady V, Harker E.  Prostaglandin vaginal gel induction of 
labor comparing amniotomy with repeat prostaglandin gel.  Am J Obstet Gynecol, 
2015. 213(6):e1-9 
15. Beckmann M, Cooper C, Pocock D.  INFORMed Choices: Facilitating Shared Decision-
Making in Healthcare.  ANZJOG, 2015. 55 (3): 294-7 
16. Allen J, Gibbons, K, Beckmann M, Tracy M, Stapleton H, Kildea S.  Does model of 
maternity care make a difference to birth outcomes for young women? A retrospective 
cohort study.  Int J Nurs Studies, 2015. 52(8):1332-42 
17. Beckmann M, Merrollini K, Kumar S, Flenady V.  Induction of labor using prostaglandin 
vaginal gel: cost analysis comparing early amniotomy with repeat prostaglandin gel.  
Eur J Obset Gyn, 2016. 199:  96-101 
18. Wilkinson S, McCray S, Beckmann M, McIntyre D.  Evaluation of a process of 
implementation of a gestational diabetes nutrition model of care into practice.  Nutrition 
& Dietetics, 2015. 73(4): 329-335 
19. Janssens S, Beckmann M, Bonney D.  Introducing a laparoscopic simulation training 
and credentialing program in gynaecology: an observational study.  ANZJOG, 2015. 
55(4): 374-8 
20. Jenkinson R, Kruske S, Kildea S, Stapleton H, Beckmann M, Reynolds M.  Maternity 
Care Plans: A retrospective cohort study of women who declined standard maternity 
care.  Women & Birth, 2015. 28(4):303-9 
21. Ng D, Beckmann M, McIntyre D, Wilkinson S.  Changing the Protocol for Gestational 
Diabetes Melllitus Screening.  ANZJOG, 2015. 55(5):427-33 
6 
 
21. Wilson E, Beckmann M.  Antenatal screening for Hepatitis C: universal or risk-factor-
based?  ANZJOG, 2015. 55(4):318-22. 
22. Beckmann MM, Widmer T, Bolton E.  Does preconception care work? ANZJOG, 2014. 
54(6): 510-4 
23. Manders M, McLindon L, Beckmann MM, Schulze B, Kremer JAM, Farquhar C.  Timed 
intercourse for couples trying to conceive. Cochrane Database of Systematic Reviews, 
2015, CD011345. DOI: 10.1002/14651858.CD011345. 
24. Wilkinson S, McCray S, Beckmann M, Parry A, McIntyre HD.   Barriers and enablers to 
translating gestational diabetes guidelines into practice.  Practical Diabetes, 2014. 
31(2):1-7 
25. Beckmann M and Chaplin J.  Bakri balloon during cesarean section for placenta 
previa. Int J Gyn Obs, 2014. 124(2):118-22 
26. Stock O, Beckmann M. Why group & save? Blood transfusion at low-risk elective 
caesarean section.  ANZJOG, 2014. 54(3): 279-82 
 
 
 
B) Conference presentations 
1.   Beckmann M, Harker E, Flenady V, and Kumar S. (2015). Artificial rupture of 
membranes versus repeat vaginal prostaglandin for induction of labour.  RCOG World 
Congress, Brisbane. 
2. Beckmann M, Janssens S.  (2015).  Consultant coverage in birth suite.  RCOG World 
Congress, Brisbane 
3. Beckmann M, Merollini K, Flenady V, and Kumar S. (2016). Cost analysis of induction 
of labour using prostaglandin vaginal gel.  RCOG World Congress, Birmingham 
4. Beckmann M, Gibbons K, Flenady V, and Kumar S. (2016). Predictors of clinical 
outcomes following induction of labour using prostaglandin vaginal gel.  RCOG World 
Congress, Birmingham 
7 
 
5.  Beckmann M, Miller Y, Thompson R, Prosser S, Flenady V, and Kumar S. (2016).  
Satisfaction with Induction of Labour using Prostaglandin Vaginal Gel.  World 
Congress on Controversies in Obstetrics Gynaecology and Infertility, Melbourne 
6.  Wilson E, Beckmann M, Janssens S.  (2015).  Simulation Training in Obstetrics and 
Gynaecology: What's really going on?  SimHealth, Melbourne  
 
 
 
Publications included in this thesis 
1. Beckmann M, Kumar S, Flenady V, Harker E.  Prostaglandin vaginal gel induction of 
labor comparing amniotomy with repeat prostaglandin gel.  Am J Obstet Gynecol, 
2015. 213(6):859.e1-9.   (Publication based on material presented in Chapter 4).  
Contributor Statement of contribution 
Michael Beckmann (Candidate) Designed experiment (100%) 
Data collection (50%) 
Statistical analysis (100%) 
Wrote the paper (100%) 
Edited paper (80%) 
Sailesh Kumar Edited paper (10%) 
Vicki Flenady Edited paper (10%) 
Ellen Harker Data collection (50%) 
 
2. Beckmann M, Gibbons K, Kumar S, Flenady V.  Predictors of mode of birth and 
duration of labour following induction using prostaglandin vaginal gel.  ANZJOG, 2017 
57(2): 168-75   (Publication based on material presented in Chapter 5). 
Contributor Statement of contribution 
Michael Beckmann (Candidate) Designed analysis (100%) 
Statistical analysis (90%) 
Wrote the paper (100%) 
Edited paper (70%) 
Kristen Gibbons Statistical analysis (10%) 
Edited paper (10%) 
Sailesh Kumar Edited paper (10%) 
Vicki Flenady Edited paper (10%) 
8 
 
3. Beckmann M, Thompson R, Miller Y, Prosser S, Flenady V, Kumar S.  Measuring 
women’s experience of induction of labor using prostaglandin vaginal gel.  Eur J Obset 
Gyn, 2016.  210:189-95  (Publication based on material presented in Chapter 6). 
Contributor Statement of contribution 
Michael Beckmann (Candidate) Designed questionnaire (50%) 
Designed analysis (90%) 
Statistical analysis (90%) 
Wrote the paper (100%) 
Edited paper (50%) 
Rachel Thompson Designed questionnaire (20%) 
Designed analysis (10%) 
Statistical analysis (10%) 
Edited paper (10%) 
Yvette Miller Designed questionnaire (15%) 
Edited paper (10%) 
Sam Prosser Designed questionnaire (15%) 
Edited paper (10%) 
Sailesh Kumar Edited paper (10%) 
Vicki Flenady Edited paper (10%) 
 
 
 
4. Beckmann M, Merrollini K, Kumar S, Flenady V.  Induction of labor using prostaglandin 
vaginal gel: cost analysis comparing early amniotomy with repeat prostaglandin gel.  
Eur J Obset Gyn, 2016.  199: 96-101  (Publication based on material presented in 
Chapter 7). 
Contributor Statement of contribution 
Michael Beckmann (Candidate) Designed analysis (90%) 
Statistical analysis (90%) 
Wrote the paper (100%) 
Edited paper (70%) 
Katharina Merollini Designed analysis (10%) 
Statistical analysis (10%) 
Edited paper (10%) 
Sailesh Kumar Edited paper (10%) 
Vicki Flenady Edited paper (10%) 
9 
 
Contributions by others to the thesis  
No contributions by others 
 
 
Statement of parts of the thesis submitted to qualify for the award of another degree 
None 
 
  
10 
 
Acknowledgements 
I wish to acknowledge the support provided by my supervisors, Prof Sailesh Kumar and 
Prof Vicki Flenady.  Their encouragement and advice, responsiveness, critical review, and 
clarity of direction have helped make what might have otherwise been a painful journey, a 
surprisingly enjoyable one.  I wish to recognise the support of my line manager Mr Sean 
Hubbard, my employer Mater Health, and my work colleagues who have generously 
provided me with the opportunity and the time to facilitate completion of this work.  I would 
like to specifically recognise A/Prof Kristen Gibbons, Dr Kat Merollini, Dr Yvette Miller and 
Dr Rachel Thompson whose generous sharing of time and expertise in statistics, health 
economics and patient reported outcomes, respectively, have enabled me to learn and 
grow as a researcher.  I wish to also thank the women who consented to be involved in 
this research, and the doctors and midwives in the Mater Mothers Hospitals birth suite who 
believed in and supported the undertaking of this research.  Finally, I wish to acknowledge 
and thank my family.  Thank you to Max, Tom and Ruth for allowing Dad to have lots of 
time in the study getting this done, and to my wife Linda who selflessly allowed me the 
necessary “me-time” to think, and who supported and encouraged me to complete this 
work.     
 
  
Keywords 
labor induced, cervical ripening, dinoprostone, patient satisfaction, health care costs, cost 
analysis, risk factors 
  
Australian and New Zealand Standard Research Classifications (ANZSRC) 
ANZSRC code: 111402, Obstetrics and Gynaecology 80% 
ANZSRC code: 140208, Health Economics 10% 
ANZSRC code: 170106 Health, Clinical and Counselling Psychology 10% 
 
Fields of Research (FoR) Classification 
FoR code: 1114 Paediatrics and Reproductive Medicine, 80% 
FoR code: 1402 Applied Economics, 10% 
FoR code: 1701 Psychology, 10%  
11 
 
Table of Contents 
 
List of Tables .................................................................................................................... 13 
List of Figures .................................................................................................................. 14 
Abbreviations ................................................................................................................... 15 
 
Chapter 1 Introduction .................................................................................................... 16 
 
Chapter 2 Literature review ............................................................................................. 19 
2.1 Literature review methods ................................................................................................... 19 
2.2 Clinical outcomes ................................................................................................................ 21 
2.3 Prediction of IOL success .................................................................................................... 33 
2.4 Women’s experiences of induction of labour ........................................................................ 36 
2.5 Cost ..................................................................................................................................... 38 
2.6 Chapter summary ................................................................................................................ 41 
 
Chapter 3 Methods........................................................................................................... 43 
3.1 Aims and Objectives ............................................................................................................ 43 
3.2 Hypotheses ......................................................................................................................... 45 
3.3 Study design ........................................................................................................................ 48 
3.4 Study population .................................................................................................................. 51 
3.5 Outcome measures ............................................................................................................. 51 
3.6 Measurements ..................................................................................................................... 52 
3.7 Recruitment of participants .................................................................................................. 56 
3.8 Randomisation .................................................................................................................... 57 
3.9 Study procedure .................................................................................................................. 57 
3.10 Patient safety ..................................................................................................................... 60 
3.11 Sample size ....................................................................................................................... 61 
3.12 Statistical methods ............................................................................................................ 62 
3.13 Ethical aspects .................................................................................................................. 63 
 
Chapter 4 Clinical outcomes ........................................................................................... 64 
4.1 Background ......................................................................................................................... 64 
4.2 Methods .............................................................................................................................. 66 
4.3 Results ................................................................................................................................ 68 
4.4 Conclusions ......................................................................................................................... 74 
4.5 Chapter Summary ............................................................................................................... 80 
 
Chapter 5 Prediction ........................................................................................................ 81 
5.1 Background ......................................................................................................................... 81 
5.2 Methods .............................................................................................................................. 82 
5.3 Results ................................................................................................................................ 83 
5.4 Conclusions ......................................................................................................................... 95 
5.5 Chapter Summary ............................................................................................................... 99 
 
Chapter 6 Healthcare Experience ................................................................................. 100 
6.1 Background ....................................................................................................................... 100 
6.2 Methods ............................................................................................................................ 101 
6.3 Results .............................................................................................................................. 103 
6.3.1 EXIT (Experiences of Induction Tool) validation .......................................................... 103 
6.3.2 Experiential outcomes ................................................................................................. 105 
6.4 Conclusions ....................................................................................................................... 110 
6.5 Chapter Summary ............................................................................................................. 114 
 
 
12 
 
Chapter 7 Cost ............................................................................................................... 115 
7.1 Background ..................................................................................................................... 1155 
7.2 Methods ............................................................................................................................ 116 
7.3 Results .............................................................................................................................. 124 
7.4 Conclusions ....................................................................................................................... 130 
7.5 Chapter Summary ............................................................................................................. 134 
 
Chapter 8 Conclusions .................................................................................................. 135 
8.1 The research questions ..................................................................................................... 135 
8.2 Other findings and impact of this research ......................................................................... 137 
8.3 Limitations ......................................................................................................................... 140 
8.4 Future research ................................................................................................................. 141 
8.5 Conclusion......................................................................................................................... 143 
 
 
References ..................................................................................................................... 144 
 
  
13 
 
List of Tables 
Table 2.1: MBS, P34 
Table 3.1: Risk of bias, P49 
Table 4.1 Baseline characteristics intention-to-treat and as-per-protocol, P69 
Table 4.2 Baseline characteristics: eligible women who were recruited and not recruited P70 
Table 4.3 IOL-to-birth time, P72 
Table 4.4 Clinical outcomes, P73 
Table 4.5 In-hours versus after-hour births and differences in length of hospital stay (post-hoc 
analysis), P76 
Table 5.1 Demographic and clinical characteristics of participants who did and did not experience a 
vaginal delivery with 24 hours, P84 
Table 5.2 Demographic and clinical characteristics of participants who did and did not give birth by 
caesarean section, P86 
Table 5.3 Demographic and clinical characteristics of participants who did and did not deliver in-
hours (08:00-17:00), P87 
Table 5.4 Demographic and clinical characteristics of participants who did and did not have a 
prolonged (i.ie greater than average) IOL-to-birth time, P88 
Table 5.5 Primary outcome: Multivariate analysis of factors associated with a vaginal delivery 
within 24 hours, P89 
Table 5.6 Secondary outcomes: Multivariate analyses of predictors of in-hours delivery, predictors 
of caesarean section, and predictors of the IOL-to-birth time, P90 
Table 5.7 Likelihood of vaginal delivery within 24 hours in nulliparous women, stratified by 
favourability of cervix at the initial and subsequent vaginal examination (post-hoc analysis), P96 
Table 5.8 Likelihood of caesarean section in nulliparous women, stratified by favourability of cervix 
at the initial and subsequent vaginal examination (post-hoc analysis), P96 
Table 6.1 Items of satisfaction questionnaire, P102 
Table 6.2 Final loading, communalities and alphas following principal components analysis with 
orthogonal rotation of 8 of 10 Items in questionnaire, P104 
Table 6.3 Baseline characteristics of women who did and did not respond to questionnaire, P106 
Table 6.4 Responses across three sub-scales of the questionnaire, stratified by PGE2 vaginal gel 
policy, P107 
 
Table 6.5 Responses to questionnaire items, stratified by PGE2 vaginal gel policy, P109 
Table 7.1 Itemised costs for women undergoing IOL (2015 $AUD) P117 
Table 7.2 Transition probabilities (95% CI) – repeat-PGE2 group, P122 
Table 7.3 Transition probabilities (95% CI) – amniotomy group, P123 
Table 7.4 Total healthcare costs for trial participants, stratified by PGE2 vaginal gel policy, P124 
Table 7.5 Results of Markov trace for amniotomy group: cohort simulation of 1000, P125 
Table 7.6 Results of Markov trace for repeat-PGE2 group: cohort simulation of 1000, P126 
14 
 
Table 7.7 Mean and median costs associated with each Markov State, P127 
Table 7.8 Costs of policy of early amniotomy and policy of repeat-PGE2 dosing: cohort simulation 
of 1000, P127 
Table 7.9 Mean and median costs, and cost differences comparing amniotomy and repeat-PGE2 
groups: 104 Markov chain Monte Carlo Simulation, P129 
 
Table 7.10 Sensitivity analyses of median costs based on 104 Markov chain Monte Carlo 
Simulation, P129 
 
 
 
 
 
 
List of Figures 
 
Figure 3.1: Maternal satisfaction tool, P54 
Figure 3.2: Trial protocol, P59 
Figure 4.1 CONSORT diagram, P66 
Figure 4.2 Patient IOL journey, P71 
Figure 5.1 AUROC of model predicting a vaginal delivery within 24 hours: sub-group analyses by 
parity, ethnicity, indication, gestation, and MBS, P91 
Figure 5.2 Prediction of vaginal delivery with 24 hours using regression equation (varying the parity 
and MBS at 1st review), P93 
Figure 5.3 Prediction of birth of by caesarean section using regression equation (varying parity and 
MBS at 1st review), P94 
Figure 5.4 Prediction of an in-hours delivery using regression equation (varying parity and MBS at 
1st review), P94 
Figure 5.5 Prediction of time (hours) from commencement of IOL to birth using regression equation 
(varying parity and MBS at 1st review), P94 
Figure 7.1: Markov chain – PGE2 vaginal gel IOL, P119 
Figure 7.2: Markov states defined, P120 
Figure 7.3 Box plot of costs of amniotomy once technically possible, and repeat-PGE2 policies: 
104 Markov chain Monte Carlo Simulation, P128 
Figure 7.4 Cumulative histogram of costs of amniotomy once technically possible, and repeat-
PGE2 policies: 104 Markov chain Monte Carlo Simulation, P129 
15 
 
Abbreviations 
 
ACOG American Congress of Obstetricians and Gynecologists 
ARM Artificial rupture of membranes 
BMI Body mass index 
CS Caesarean section 
CTG Cardiotocograph 
EASI Extra-amniotic saline infusion 
FHR Fetal heart rate 
IOL Induction of labour 
mg Milligrams  
ml Millilitres 
MBS Modified Bishop’s score 
NICE National Institute of Clinical Excellence 
PG Prostaglandin 
PGE2 Prostaglandin E2 (dinoprostone) 
RANZCOG Royal Australian and New Zealand College of Obstetricians and Gynaecologists 
RCOG Royal College of Obstetricians and Gynaecologists 
RCT Randomised controlled trial 
SCN/ICN Special care nursery / intensive care nursery 
VD < 24h Vaginal delivery within 24 hours 
WHO World Health Organisation 
  
16 
 
Chapter 1 Introduction  
1.1 Background 
Australia has a high rate of obstetric intervention and this rate is rising. Although there has 
been much commentary of the rising caesarean section (CS) rate, more women undergo 
the intervention of induction of labour (IOL) (26.3%) than give birth by elective CS (19.4%).  
In Australia in 2013, more than one in four labours were induced [1].   
Generally, IOL is indicated when the benefits of delivery for mother and baby outweigh the 
risks of continuing the pregnancy.  However, the clinical decision to undertake IOL 
represents one of the most complex decisions for healthcare providers and women.  
Common indications for labour induction include pre-labour rupture of membranes, fetal 
growth restriction, fetal anomalies and maternal medical conditions, where IOL has 
demonstrable clinical benefits.    In such high-risk pregnancies, this balance between risk 
and benefit often favours IOL, and at an earlier gestation.    However, the appropriate time 
to deliver lower-risk pregnancies, and even the question as to whether induction is 
indicated at all, is subject to much debate.   
One of the commonest indications for IOL amongst women with otherwise low-risk 
pregnancies is because the pregnancy is post-term, recognizing the higher perinatal 
morbidity and mortality associated with  pregnancies that continue beyond term [2].  At 
face-value, IOL would seem an appropriate intervention, but the absolute risk of perinatal 
mortality in a post-term pregnancy is low, and at least 400 women need to be induced at 
41 weeks to prevent one perinatal death [3].  Even less clear, is the appropriateness of 
undergoing IOL solely for social / elective reasons (including maternal discomfort, 
convenience for women or healthcare provider) where emerging data showing a reduction 
in perinatal mortality is challenging long-held views that social IOLs is associated with 
unnecessary medical intervention [4].  An increasingly common event, IOL for “other-than-
defined” reasons, constituted almost one third of all IOLs in Australia in 2010 [5].       
Notwithstanding the need to carefully consider and appraise the evidence-base under-
pinning the rationale for certain indications for IOL, there will remain large numbers of 
women who will undergo this intervention.  Although IOL using prostaglandin vaginal gel 
(PGE2) is the most commonly used method to commence an IOL, there are many different 
methods available for labour induction, and there are many protocols for each of these 
methods of IOL.  There are unanswered questions regarding these protocols of IOL in 
17 
 
terms of efficacy, clinical outcomes, costs related to these outcomes and hospital stay, and 
the healthcare experience of women and families undergoing this intervention.  
Considering that over 80,000 Australian women will be induced this year, it is important to 
identify clinically appropriate, efficacious, cost-effective and safe methods of IOL, that are 
acceptable to women.   
 
1.2 Aims, objectives and hypothesis 
This research project investigates two different policies of IOL using PGE2 vaginal gel.  
The aim was to explore the clinical outcomes, the healthcare experience, and the 
healthcare costs associated with two common approaches to PGE2 vaginal gel IOL.   
 
The main objectives were to investigate how best to undertake IOL using PGE2 vaginal 
gel.  The outcomes for women undergoing PGE2 vaginal gel IOL, following a policy of 
amniotomy once technically possible (regardless of MBS), or a policy of giving more PGE2 
vaginal gel (repeat administration and amniotomy only when MBS ≥7) were compared in 
order to: 
 
 
a) Determine which policy of PGE2 vaginal gel IOL results in the shorter IOL-to-birth 
time and is associated with lower rates of obstetric intervention and morbidity; and   
 
b) Determine the clinical characteristics of women who might experience the 
shortest labours and lowest rates of caesarean section with each policy of PGE2 
vaginal gel IOL; and 
 
c) Determine which policy of PGE2 vaginal gel IOL is associated with the more 
positive healthcare experience for women; and 
 
d) Determine which policy of PGE2 vaginal gel IOL is associated with lower 
healthcare costs 
 
 
The following four hypotheses for women undergoing IOL using PGE2 vaginal gel were 
tested: 
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• A policy of amniotomy once technically possible compared with a policy of giving 
more PGE2 vaginal gel will result in a reduction in the IOL-to-birth time, and a 
greater number of “in hours” births 
• Parity, age, BMI, MBS, and gestation are predictive of IOL-to-birth-time, likelihood 
of “in-hours birth”, and mode of birth   
• A policy of amniotomy once technically possible compared with a policy of giving 
more PGE2 vaginal gel will result in a more positive healthcare experience for 
women  
• A policy of amniotomy once technically possible compared with a policy of giving 
more PGE2 vaginal gel will result in less overall healthcare-associated costs 
 
In addition, the thesis will address the following secondary aims 
• To explore if a policy of amniotomy once technically possible compared with a 
policy of giving more PGE2 vaginal gel is associated with differences in the rate of 
obstetric intervention (operative delivery, epidural), or adverse maternal / perinatal 
outcomes (including estimated blood loss > 500ml, use of antibiotics in labour, 
admission to nursery, uterine hyperstimulation). 
• To define the indications for adopting a policy of amniotomy once technically 
possible versus a policy of giving more PGE2 vaginal gel, by identifying the clinical 
characteristics (parity, age, BMI, MBS, and gestation) that predict superior IOL 
outcomes (shorter IOL-to-birth-time, an “in-hours birth”, and vaginal birth) with each 
policy.  
 
I begin with a literature review chapter exploring the evidence around IOL, different 
methods of IOL, and different protocols of PGE2 vaginal gel IOL.   In the following 
chapters, I present findings of a RCT (and sub-studies) on clinical outcomes, predictors of 
IOL success, healthcare costs, and healthcare experience associated with different 
protocols of PGE2 vaginal gel.   
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Chapter 2 Literature review 
 
 
This chapter will focus on the methods of IOL and specifically the most commonly used 
method of induction of labour in Australia - cervical priming using prostaglandin E2 (PGE2) 
vaginal gel.  In understanding more about the clinical outcomes, predictors of IOL success, 
costs, and healthcare experience for women undergoing different protocols of PGE2 
vaginal gel IOL, it is necessary to first explore what is known more generally about IOL 
when compared to spontaneous labour or expectant management.  Next, the data 
comparing the many different methods of IOL will be outlined, before describing the 
current gaps in knowledge around the different PGE2 vaginal gel methods.   
 
2.1 Literature review methods 
Objectives 
1. To assess the effect of IOL on maternal and perinatal outcomes 
2. To explore and compare the different methods of IOL, and specifically different 
protocols of PGE2 vaginal gel IOL, and their effect on maternal and perinatal 
outcomes, the healthcare experience for women, and healthcare costs 
3. To identify the predictors of IOL success 
 
Types of studies 
All clinical trials (including randomised and quasi-randomised trials and cohort studies), 
evaluating any described method of IOL were considered for inclusion in the literature 
review. 
 
Types of participants 
All pregnant women undergoing IOL  
 
Types of interventions 
Any described method of IOL (mechanical, pharmacological, other methods), and any 
described protocol of administration of PGE2 vaginal gel IOL. 
 
Types of measures 
(a) Clinical outcomes 
(b) Healthcare experience 
(c) Cost 
(d) Predictors of clinical outcomes, healthcare experience, cost 
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Search methods for identification of studies 
a) PubMed (1966 to October 2016) 
b) CENTRAL (Cochrane Central Register of Controlled Trials) from inception to October 
2016 
c) Google Scholar (for recent trials not yet indexed in MEDLINE) 
d) Hand search of reference lists of articles retrieved by the search   
 
Search strategy 
1. Labor, Induced (MeSH) 
2. Induc* 
3. Labor, Obstetric (MeSH) 
4. Oxytocin (MeSH) 
5. Synto* 
6. dinoprostone (MeSH) 
7. Dinoprost* 
8. PGE2 
9. Patient Satisfaction (MeSH) 
10. Satisfaction 
11. Health Care Costs (MeSH) 
12. Cost-Benefit Analysis (MeSH) 
13. Markov 
14. Cost-effectiveness 
15. Caesarean section (MeSH) 
16. Vacuum Extraction, Obstetric (MeSH) 
17. Obstetric Forceps (MeSH) 
18. Postpartum Hemorrhage (MeSH) 
 
19. Endometritis (MeSH) 
20. Meconium (MeSH) 
21. Apgar Score (MeSH) 
22. Intensive Care, Neonatal (MeSH) 
23. Clinical Trial (MeSH) 
24. Cohort Studies (MeSH) 
25. Predictive Value of Tests (MeSH) 
26. After Hours Care (MeSH) 
27. (#1 or #2) AND (#9 or #10 or #11 or 
#12 or #13 or #14 or #15 or #16 or #17 or 
#18 or #19 or #20 or #21 or #26) 
28. (#6 or #7 or #8) AND (#9 or #10 or 
#11 or #12 or #13 or #14 or #15 or #16 or 
#17 or #18 or #19 or #20 or #21 or #26) 
29. (#1 or #2) AND (#23 or #24 or #25) 
30. (#6 or #7 or #8) AND (#23 or #24 or 
#25) 
31 (#1 AND #3) AND (#23 or #24 or #25) 
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2.2 Clinical outcomes 
 
2.2.1 IOL versus spontaneous labour / expectant management 
Induction of labour is an obstetric intervention, recommended by clinicians when it is 
perceived that the benefits of intervening outweigh the risks of continuing the pregnancy, 
and where the risks of the intervention are perceived to be low.  In counselling women 
regarding IOL, possible maternal, fetal, and neonatal risks and benefits should be 
included. The data used to inform these discussions are often flawed, derived from 
observational studies of IOL where the pregnancy complication that was the indication for 
IOL is a significant confounder in demonstrating an association between IOL and maternal 
/ perinatal outcomes.  Furthermore, most of the observational studies that evaluate these 
risks and benefits compare IOL to spontaneous labour [6].  Comparing outcomes of 
women being induced to those in spontaneous labour, does not assist clinicians (and 
women) in making the clinical decision to undergo IOL or not.  In weighing up the risks and 
benefits of IOL, spontaneous labour on the same day as the planned IOL is not an option 
that the woman is able to choose, as spontaneous labour is labour that starts on its own 
and not at a prescribed time.  The alternative option to IOL is expectant management, 
which means the pregnancy continues until the spontaneous onset of labour occurs.      
 
 
2.2.1.1 IOL and the risk of caesarean section 
Examining the mode of birth outcomes following IOL, helps to illustrate this point.  In 
earlier observational studies, investigators reported that term IOL (using a variety of 
induction methods) compared with spontaneous labour is associated with a doubling of the 
risk of CS [7-10].  But when cervical favourability is also considered by controlling for the 
Bishop’s score at the start of labour / IOL, the mode of birth does not seem to be different 
between women undergoing IOL and those in spontaneous labour [11-14].  When studies 
compare IOL with expectant management rather than women in spontaneous labour, it is 
apparent that IOL may indeed be associated with a decreased risk of CS.  In a 
retrospective study of over 100,000 births across 10 United States maternity services, the 
CS rate was the lowest in spontaneous labour group at each gestational age until 39 
weeks.  After 39 weeks, the CS rate was observed to be lower in the IOL group [15]. In 
similar large analyses using population datasets, Darney [16], Stock [4] and Gibson [17] 
compared non-medically indicated IOL after 37 weeks, to expectant management for 
women who delivered in the next week or beyond, and reported that the CS rate was not 
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increased either.  In randomised controlled trials [14, 18-20], IOL is not associated with 
birth by CS when compared to expectant management.  In both the Hannah randomized 
controlled trial (low-risk post-term women) [18], and the more recent Hypitat RCT (women 
with gestational hypertension and pre-eclampsia) [19], IOL is associated with a lower risk 
of birth by CS when compared to those expectantly managed, and this is true in both 
nulliparous and multiparous women [21], and for those with more and less favourable 
cervixes [22].  Furthermore, systematic reviews of randomised controlled trials are 
consistent in their findings, that women undergoing IOL are less likely to give birth by CS 
than women managed expectantly (6588 post-term women in 16 trials [23]; 6248 women 
in 31 trials [24]; 6617 in 13 trials [25]; 31885 in 157 trials [26]).     
 
2.2.1.2 IOL and the risk of instrumental birth  
Randomised controlled trials [14, 18, 27] do not show a statistical difference in the rate of 
operative vaginal delivery, when comparing women being induced to those being 
expectantly managed.   
 
2.2.1.3 IOL and maternal infection 
In a large retrospective cohort study, the rate of endometritis is statistically higher in 
spontaneous labour when compared with IOL after 38 weeks [15].  But in randomised 
controlled trials [14, 18] IOL was not associated with any greater or lesser risk of maternal 
infection than expectant management.  
 
2.2.1.4 IOL and maternal blood loss 
Al-Zirqi [28] reported on the incidence of severe postpartum haemorrhage in a study 
analysing more than 300,000 births in Norway’s Birth Registry. IOL carries a significantly 
higher risk of severe postpartum haemorrhage compared with spontaneous labour, with 
emergency CS after IOL having the highest risk.   This finding however has not been 
replicated in randomised controlled trials [27, 29]. 
 
2.2.1.5 IOL and meconium stained liquor 
In meta-analyses of randomised controlled trials [3, 6] meconium-stained amniotic fluid is 
observed more frequently in nulliparous women undergoing expectant management.  IOL 
at or beyond term is associated with a halving of the risk of meconium aspiration syndrome 
when compared to expectant management (RR 0.50, 95% CI 0.34-0.73).   
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2.2.1.6 IOL and low Apgar scores 
Low (<7) 5-minute Apgar score, is no different between women undergoing expectant 
management and IOL in two meta-analyses of the RCTs that have assessed this outcome 
[3, 6]. 
 
2.2.1.7 IOL and admission to NICU 
Similarly admission to NICU is no different between women undergoing expectant 
management and IOL in the same meta-analyses [3, 6]. 
 
2.2.1.8 IOL and likelihood of “in-hours” birth 
Only four IOL RCTs [30-33], have reported the outcome of time of birth.  Two of these 
trials [30, 31] appraised IOL protocols that commenced in the morning versus the evening.  
Overall, the likelihood of an in-hours birth was similar regardless of when the IOL 
commenced, however nulliparous women receiving evening PGE2 were less likely to give 
birth overnight than those commencing IOL in the morning.  The third trial [32] randomised 
women to an IOL protocol designed to maximise the likelihood of in-hours birth, or to 
spontaneous labour.  Significantly more women randomised to the IOL protocol 
experienced an in-hours birth (80.3% versus 29.6%), and there were no differences in 
mode of birth or other maternal / perinatal outcomes.  The fourth trial [33] was a post-hoc 
analysis of data from an RCT of IOL using controlled release PGE2 and PGE1 tapes.   In 
order to maximise the likelihood of an in-hours birth, the authors calculated that active 
labour needed to commence by 08:30, and hence the optimal start time for IOL needed to 
be 19:00 (nulliparas) or 23:00 (multiparas).  
 
An “in-hours” birth represents a desired outcome following IOL in terms of safety, 
efficiency, and satisfaction.  In terms of safety, “in-hours” reflects a time when there is 
more senior staffing and direct Consultant presence in most birth suites [34].  The majority 
of maternity services are able to meet the RCOG minimum standard of 40-hours of 
obstetrician presence in birth suite [35] through in-hours specialist coverage only.   
Numerous authors have reported the association between evening / night-time births and 
the risk of adverse perinatal outcomes [36-42].  It is therefore plausible that safer 
outcomes would be expected if these sometimes complex operative births were to happen 
during the day when more experienced clinicians are able to provide care and/or supervise 
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more junior clinicians.   In terms of efficiency, “in-hours” represents a time of peak 
numbers of clinical staff, and a time when the system is most able to accommodate 
additional scheduled activity.  IOL protocols that result in more after-hours birth, at a time 
when there are less resources, are likely to have a negative impact on the timely delivery 
of care to all patients in the system at that time.  And in terms of the healthcare 
experience, satisfaction with an “in-hours” as opposed to “out-of-hours” birth has not 
previously been measured.  However some data [43] does suggest women undergoing 
IOL dislike a lack of sleep.  Hence a quicker IOL that results in an in-hours birth could be 
assumed to generate higher satisfaction with the healthcare experience than a birth in the 
middle of the night.  
 
In summary, randomised controlled trials that have compared clinical outcomes of 
women undergoing IOL to women managed expectantly, have reported no 
difference in instrumental birth, maternal infection, blood loss, low Apgar scores or 
admission to NICU.  IOL is associated with a reduced incidence of meconium 
stained liquor and meconium aspiration syndrome and birth by CS.  Indeed, whilst 
there has been much focus recently on reducing obstetric intervention and 
especially operative birth, IOL appears to be the only strategy that has been 
consistently shown in clinical trials to reduce the risk of CS.  The outcome of an “in-
hours” birth following IOL may be desired in terms of safety, efficiency and 
maternal satisfaction; however few trials have reported this outcome.   
 
 
2.2.2 Methods of IOL  
A wide variety of IOL methods are available, and there is much variation in practice 
between practitioners both within and between hospitals, and across different cities and 
countries, and there is little consensus on the best method [44, 45].  These methods may 
be divided into mechanical, pharmacological and other methods of induction of labour.  
Most methods aim to “ripen” (to soften, thin and dilate) the unfavourable cervix.  In ripening 
the cervix some agents may induce labour.  Indeed, it is often difficult to clinically 
differentiate ripening from induction.   This literature review will concentrate on describing 
those methods which primarily aim to ripen the cervix, and the evidence supporting their 
use.  
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2.2.2.1 Mechanical Methods 
Mechanical methods include hygroscopic dilators, osmotic dilators (eg laminaria), the 
Foley catheter, double–balloon catheter and extra-amniotic saline infusion (EASI). Various 
studies have shown mechanical methods to be safe and efficacious. When compared with 
IOL using oxytocin alone, all mechanical methods (with the exception of EASI) have been 
associated with a reduction in CS rate (RR 0.62, 95% CI 0.42-0.90) [45].  In Australia, 
hygroscopic and osmotic dilators and EASI for IOL are not used.  There is variation in 
clinical practice guideline recommendations regarding balloon catheter IOL. For example, 
the World Health Organisation (WHO) recommends balloon catheters for IOL [46] whereas 
the National Institute for Clinical Excellence (NICE)  in the United Kingdom takes the 
opposite view that balloon methods should not be routinely used [47].  At present, there is 
no published RANZCOG position.  In Australia, balloon methods are also less commonly 
used than PG, with some centres using balloon methods routinely, and others reserving 
balloon catheter IOL for certain indications for cervical ripening such as small for 
gestational age, fetal growth restriction, vaginal birth after caesarean section (VBAC) and 
grand multiparty.   
 
Balloon catheters encourage cervical ripening by applying pressure on the internal os, 
stretching the lower segment and indirectly increasing local prostaglandin (PG) production 
[44].  Foley catheter IOL was first described in 1967 by Embrey and Mollison [48].  Since 
then, other authors have reported numerous protocols for balloon catheter IOL using 14F 
to 26F Foley catheters with inflation volumes of 30 to 80 mL, single or double-balloon 
catheters and more recently, catheters with stylets.  Insertion typically comprises a 
speculum examination and insertion of the un-inflated catheter using forceps.  The 
catheter is passed through the cervix, inflated, pulled firmly against the cervix and taped to 
the inner thigh.  In general, the catheter remains in situ for 12-24 hours.      
 
All these balloon methods have been shown to be safe, with higher balloon volumes more 
efficacious in most studies [49, 50].   Only one randomised controlled study [51] has 
compared balloon catheter IOL with no treatment but did not report either IOL-to-birth time 
or change in the Bishop’s score after 12 hours.  However, more than 20 RCTs have 
compared balloon catheter with prostaglandins (PG) [45]. These RCTs have shown that 
balloon catheters have the advantages of lower cost, simplicity, reversibility, stability at 
room temperature, reduced risk of uterine hyper-contractility with or without fetal heart rate 
(FHR) changes, and appropriateness in an outpatient setting [52].  In two of the largest 
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RCTs comparing  balloon catheter IOL versus dinoprostone (PGE2) vaginal gel [53, 54], 
balloon catheter IOL was associated with less uterine hyperstimulation, but there were no 
differences in mode of birth or neonatal outcomes.  In a single small RCT comparing 
outpatient Foley catheter with inpatient PGE2 vaginal gel [55], there were similarly no 
differences in mode of birth or neonatal outcomes.  In meta-analyses [45, 56], balloon 
catheter methods compared to PG similarly showed no difference in mode of delivery, 
proportion of women with an unfavourable Bishop score after 12-24 hours, IOL-to-birth 
time, proportion of women who deliver before 12 or 24 hours, maternal fever, use of 
epidural analgesia, neonatal Apgar score of less than 5 at 7 minutes, or admission to 
neonatal intensive care unit.  PG methods appeared more likely to cause uterine 
hyperstimulation with fetal heart rate changes (RR 6.25, 95% CI 2.56-16.67)  [45, 56] 
whilst balloon catheters could result in rupture of membranes, vaginal bleeding (in women 
with a low-lying placenta [52]), febrile morbidity (when used in combination with EASI  [57]) 
or displacement of the presenting part (if the fetal head is unengaged [58]).  
 
More recently, a double balloon catheter device has been available to assist in ripening an 
unfavourable cervix. The double-balloon catheter may have the additional benefit by 
applying pressure simultaneously on the internal and external os of the unfavourable 
cervix.   Compared to single balloon catheters, double balloon catheter IOL is, however, 
associated with a similar IOL-to-birth time, and similar mode of birth outcomes [53, 59]. 
 
 
2.2.2.2. Pharmacological Agents 
Pharmacologic methods of IOL include the use of PGE2, PGE1, oxytocin, and isosorbide 
mononitrate.  There are 2 PG available for cervical ripening, both of which imitate normal 
physiological cervical ripening and increase myometrial sensitivity to oxytocin.     PGE2 
(dinoprostone) is available in Australia as a vaginal gel containing 0.5 mg dinoprostone 
and a vaginal tape that contains 10 mg of dinoprostone, which releases 0.3 mg/h.  
Overseas, PGE2 is also available as a sustained release pessary and intracervical tablet.  
PGE1 (Misoprostol) has also been used for cervical ripening, administered vaginally, orally 
or sublingually.    In Australia, Misoprostol is rarely used for IOL in the setting of a live fetus 
at term and still is only licensed by the Therapeutic Goods Administration (TGA) for the 
treatment of peptic ulcer disease.  As per product recommendations in Australia [60], 
PGE2 is only used in the setting of intact membranes.  Oxytocin is only used as an 
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induction/augmentation agent in the setting of ruptured membranes, and not as an agent 
to ripen the cervix.   
 
PGE2 vaginal gel is inserted into the posterior vaginal fornix, and the women asked to lie 
down for about 30 minutes.  A second or third dose may be administered at intervals of at 
least 6 hours.   Adverse reactions are uncommon and include vomiting, nausea, and 
diarrhoea, uterine hyper-stimulation, fetal distress, maternal hypertension, bronchospasm, 
backache, rash, and very rarely amniotic fluid embolism [60]. 
 
PGE2 vaginal gel is an effective cervical priming agent and the commonest method used 
in Australia [61].  In a 2014 meta-analysis [62], PGE2 vaginal gel compared to placebo 
was less  likely to result in an unfavourable / unchanged cervix after 12-24 hours (RR 0.41, 
95% CI 0.27-0.65).  Compared to placebo, the time to onset of labour and median IOL-to-
birth time were shortened, and women were less likely to remain undelivered within 24 
hours of the first dosing (RR 0.32, 95% CI 0.02-4.83).  PGE2 vaginal gel was however 
more likely than placebo to cause uterine hyperstimulation with fetal heart rate changes 
(RR 3.16, 95% CI 1.67-5.98), but less likely to be associated with meconium stained liquor 
(RR 0.82, 95% CI 0.68-0.98), with no difference in NICU admissions or Apgar scores, and 
no difference in the likelihood of birth by CS.  Within subgroups of the meta-analysis, 
similar results were observed in nulliparous women and multiparous women, and those 
with and without a favourable cervix.     
 
PGE2 controlled-release vaginal tape, compared to other PG methods, is not associated 
with any difference in the likelihood of delivery within 24 hours, or birth by CS, but it may 
be associated with a reduction in instrumental births (RR 0.47, 95% CI 0.47-0.68) [62].  
Whilst Hughes [63] study of sustained release pessaries reported that there were no 
differences in the rates of uterine hyperstimulation, the meta-analysis [62] raised concerns 
regarding increased rates of hyperstimulation with fetal heart rate (FHR) changes when 
compared to PGE2 gel (RR 6.25, 95% CI 1.15-33.33).  Intracervical PG administration is a 
less frequently used method of cervical priming.  In a meta-analysis comparing to PGE2 
intravaginal gel, fewer women receiving intracervical PGE2 achieved a vaginal birth within 
24 hours (RR 0.79, 95% CI 0.71-0.89), however there were no differences in mode of birth 
or rates of uterine hyperstimulation [64].  Intravaginal PGE2 tablets are also infrequently 
used.  In a meta-analysis comparing the use of intravaginal tablets with intravaginal gel, 
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tablet use was associated with similar clinical outcomes, with no differences in IOL-to-birth 
time, birth within 24 hours, mode of birth or uterine hyperstimulation [62].     
 
 
2.2.2.3 Other methods of IOL 
Other methods of IOL include acupuncture [65], castor oil [66], corticosteroids [67], 
homeopathy [68], oestrogens [69], relaxin [70], sexual intercourse [71] and breast 
stimulation [72].  Efficacy, as measured by vaginal delivery within 24 hours, was not 
reported in meta-analyses of IOL trials involving any of these methods.  
 
Membrane sweeping involves introducing a finger through the os to strip membranes from 
the internal os and lower segment, inducing phospholipase A2 and prostaglandin F2-a- 
release [73].  In a 2005 meta-analysis of 22 trials [74] routine membrane sweeping 
significantly reduced the need for “formal” induction of labour (RR 0.60, 95% CI 0.51-0.71), 
reduced the length of gestation (WMD -2.48 days, 95% CI -3.00,-1.97), and reduced the 
incidence of pregnancies beyond 41 weeks (RR 0.59, 95% CI 0.46-0.74), with no 
difference in mode of birth.   It has been mainly studied in women at term gestation to 
reduce the likelihood of post-term pregnancy, and is not considered an appropriate IOL 
method when the need for delivery is considered more “urgent”.    
 
Amniotomy as a method of IOL is usually indicated where the cervix is already favourable. 
In a 2007 meta-analysis [75] just two trials were eligible for inclusion, and the authors 
concluded that there is insufficient data to adequately determine the efficacy and safety of 
amniotomy alone for labour induction.   
 
 
In summary, there are many mechanical, pharmacological and other methods of 
induction of labour.  Of these, PGE2 vaginal gel is the most commonly used and is 
an effective cervical priming agent.  Balloon catheter induction is also effective and 
the commonest of the mechanical methods of cervical priming used.  PG appears 
more likely to cause uterine hyperstimulation with fetal heart rate changes whilst 
balloon catheters can result in rupture of membranes, vaginal bleeding if used in 
the setting of a low-lying placenta, and displacement of the presenting part, if 
inserted when the fetal head is unengaged.   
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2.2.3 Outcomes following different PGE2 vaginal gel protocols  
There is considerable variation in PGE2 vaginal gel induction regimens, in the number of 
applications of each medication used, the dosages used and time intervals between 
doses.  There is however surprisingly little information to guide clinicians.    
 
2.2.3.1 Low-dose versus high-dose PGE2 vaginal gel protocols 
The published papers that address different PGE2 vaginal gel regimens include 
comparisons of low-dose PGE2 protocol with high-dose protocols.  Whilst definitions vary, 
low dose protocols typically comprise up to a total maximum dose of 3mg PGE2 vaginal 
gel, whereas higher dose protocols comprise total doses of more than 3mg.  In a meta-
analysis of 8 RCTs [62], low-dose compared to high-dose protocols appear to be 
associated with lower risk of uterine hyperstimulation with FHR changes (RR 0.15, 95% CI 
0.02-1.13), and a trend toward lower NICU admissions (RR 0.51, 95% CI 0.24-1.09).  
However, only one of the 8 included trials compared a low dose PGE2 vaginal gel policy 
with a high-dose PGE2 vaginal gel policy, with the other 7 comparing different doses (low-
dose versus high-dose) but by different methods of administration (vaginal gel versus 
controlled-release pessary, or vaginal gel versus intracervical tablet).  It is therefore not 
possible to conclude if the observed differences in outcomes between low-dose and high-
dose protocols are related to the dose or the method of administration.   
 
2.2.3.2. Morning versus evening commencement of PGE2 vaginal gel IOL 
Two trials [30, 31] have assessed PGE2 vaginal gel administration time in women 
receiving PGE2 vaginal gel after 37 weeks, and having a Bishops score less than 5 or 6.  
Comparing morning administration (approximately 8:00am) to evening administration 
(between 8:00-10:00pm), these trials report no difference in perinatal mortality, admission 
to NICU or any of the pre-specified secondary neonatal outcomes.  Morning administration 
was no more or less likely to result in birth by CS, but the risk of an instrumental vaginal 
delivery in nulliparous women was higher in one trial (RR 4.2, 95% CI 1.4-13) [31].  
Overall, the likelihood of an in-hours birth was similar regardless of when the IOL 
commenced, however nulliparous women receiving evening PG were less likely to give 
birth overnight than those commencing IOL in the morning.  Duration of labour was not 
reported in either trial.    
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2.2.3.3 Inpatient versus outpatient PGE2 vaginal gel protocols 
Two randomised controlled trials [76, 77] have compared PGE2 vaginal gel administered 
either as an inpatient or outpatient. One trial [76] reported that fewer than half of the 
women randomised to outpatient care went home and remained home overnight.  Neither 
trial reported differences in mode of birth or any measures of neonatal morbidity, but were 
not adequately powered to make any conclusions about safety.  Of note, the dinoprostone 
product information [60] directs that “dinoprostone should only be used .... in obstetric units 
with facilities for fetal and maternal monitoring and operative delivery” and that “continuous 
monitoring of uterine activity and fetal heart rate be employed”.  As such, clinical practice 
guidelines recommend that women undergoing PGE2 IOL remain in hospital, and receive 
electronic fetal monitoring for 30-60 minutes both before and after the insertion of PGE2.   
In Australia, very few maternity services commence IOL using PGE2 vaginal gel as an 
outpatient. 
 
2.2.3.4. Single dose versus multiple dose PGE2 vaginal gel protocols 
Individual trials have compared single dose PGE2 vaginal gel administration to placebo 
and multiple dose PGE2 vaginal gel to placebo. Meta-analyses of these trials suggest that 
the clinical outcomes appear similar albeit that there are many more participants in trials of 
multiple dose PGE2 vaginal gel versus placebo.  To date, however, there has been only 
one prospective trial that has compared single dose PGE2 vaginal gel administration with 
multiple dose administration.   
 
In a 1997 randomised controlled trial of women with a Bishop score of 8 or less [78], IOL 
was commenced using 2mg PGE2 vaginal gel administered in the evening.  Women were 
randomised to receive either a single dose of PGE2 vaginal gel or repeat dose 6 hours 
later.  Women randomised to the repeat dose arm received a second unspecified dose of 
PGE2 vaginal gel 6 hours later, unless already in labour or the Bishop’s score was 9 or 
more.  Women randomised to both arms remained in hospital and, if not in labour, were 
reviewed 14-20 hours following the first dose of PGE2 vaginal gel, an artificial rupture of 
membranes (ARM) was performed and an oxytocin infusion was commenced.  If an ARM 
could not be performed, the oxytocin infusion was commenced (with intact membranes) 
and ARM attempted 4 hours later.  Just over half of the women in the repeat dose arm 
were given the second dose according to the trial protocol.     
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Overall there were few differences between the two groups and no clear advantage of one 
protocol over another; no differences were seen in maternal or neonatal outcomes or 
mode of birth.  However  fewer than 10% of babies in the study were born by CS, which 
contrasts markedly with the current Australian experience as reported in maternity clinical 
indicator data [5].  Amongst multiparous women only, fewer women receiving repeat dose 
PGE2 vaginal gel required an ARM or oxytocin infusion.  But despite labouring without 
further intervention, they had similar analgesic requirements and no difference in the 
duration of labour.  The finding that there was no difference in the duration of labour may 
not have been entirely unexpected when considering the mechanism of action of PGE2 
vaginal gel as primarily a cervical priming agent.  Most commonly during an IOL, regular, 
painful contractions do not commence until the membranes are ruptured and an oxytocin 
infusion is commenced.  In their discussion, the authors outlined their rationale for not 
proceeding with an ARM and oxytocin infusion 6 hours after the first (or subsequent) dose 
of PGE2 vaginal gel, citing the time of night as a reason not to progress with the IOL.  
However, the authors also describe that women randomised to a repeat dose had “a more 
prolonged disturbance through the night” regardless (but do not specifically report this or 
other patient satisfaction measures).  Had the review for women in the single dose arm 
occurred at the same time as women in the repeat dose arm, it is likely that an ARM would 
have been performed and an oxytocin infusion commenced earlier.  Hence it is plausible 
that analysis of IOL-birth time and likelihood of in-hours birth, and possibly length of 
hospital stay may have demonstrated greater differences between the two IOL protocols.      
In Australia, there is much variation in policy and practice in use of PGE2 vaginal gel for 
IOL. The Queensland State-wide Maternity Clinical Practice Guidelines [79] recommend an 
initial dose of PGE2 vaginal gel for nulliparas and multiparas, and recommend that the 
MBS be reassessed after 6 hours, but provides no specific advice as to the MBS value or 
any other clinical parameter that would help direct when a second dose should be 
administered or ARM performed.    The South Australian Clinical Practice Guidelines [80] 
recommend an ARM once the maximum daily dose of PGE2  is reached or when the 
cervix is favourable (not defined), yet in their “Best Practice Notes”, recommend the 
second dose of prostaglandins should be withheld if an ARM can be performed.  The 
Victorian Maternity and Neonatal Clinical Network IOL Guidelines [81], recommend 
reassessment 6 hours after PGE2 insertion but also offer no guidance on whether to 
administer more PGE2 vaginal or to perform ARM.  The RANZCOG guideline [82] does 
not address PGE2 vaginal gel protocols.  The 124-page RCOG-endorsed NICE guideline 
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on Induction of Labour [47] comments that the optimal frequency of use and the maximum 
dose are not clear from the evidence.  “Despite extensive studies carried out over the past 
30 years to determine the most effective ways of inducing labour with vaginal PGE2, 
uncertainties remain about how best to apply these agents in terms of their dosage and 
timing.” The NICE Guideline provide an unreferenced recommendation that “vaginal PGE2 
products should be used in accordance with the manufacturers’ Instructions”.  The Product 
Information [60] does not provide this advice either.   
 
There is widespread acceptance that the use of cervical priming to commence an IOL is of 
value.  However, if the woman is not in labour 6 hours later, clinicians interpret guideline 
recommendations as meaning to either to give more PGE2 vaginal gel and ARM once the 
MBS is 7 or more, or they give no more PGE2 vaginal gel and attempt an ARM regardless 
of the MBS.  Proponents of giving more PGE2 vaginal gel argue that the likelihood of failed 
IOL is lower and maternal satisfaction higher (and pain less) if the cervix is more 
favourable prior to ARM.  Supporters of the “early ARM” approach believe that the IOL-to-
birth time is unnecessarily delayed by giving more PGE2 vaginal gel, that the goal of 
PGE2 vaginal is to prime the cervix only and hence earlier ARM and commencement of an 
oxytocin infusion is associated with similar clinical outcomes, a shorter labour, less overall 
discomfort, and higher maternal satisfaction.   
 
 
 
In summary, it is well established that in commencing an IOL, cervical priming of an 
unripe cervix is of value.  However clinical practice guidelines provide no evidence-
based recommendations regarding the optimal dosage and frequency of PGE2 
vaginal gel that will deliver the safest, most effective, least costly and more positive 
healthcare experiences for women undergoing this commonest method of cervical 
priming.   There is very little objective data of the value of repeated dosing of PGE2 
vaginal gel.  The single randomised controlled trial that addressed this question, 
reported no difference in any outcomes, however no attempt was made to 
commence labour with an ARM and oxytocin infusion until 14-20 hours after the first 
dose of PGE2 vaginal gel, irrespective of how many doses were administered.   
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2.3 Prediction of IOL success 
Some women’s experience of IOL is a rapid onset of labour and progression to birth, 
whereas in other circumstances, IOL may lead to a long and protracted labour which more 
commonly culminates in an instrumental birth or CS.  A common indication for CS in this 
setting is because of a “failed IOL” [8, 13, 83], where despite many hours of an oxytocin 
infusion, the woman does not reach the active phase of labour.  Surprisingly there is no 
agreement as to when an IOL has failed.  There is much variation in practice, and there is 
inconsistency in the definitions used in papers addressing this topic [84-86].  Some 
researchers have investigated “screening tests” and others have focussed on identifying 
the maternal and fetal characteristics that might better predict the likelihood of IOL 
success.  There is clearly a need to identify and validate the factors that can help predict 
successful IOL, in order to reduce the likelihood of birth by CS (especially the first CS), 
reduce the associated morbidity and reduce cost.   
 
There are both non-modifiable and potentially-modifiable factors that may influence the 
outcomes following IOL.  IOL is more likely to be successful in multiparous women (RR 
3.88, 95% CI 1.22-12.30) [87-90], in women taller than 170cm (OR 2.21, 95% CI 1.20-
4.01) [90, 91], in younger women (20-29 years) compared to those aged ≥ 40 years (RR 
2.91, 95% CI 1.36-6.19) [89], and in women with a lower BMI [13, 90, 92-94], and less 
likely to be successful where baby has a birthweight >4000g (aOR 2.38, 95% CI 1.56-
3.70) [13, 93] or is in a persistent occipito-posterior position (OR 2.9, 95% CI 1.3–6.7) [87, 
95, 96].  There are also studies reporting an association between IOL performed for some 
specific indications (hypertension, diabetes [97], post-dates [98]) and the outcome of CS 
birth.  There is limited capacity to modify any of these factors at the time when the decision 
for IOL is made.  Therefore, they do not clearly add value to the clinical decision.  The 
degree of cervical ripeness, however, is a potentially-modifiable factor that has been 
consistently recognized as one of the most important predictors of induction success and 
mode of birth outcomes [83, 92, 99].     
 
The changes in the cervix that prepare it for labour are termed “ripening”.  The softening, 
thinning, and dilation of an unfavourable cervix is an essential component of normal 
labour, reflecting the changes in the cervix ground substance and collagen fibres; 
specifically an increase in vascularity, protease activity and collagen dissociation, and a 
decrease in collagen solubility [100].  The cervix will naturally ripen as pregnancy 
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progresses, accelerated by pharmacological, mechanical and other methods of IOL 
described above.  Therefore, altering either the gestation (where clinically appropriate) 
and/or method by which labour is induced, has the potential to affect the favourability of 
the cervix, and so potentially alter the outcomes following IOL.   
 
The most commonly utilised objective measure of cervical ripening is a scoring system, 
originally described by Bishop in 1964 [101].  The Bishop score which is based on the 
cervical characteristics of dilatation, position, effacement, fetal station and consistency, 
was subsequently modified (the modified Bishop’s score (MBS), or Calder score) by 
including cervical length as a substitute for cervical effacement [102].  Although it was 
developed to predict time until spontaneous onset of labour in multiparous women, it is 
now predominantly used to predict IOL success, mainly in nulliparous women.  
 
Table 2.1: Modified Bishop’s score (MBS) 
 
Although some investigators [13, 92] describe a strong association between Bishop’s 
score and IOL success and outcomes, others [103, 104] suggest the score to be a poor 
predictor.   The score is subjective and has high intra and inter-observer variability [105, 
106].  In its favour, some argue that a digital assessment of the cervix is able to provide 
information on consistency and fetal station, which have been associated with outcomes of 
IOL [107] and are unable to be determined by ultrasound.  Others have argued for 
changes to the Bishop score.  The contribution of the length of the cervix to the Bishop 
score is criticised as it cannot be measured precisely by digital examination, and the 
dilatation and fetal station have been shown by some [107, 108] to be more discriminating 
than the total score as to whether or not an IOL will be successful.  Nevertheless, in a 
meta-analysis of 59 studies, Teixeira [109] demonstrated an association between higher 
Bishop score and likelihood of vaginal delivery, and the IOL-to-birth time after adjusting for 
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parity, gestation, maternal age and BMI.  Tests like ultrasound scan for cervical length, 
transperineal ultrasound measuring fetal head-perineum distance, cervical elastography 
and fetal fibronectin are objective measures, but in RCTs and meta-analyses, none has 
been shown to be superior to Bishops score in predicting IOL success and outcomes [88, 
92, 110-114].  
 
Whilst there is nil or limited capacity to modify factors such as maternal age, parity, height, 
weight, and birthweight, there is the potential that the outcomes following IOL using 
different methods, may be different in different patient cohorts.  In other words, certain 
methods of IOL in specific patient groups may be associated with fewer failed IOLs, more 
in-hours births and shorter IOL-to-birth times.  There are however no published studies 
that have addressed these questions. In a general population of women undergoing IOL, 
differences have been reported in the IOL-to-birth time [115] and in CS rates according to 
the method of IOL.  But because the Bishop Score is used to select women receiving 
different methods of IOL, it is not possible to gauge the independent influence of the 
Bishop Score on successful IOL using a particular method. 
 
Looking specifically at women undergoing IOL using PGE2 vaginal gel several factors 
have been investigated that may predict vaginal delivery.  These include multiparity (OR, 
4.63; 95% CI, 3.39–6.32), Bishop score greater than 4 (OR, 2.15; 95% CI, 1.12–4.20), BMI 
<30 kg/m2 (OR, 1.69; 95% CI,1.32–2.22), height > 165cm (OR, 1.47; 95% CI, 1.15–1.90), 
birthweight < 4000g (OR, 2.17; 95% CI, 1.51–3.13), maternal age < 35 years (OR, 1.81; 
95% CI, 1.15–2.86) and Hispanic ethnicity (OR, 1.45; 95% CI, 1.02–2.05) [93].  Again, no 
studies have specifically addressed the question as to whether a certain patient cohort 
might expect better outcomes with a certain protocol of PGE2 vaginal gel administration.  
   
 
 
In summary, numerous factors have been identified that may influence the 
outcomes following IOL by a variety of methods, but it is the degree of cervical 
ripeness (as measured by the Bishop score) that most consistently predicts IOL 
outcomes.  Whist some associations have been demonstrated, studies have not 
addressed whether certain patient groups might benefit from specific methods or 
protocols of IOL.   
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2.4 Women’s experiences of induction of labour 
The maternal and perinatal risks associated with childbirth and IOL are so low in 
developed countries [116] that, contrary to the views of healthcare providers, many 
consumers just assume safe clinical outcomes, and measure the quality of their care by 
the psychological and emotional experience of the healthcare encounter [117].  This 
underpins the importance of exploring women’s wishes for care during pregnancy, labour 
and birth, and for including women in decisions regarding their care.  There are 
surprisingly few published studies addressing women’s experience of IOL, and there is 
inconsistency in women’s reported responses when comparing findings from retrospective 
and prospective studies.  Most women undergo IOL for a defined clinical indication which 
is usually not present in those women who await spontaneous labour.  Hence, in 
comparing the reported experiences of women who are induced with those in spontaneous 
labour, it is important to remember there may be significant baseline differences in these 
groups.   
 
In retrospective observational studies [118, 119], women undergoing IOL have reported 
being less satisfied than women who labour spontaneously, with more than one third of 
those induced dissatisfied with the information received before IOL. These studies also 
report women’s concerns regarding the duration of the IOL, route of administration, 
number of examinations, and medical interventions associated with an induced birth.  
However, the results from prospective trials are quite different.  Salmon [120] explored the 
experience of childbirth through survey, amongst 104 antenatal and 210 postnatal women 
having their first child.  Women who were induced reported greater fulfilment (F (1, 109) = 
3.92, p=0.05), less distress (F (1, 109 = 4.89, p <0.05) and less difficulty (F (1, 109) = 
20.11, p <0.001), even when controlled for mode of birth, attendance at antenatal classes, 
previous termination of pregnancy and whether or not the pregnancy was planned.  In 
another prospective study Out [121] investigated women’s experience through face-to-face 
interviews and then follow-up questionnaires, identifying that women being induced felt 
less anxious and more self-confident compared to those in spontaneous labour, but there 
was also a non-significant trend toward feeling emotionally disengaged from their baby.   
In randomised controlled trials [27, 122] comparing IOL with expectant management post-
term, women report being less satisfied overall with a policy of expectant management 
(38% vs 74%; p<0.001).  This is despite their perception that the intervention and 
complications would be higher if labour is induced.    
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Healthcare experience outcomes have also been reported in various trials of comparing 
different IOL methods and protocols. Two small qualitative studies [123, 124] have 
explored a total of 38 women’s experiences of undergoing cervical priming as an 
outpatient.  Only one woman expressed a preference for inpatient care if she were to be 
induced again, with most women citing the comfort, safety and familiarity of being at home, 
and the feeling of support from family as important factors in their birth experience.  Both 
trials comparing timing of PG administration [30, 31] reported on women’s healthcare 
experience.  More women in the evening group reported a bad quality of sleep the night 
before delivery, and expressed dissatisfaction with the timing of induction.  In a RCT of 
combination oral misoprostol plus double-balloon catheter compared with oral misoprostol 
alone [125], healthcare experience outcomes were measured using a non-validated 
questionnaire.  Women receiving balloon induction were more likely to recommend this 
method to others (75.0% vs 52.6%; p=0.040), and reported greater satisfaction overall with 
their birthing experience (SIL-Ger score 87.7 vs 79.3; p = 0.030).  And two randomised 
controlled trials of balloon catheter IOL versus prostaglandin gel [53, 55] reported balloon 
catheter IOL to be associated with significantly less pain than PGE2 vaginal gel (pain 
score ≥ 4: 63% vs 36%; p <0.001) .   Healthcare experience outcomes were not reported 
in the sole trial that compared single versus repeat PGE2 vaginal gel protocols.   
 
 
In summary, there are few published studies addressing women’s experience of 
IOL, but most prospective studies report that IOL is associated with a more positive 
healthcare experience.  There are even fewer trials reporting experiential outcomes 
with different methods of IOL and healthcare experience was not reported in the 
sole trial that compared single versus repeat PGE2 vaginal gel protocols.  
Irrespective of the method or protocol for IOL, there is an emerging theme that 
women may be dissatisfied with the information they are provided about IOL and 
the degree of their involvement in decision-making [118, 119, 126].     
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2.5 Cost 
The cost of healthcare continues to rise far in excess of economic growth.  Amongst 
OECD countries between 2000 and 2012, the percentage of GDP being spent on 
healthcare increased by 12% [127].  In Australia in 2011-2012, the total expenditure on 
health was estimated at $140 billion or 9.5% of GDP, which is approximately 1.7 times 
higher in real terms (once inflation is accounted for) than in 2001–02 [128].  Considering 
the finite healthcare resources available, the decision to use resources in one way causes 
an inability to use resources elsewhere in the healthcare sector 
 
Having a baby is one of the commonest of all healthcare encounters.  More than 300,000 
babies were born in Australia in 2013 [1].  There is, however, very sparse detailed 
information as to how much this costs, and there have only been a handful of papers 
analysing the specific costs of maternity care in Australia [129-131].  These studies are 
now more than 15 years old.  They are also limited in their ability to describe the cost for 
both mother and baby, to describe costs for vaginal birth versus CS or spontaneous 
versus induced birth, or to adequately calculate the real cost of the whole episode of 
maternity care (antenatal, intrapartum and postpartum care) [132, 133].  Further, there is 
currently no internationally accepted childbirth costs and clinical outcome classification 
systems to facilitate comparisons between different aspects of care and delivery, and 
between different clinical units, hospitals and countries.   
 
Health services resources are finite.  It is clearly important for hospitals, health services, 
and government to have a clear understanding of both clinical outcomes and healthcare 
costs associated with maternity care [134].  An analysis of methods of induction of labour 
therefore needs to consider not just the clinical effectiveness of different protocols of IOL, 
but also their cost-effectiveness.   
 
In developed countries almost one quarter of women will be induced, however there are 
only two studies that have assessed costs associated with IOL, as opposed to not 
undergoing IOL.  Similar to observational studies reporting clinical outcomes of IOL, 
studies addressing healthcare costs can reach different conclusions depending on the 
cohort of women chosen for comparison.  Kaufman [135] used a Markov analysis to show 
that, when compared to a theoretical cohort of women in spontaneous labour, IOL resulted 
in an increase in birth by CS and therefore was not associated with any cost saving.  By 
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contrast, Kaimal’s decision analytic costing model [136] compared a theoretical cohort of 
women undergoing IOL at 41 weeks with another who were expectantly managed, and 
determined IOL was cost-effective (USD$10,945 per QALY gained).   
 
There are a number of unanswered questions about the cost of IOL.  For low-risk, 
otherwise uncomplicated pregnancies continuing beyond 41 weeks, IOL is associated with 
improved maternal and fetal outcomes [3] and it may be cost-effective [6].  However, it is 
less clear if IOL before 41 weeks would reach thresholds for cost-effectiveness.  
Commencing IOL as an outpatient also holds some promise as a cost-effective model of 
care, though there is very little published data to support the supposition that allowing 
women to go home after commencing IOL and then come back to hospital would save 
money [137].  In one RCT of inpatient versus outpatient IOL using PGE2, outpatient care 
was associated with “cost savings” but no specific data were reported [77].  In another 
[138], outpatient IOL was associated with fewer inpatient hours prior to birth, but no overall 
reduction in either length of stay or cost.   
 
Similarly, little is known about the cost of different methods of cervical priming or of the 
costs associated with one IOL protocol compared with another.  In the single meta-
analysis of cost-effectiveness of IOL methods [139], the most widely accepted measure of 
IOL efficacy (vaginal delivery within 24 hours) was reported in less than one quarter of 
included trials, severe events rates were too low to enable pooled analysis, and many 
model assumptions were based on data from a single UK hospital.  A bottom-up costing 
methodology, comprising assessment of the cost of all resources used by an individual 
woman throughout all aspects of the maternity episode of care, would help define the real 
cost of having a baby following IOL, and help distinguish which scenarios are associated 
with more or less cost.  Nevertheless, such an approach would still not include the costs 
borne by the woman, her family and the community.   
 
The sole RCT [140] that compared single dose versus multiple dose PGE2 vaginal gel 
regimens also reported on cost-effectiveness.  The authors based their costing 
methodology on a paper by Sculpher [141] which reported costs associated with 
hysterectomy.  The authors described very similar overall costs between the two IOL 
protocols.  Women receiving the single dose regimen incurred less antenatal ward 
expenses related to a short IOL-birth time, and also less neonatal costs, but greater birth 
suite costs, presumably due to a slightly increased assisted vaginal delivery rate.  
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However, only the women in the repeat dose arm of the trial were reviewed at 6 hours 
where a second dose was administered.  Women in both arms were then induced at the 
same time, with an ARM and oxytocin infusion commenced 14-20 hours following the 
initial dose of PGE2 vaginal gel.  Had the review for women in the single dose arm 
occurred at the same time as women in the repeat dose arm, it is likely that an ARM would 
have been performed and an oxytocin infusion commenced earlier.  Hence it is plausible 
that analysis of IOL-birth time and length of hospital stay may have demonstrated greater 
differences and more significant cost differences between the two IOL protocols.      
 
In summary, little is known about how much it costs to have a baby, and very few 
papers have described the costs associated with one IOL method / protocol 
compared with another.  The sole RCT that compared single dose versus multiple 
dose PGE2 vaginal gel regimens found there was no difference in the IOL-to-birth 
and therefore similar overall costs.  However, no attempt was made to commence 
labour with an ARM and oxytocin infusion until 14-20 hours after the first dose of 
PGE2 vaginal gel, irrespective of how many doses were administered.  A bottom-up 
costing methodology would help determine which scenarios are associated with 
more or less cost.   
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2.6 Chapter summary  
In Australia each year, one in four women will undergo IOL.  Compared to women 
managed expectantly, IOL is not associated with adverse maternal or perinatal outcomes.  
Indeed, the best available evidence would suggest IOL is associated with an 11% 
reduction in the  likelihood of birth by CS (RR 0.89, 95% CI 0.81 to 0.97).   PGE2 vaginal 
gel is the most commonly used IOL method in Australia and is an effective cervical priming 
agent, although there are no evidence-based recommendations regarding protocols of 
administration that are associated with the best clinical outcomes overall or in specific 
patient cohorts. Whilst it is common practice for clinicians to administer subsequent doses 
of PGE2 vaginal gel if the woman is not labouring or her cervix is still considered 
unfavourable, there is no objective data supporting this practice.  Little is known of the cost 
or the acceptability to women, of any protocol of PGE2 vaginal gel IOL.  
 
IOL may not be associated with any higher rate of obstetric intervention and complications 
when compared to women managed expectantly, however these adverse events do occur.  
Presumably, safer outcomes would be expected if these sometimes complex operative 
births were to happen during the day when more experienced clinicians are able to provide 
care and/or supervise more junior clinicians.  Identifying protocols of PGE2 vaginal gel 
administration that are associated with shorter IOL-to-birth times and more in-hours births, 
may well lead to safer outcomes for mothers and babies, as well as decreased cost and 
improved healthcare experience outcomes.   Identifying factors that are predictive of IOL 
success (and in-hours births and IOL-to-birth times) may also lead to the identification of 
IOL protocols that maximise outcomes for certain patient cohorts.  IOL using PGE2 vaginal 
gel is a very common event about which we know surprisingly very little. 
 
Having identified these gaps in knowledge for women undergoing IOL using PGE2 vaginal 
gel with respect to clinical outcomes, costs, healthcare experience outcomes, and 
prediction of IOL outcomes, this thesis will test the following four hypotheses  
 
• A policy of amniotomy once technically possible compared with a policy of giving 
more PGE2 vaginal gel will result in a reduction in the IOL-to-birth time, and a 
greater number of “in hours” births 
• Parity, age, BMI, MBS, and gestation are predictive of IOL-to-birth-time, likelihood 
of “in-hours birth”, and mode of birth   
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• A policy of amniotomy once technically possible compared with a policy of giving 
more PGE2 vaginal gel will result in a more positive healthcare experience for 
women  
• A policy of amniotomy once technically possible compared with a policy of giving 
more PGE2 vaginal gel will result in less overall healthcare associated costs 
 
In addition, the thesis will address the following secondary aims 
• To explore if a policy of amniotomy once technically possible compared with a 
policy of giving more PGE2 vaginal gel is associated with differences in the rate of 
obstetric intervention (operative delivery, epidural), or adverse maternal / perinatal 
outcomes (including estimated blood loss > 500ml, use of antibiotics in labour, 
admission to nursery, uterine hyperstimulation). 
• To define the indications for adopting a policy of amniotomy once technically 
possible versus a policy of giving more PGE2 vaginal gel, by identifying the clinical 
characteristics (parity, age, BMI, MBS, and gestation) that predict superior IOL 
outcomes (shorter IOL-to-birth-time, an “in-hours birth”, and vaginal birth) with each 
policy.  
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Chapter 3 Methods 
3.1 Aims and Objectives 
This research has investigated two different policies of IOL using PGE2 vaginal gel, 
specifically a policy of amniotomy once technically possible, compared with a policy of 
giving more PGE2 vaginal gel. The aim was to explore the clinical outcomes, the 
healthcare experiences, and the healthcare costs associated with two common 
approaches to PGE2 vaginal gel IOL.  
 
The objectives of this thesis were to investigate how best to undertake IOL using PGE2 
vaginal gel.  The outcomes for women undergoing PGE2 vaginal gel IOL following a policy 
of amniotomy once technically possible (regardless of MBS), or a policy of giving more 
PGE2 vaginal gel (repeat administration and amniotomy only when MBS ≥7) were 
compared in order to: 
 
 
 
 
a) Determine which policy of PGE2 vaginal gel IOL results in the shorter IOL-to-birth 
time and is associated with lower rates of obstetric intervention and morbidity; and   
 
b) Determine the clinical characteristics of women who might experience the 
shortest labours and lowest rates of caesarean section with each policy of PGE2 
vaginal gel IOL; and 
 
c) Determine which policy of PGE2 vaginal gel IOL is associated with the more 
positive healthcare experience for women; and 
 
d) Determine which policy of PGE2 vaginal gel IOL is associated with lower 
healthcare costs 
 
Determining which of the two IOL policies results in the shorter IOL-to-birth time has 
been assessed by measuring and comparing the time intervals  
• Between 1st dose PGE2 and ARM 
• Between ARM and birth 
• Between 1st dose PGE2 and birth 
 
 
 
 
 
It was unclear if the administration of repeat doses of PGE2 vaginal gel when the MBS is 6 
or less, would increase or decrease the overall time from 1st dose PGE2 until birth.  It was 
assumed that subsequent administration of PGE2 vaginal gel, when already technically 
possible to perform an ARM, might increase the time from 1st dose PGE2 vaginal gel until 
44 
 
ARM.  However, this additional priming might then reduce the time from ARM until birth, 
when compared to aiming to perform an amniotomy following just a single dose.   
 
The rate of obstetric intervention and morbidity associated with the two IOL policies 
has been assessed by recording maternal outcomes such as: 
• Mode of birth  
• Need for broad-spectrum antibiotics in labour (as a surrogate marker of 
chorioamnionitis)  
• Post-partum haemorrhage (defined as estimated blood loss >500ml)  
 
The relevant perinatal outcomes comprised: 
• Uterine hyperstimulation with fetal heart rate changes, requiring removal of PGE2 
vaginal gel and/or administration of acute tocolysis  
• Admission to Special Care or Intensive Care Nurseries  
• Duration of nursery admission 
 
 
 
The concept of an “in-hours” birth has been used as one measure of both duration of 
IOL and safety, and has been defined as birth occurring during daytime rostered hours 
(between 08:00am and 5:00pm).  Presumably, safer outcomes would be expected if these 
sometimes complex operative births were to happen during the day when more 
experienced clinicians are able to provide care and/or supervise more junior clinicians. 
   
Determining which women might experience superior IOL outcomes with each policy 
of PGE2 vaginal gel IOL, has been determined by analysing the clinical characteristics of 
women induced following each policy, the clinical characteristics of women experiencing 
shorter labours and fewer CS, and performing logistic regression modelling. 
 
Women’s healthcare experience has been determined by questionnaire, completed by 
the woman in the days following birth.  No validated measure of healthcare experience for 
women undergoing IOL currently exists. 
 
The total healthcare costs for women following a policy of amniotomy once technically 
possible compared with a policy of giving more PGE2 vaginal gel have been compared.  A 
combination of both bottom-up and top-down costing methodologies were used, to 
estimate the cost of all resources used by an individual woman and her baby throughout 
all aspects of the labour and birth episode of care until hospital discharge.    
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3.2 Hypotheses 
The thesis has tested four hypotheses pertaining to clinical outcomes, prediction, 
healthcare experience and costs, for women undergoing IOL using PGE2 vaginal gel 
 
 
1. Clinical outcomes: A policy of amniotomy once technically possible compared 
with a policy of giving more PGE2 vaginal gel will result in a reduction in the 
IOL-to-birth time, and a greater number of “in hours” births. 
PGE2 vaginal gel is an agent used to ripen the cervix prior to IOL with an ARM and 
commencement of an oxytocin infusion.  The use of PGE2 vaginal gel alone may 
sometimes initiate contractions but this is a less common outcome.  It has been 
hypothesised that in most women, administering more doses of PGE2 vaginal gel 
merely delays the time until labour is established, and that the IOL-to-birth time is 
shorter if an ARM and commencement of an oxytocin infusion happens sooner.  Given 
that PGE2 vaginal gel administration happens in the evening, early morning ARM and 
commencement of an oxytocin infusion after a single dose of PGE2 vaginal should 
result in more in-hours births, than having these steps delayed until 6 or 12 hours after 
a second or third dose of PGE2 vaginal gel.  
 
 
2. Prediction: Parity, age, BMI, MBS, and gestation are predictive of IOL-to-birth-
time, likelihood of “in-hours birth”, and birth by CS.   
There is data amongst women undergoing IOL demonstrating an association between 
the MBS, and the outcomes of IOL-to-birth time and mode of birth [13, 92].  There is 
also data amongst women in spontaneous labour reporting associations between 
clinical characteristics like parity, age, BMI and gestation, and the outcome of mode of 
birth [13, 87, 88, 92-94].  It has been hypothesised that these clinical characteristics 
(independent of the MBS) might also predict outcomes for women being induced, 
including the IOL-to-birth-time, likelihood of “in-hours birth”, and birth by CS.   
 
 
3. Healthcare experience: A policy of amniotomy once technically possible 
compared with a policy of giving more PGE2 vaginal gel will result in a more 
positive healthcare experience for women    
Following administration of PGE2 vaginal gel, subsequent vaginal examinations can 
be more tender.  This discomfort has been observed to be greater when more than 
one dose of PGE2 vaginal gel is given.  Whilst it is acknowledged that ARM is also a 
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potentially painful procedure especially when the cervix is long and/or not very dilated, 
it hypothesised that the additional vaginal examinations that would follow multiple 
doses of PGE2 vaginal gel will lead to greater discomfort and therefore a less positive 
healthcare experience.  Further to Hypothesis 1, if it were true that a policy of 
amniotomy once technically possible was associated with a shorter IOL-to-birth time 
and greater likelihood of an “in-hours birth”, it is hypothesised that women will have a 
more positive healthcare experience with this daytime birth and shorter duration of 
birth. 
 
 
4. Costs: A policy of amniotomy once technically possible compared with a policy 
of giving more PGE2 vaginal gel will result in less overall healthcare costs 
Building upon Hypothesis 1, a shorter IOL-to-birth time is likely to have a direct effect 
upon the use of resources in the birth suite and also the overall length of hospital stay.  
As the cost of the episode of care is heavily influenced by time spent by clinicians in 
“hands on” patient care, and the ratio of staff to patients and direct involvement of 
medical staff is highest when the woman in the birth suite, reducing the IOL-to-birth 
time is likely to be associated with cost-savings.  Hospitals tend to only discharge 
patients during business-hours.  Therefore, increasing the proportion of in-hours births 
may facilitate hospital discharge on post-partum day 2 or 3 (rather than the expected 
day 3 or 4) and therefore be associated with a further reduction in length-of-stay, 
above that expected from just the decreased IOL-to-birth time. Whilst the study has 
not been powered to detect differences in the mode of birth, or rates of postpartum 
haemorrhage and nursery admissions, differences in these outcomes will also impact 
total healthcare costs. 
 
In addition, the thesis has addressed two secondary aims pertaining to clinical outcomes 
and prediction: 
 
a.   Clinical outcomes: To explore if a policy of amniotomy once technically possible 
compared with a policy of giving more PGE2 vaginal gel is associated with 
differences in the rate of obstetric intervention (operative delivery, epidural), or 
adverse maternal / perinatal outcomes (including estimated blood loss > 500ml, 
use of antibiotics in labour, admission to nursery, uterine hyperstimulation). 
Neither the proposed study design nor sample size will allow for this study to conclude 
that a policy of earlier amniotomy and a policy of repeat-PGE2 administration are 
equivalent in terms of the rate of obstetric intervention or adverse maternal / perinatal 
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outcomes.  A non-inferiority design would be required.  Instead, this randomised 
controlled trial will report and comment upon these outcomes.  The data will help 
inform future investigators as to the magnitude of these differences and therefore the 
sample sizes required for future research into these outcomes. 
  
 
b. Prediction: To define the indications for adopting a policy of amniotomy once 
technically possible versus a policy of giving more PGE2 vaginal gel, by 
identifying the clinical characteristics (parity, age, BMI, MBS, and gestation) that 
predict superior IOL outcomes (shorter IOL-to-birth-time, an “in-hours birth”, 
and vaginal birth) with each policy.   
Whilst there is nil or limited capacity to modify factors such as maternal age, parity, 
height, weight, and birthweight, there is the potential that the outcomes following IOL 
using different policies, may be different in different patient cohorts.  The data from 
women in this RCT will be used to determine if a single clinical characteristic, or a 
combination of several characteristics, predict superior IOL outcomes with one or 
either policy of PGE2 vaginal gel IOL.   
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3.3 Study design 
In comparing the outcomes of women following a policy of amniotomy once technically 
possible versus a policy of giving more PGE2 vaginal gel, several study designs could be 
considered.  Both policies are in common practice, therefore a retrospective (historical) 
cohort study of outcomes following IOL using either policy would be a plausible research 
design.  However, as a non-experimental design, there would have been no obligation for 
clinicians to follow specific documented IOL policy, no certainty that clinicians following 
each policy would deliver similar care, or that the outcomes of interest would be recorded 
consistently or accurately.  If the cohort study was a prospective cohort, it would usually 
have clearly defined protocols and data collection methods and so could overcome some 
of these disadvantages.  However, for both prospective and retrospective cohort designs, 
there would be the potential for differences in the baseline characteristics (and other care-
in-labour practices) between women receiving care under each policy.  It would be 
possible to statistically control for some confounders that might otherwise explain 
observed differences (or lack of differences) between women receiving care under each 
policy, and a logistic regression analysis would be one of the commoner methods of 
statistically controlling for these differences.  Confounders in the statistical model would be 
identified through a bivariate analysis of the characteristics of women receiving each 
protocol.  Nevertheless such a design would not be able to control for all confounders, and 
causation could not be established from this design [142, 143].   
 
A case-control study would also be plausible research design.  Case-control studies are 
generally quick and relatively inexpensive to complete, and typically undertaken when 
studying rare diseases or outcomes.  As another retrospective study design, there would 
again be uncertainty that all women receiving each protocol received similar care, and that 
the outcome measures were recorded consistently and accurately.  A case-control study 
design would control for confounders by matching one women receiving amniotomy 
protocol with one (or more) receiving repeat-PGE2 protocol.  This matching would be an 
alternative way of addressing the allocation bias inherent in this study design, however a 
major potential for bias exists because the controls are selected by the investigators.  And 
similar to the retrospective cohort design described above, a case-control study is also 
unable to control for all confounders [142, 143]. 
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A randomised controlled trial is a study design that is most likely to obtain unbiased data, 
and is considered the scientific gold standard against which other study designs are 
compared [144].  It has clearly defined protocols and agreed consistent methods of data 
collection.  The prospective nature of this design facilitates comparison of two defined and 
consistently administered protocols.  Hypotheses 1, 3 and 4, and Secondary Aim 1 have 
therefore been examined using a randomised controlled design.  In randomising 
participants to one protocol or the other, it is the most appropriate design to minimise 
selection bias, ensuring that the distribution of both known (and unknown) confounders are 
randomly equal between the two study groups.  Allocation concealment has been 
addressed through the use of sequentially numbered opaque envelopes.   Whilst it was not 
possible to blind women or the clinicians caring for them to the allocated treatment 
protocol, detection bias has been addressed by ensuring that researchers involved in the 
postpartum collection of satisfaction data via questionnaire, remained blinded to the 
woman’s treatment allocation.  A single research midwife was employed to undertake data 
collection for all women in the trial and this therefore minimise the risk of attrition bias.  The 
trial and proposed outcome measures were prospectively publically registered with 
ANZCTR limiting the chance that only certain outcomes will be reported (thereby 
minimising reporting bias).   
 
 
 
Bias Risk of bias Comment 
Random sequence generation 
(selection bias) 
Low risk. Random generation prepared by Mater Research 
Allocation concealment 
(selection bias) 
Low risk. Use of sequentially numbered opaque envelopes 
prepared by Mater Research 
Blinding of participants and 
personnel (performance bias) 
Moderate risk. Not possible to blind women or the clinicians caring for 
them to the allocated treatment protocol.   
Blinding of outcome 
assessment (detection bias) 
(patient-reported outcomes) 
Low risk. Researchers involved in the postpartum collection of 
satisfaction data via questionnaire, have remain blinded 
to the woman’s treatment allocation. 
Incomplete outcome data 
addressed (attrition bias)  
Low risk. A single research midwife, not involved in clinical care of 
women in trail, employed to undertake data collection for 
all women in the trial 
Selective reporting (reporting 
bias) 
Low risk. Proposed outcome measures were prospectively 
publically registered with ANZCTR. 
Table 3.1: Risk of bias   
 
Hypothesis 4 has been further examined using the clinical outcomes and costing data 
from participants in the RCT to help build a costing model.  Modelling allows the 
integration of RCT data, with already-known overhead costs and human resource costs 
associated with the delivery of clinical care in birth suites and postnatal wards, as well as 
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other published clinical trial and epidemiological data.  Data are sourced from the best 
quality evidence according to a hierarchy established by Drummond [145].  Considering 
that a single RCT is unlikely to provide all the information required for decision-making, 
modelling allows the relatively limited short-term data of the clinical trial to be “extended” 
into the future, where the outcomes and costs can be translated into health economic 
outcomes.  Specifically, a Markov model has been used, to enable the simultaneous 
assessment of both cost and clinical outcome.  Using this methodology, the various points 
in the IOL journey (administration of PGE2 doses, labour, birth in birth suite or theatre), 
and inpatient journey (postnatal care and accommodation for mother and baby) become 
the mutually exclusive “states” that women transition through.  Other longer-term “states” 
can also be considered using a Markov model.  For example, the “state” of having 
placenta praevia or placenta accreta in the next pregnancy can (in theory) be considered, 
which could follow on from the “state” of giving birth by caesarean section after IOL in this 
pregnancy.  The likelihood of transition from one state to the next (eg from PGE2 dose to 
labour) has a specific probability, which can be derived from the RCT data.  And once 
each of these Markov states are ascribed a cost, a hypothetical cohort model run over say 
1000 cycles can generate a clearer understand of the long-term cost and clinical outcomes 
for women receiving one IOL protocol versus the other.  Sensitivity analyses and/or Monte 
Carlo simulations can then test the robustness of the model, acknowledging the statistical 
uncertainty of some parameters and the heterogeneity of the patient cohort studied, 
varying both the cost and probabilities of transition from one state to the next [145, 146].   
 
Hypothesis 2 and Secondary Aim 2 have been examined using a multivariate prediction 
model.  A multivariate analysis is a method of simultaneously considering the effects of the 
many variables (eg parity, age, BMI, MBS and gestation), and their relationship to the 
outcomes (IOL-to-birth-time, likelihood of “in-hours birth”, and mode of birth).  This analysis 
was used to control/adjust for the effects of these inter-related variables and therefore 
determine which variable(s) might independently predict the outcome(s).  Performing 
multiple subgroup analyses would allow for a rudimentary consideration of the role of 2-3 
predictive factors at a time.  However, a multivariate analysis is the only practical way to 
consider this number of predictor variables at one time.  Causation cannot be determined 
using this design.  The results illustrate potential associations and relationships between 
certain predictor variables and outcomes.   Given the relatively small sample size, the 
model is limited in its ability to consider all relevant predictor variables [142, 143].   
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3.4 Study population 
The study population was drawn from women planning to give birth at Mater Mothers’ 
Hospital.  All women with live singleton pregnancies ≥37+0 weeks planning IOL using 
PGE2 vaginal gel (generic name: dinoprostone; trade name: Prostin) were screened for 
eligibility in a randomised controlled trial comparing the two policies of PGE2 vaginal gel 
IOL.  To limit heterogeneity in the sample, participants were not eligible for inclusion if they 
had a multiple pregnancy, had previously given birth by caesarean section or had 
undergone other uterine surgery, if the baby was known to have a major congenital 
abnormality or had died in-utero.  Participants were also not eligible if there were any 
contraindications to vaginal birth (eg major placenta praevia), or if the woman was aged 
less than 18 years or unable to consent for whatever reason.  Younger people and others 
who were unable to consent were excluded because of their potentially diminished 
capacity to understand what the research entails.    
 
 
3.5 Outcome measures 
The Primary Outcome Measure was the time from commencement of IOL until birth.  
This measure closely aligns with the first primary outcome measure specified in the 
Cochrane Review Vaginal prostaglandin for induction of labour at term [62], which is 
described as “vaginal delivery not achieved within 24 hours”.    
 
Similarly, many of the Secondary Outcome Measures mirror those of the Cochrane review  
1) Mode of birth   
2) Use of epidural analgesia in labour 
3) Need for broad-spectrum antibiotics in labour 
4) Admission of baby to Special Care or Intensive Care Nurseries 
5) Post-partum haemorrhage (= estimated blood loss >500ml)  
6) Uterine hyperstimulation with fetal heart rate changes  
7)  Women’s experience of IOL (by questionnaire) 
8) Duration of hospital admission 
 
In addition, the following additional Secondary Outcome Measures were collected: 
9) Total healthcare costs 
10) Proportion of births occurring during “business hours” (0800-1700).    
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3.6 Measurements 
The study involved the collection of the following data: 
1) Patient age 
2) Booking BMI 
3) Ethnicity 
4) Indication for induction 
5) Gestation at time of induction 
6) Date and time of admission 
7) MBS at time of 1st dose PGE2 vaginal gel 
8)  MBS at time of subsequent doses of PGE2 vaginal gel 
9)  MBS at time of ARM  
10) Time and date of administration of each dose of PGE2 vaginal gel 
11) Uterine hyperstimulation with fetal heart rate changes 
12) Time and date of spontaneous or artificial rupture of membranes 
13) Time and date of administration of oxytocin infusion  
14) Analgesia used  
15) Mode of birth 
16) Time of birth 
17) Administration of broad-spectrum antibiotics in labour 
18) Documented estimated blood loss at time of delivery 
19) Admission to SCN/ICN 
20) Date and time of hospital discharge 
21) Questionnaire of woman’s healthcare experience  
 
Clinical and patient administration data at the study site were primarily recorded in the 
hospital’s electronic maternity record, with supplementary notes recorded in the paper 
health record.  Outcome measure data have been extracted from the hospital’s electronic 
maternity record system by a research midwife.  Where there was concern regarding the 
veracity of this information, the research midwife perused the paper medical record.   
 
Mode of birth was defined as unassisted vaginal birth, assisted vaginal birth, caesarean 
section.  Use of epidural analgesia in labour, and admission of baby to Special Care 
or Intensive Care Nurseries, was collected as dichotomous outcomes.  Duration of 
hospital admission was the number of hours from administration of first dose PGE2 
vaginal gel until the woman’s hospital discharge.   
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Uterine hyperstimulation with fetal heart rate changes, has been recorded as any event 
of excessive uterine activity (>5 contractions in 10 minutes) [47, 147] where PG2 vaginal 
gel has been removed from the vagina or acute tocolysis administered. 
 
A combination of visual inspection by clinicians and weighing of pads/linen has been used 
to estimate intrapartum / postpartum blood loss.  Hospital policy dictates that all blood 
loss greater than an estimated 500ml is weighed.  Therefore, for clinically significant 
amounts of blood loss, a low incidence of measurement error is expected.    
 
Need for broad-spectrum antibiotics in labour has been collected as a surrogate 
marker of chorioamnionitis.  It is hypothesised that more vaginal examinations, and/or a 
longer time from IOL-to-birth may be associated with a greater risk of maternal infectious 
morbidity.  In practice, the diagnosis of chorioamnionitis is assumed when a woman is 
febrile (>38.0C) in labour and intravenous antibiotics are prescribed.  Only rarely would 
clinicians attempt to culture blood or liquor, and histological examination of the placenta is 
performed sparingly.  The administration of antibiotics in labour is common, but to observe 
a statistically significant difference in rates of administration of broad-spectrum antibiotics 
between women cared for under the two policies, would infer a higher rate of the clinical 
diagnosis of chorioamnionitis.   
 
Women’s experience of IOL has been determined by questionnaire, administered by a 
research midwife who was not involved in the woman’s intrapartum or postpartum care 
and who was also blinded to the woman’s treatment allocation.  The questionnaire was 
administered by phone at a consistent 7-9 days post-partum.  For non-English speaking 
woman, this was undertaken with the assistance of a phone interpreter.  Phone 
administration has been shown to improve completion (and reduce loss-to-follow-up), and 
also aid comprehension when compared to completion of written questionnaires [148, 
149].   And when compared to face-to-face interviews in other health encounters, 
telephone interviews appear equally likely to derive robust outcome measures [150-152].  
Delaying the administration of the questionnaire to approximately one week post-partum 
may have helped avoid the potentially false-positive satisfaction results associated with the 
woman’s relief that the labour is over and the baby is healthy [153].     
 
In broad terms, satisfaction may be determined either by the outcome of the healthcare 
event (so-called fulfilment theory) or by the degree to which the experience meets or does 
not meet expectations (so-called discrepancy theory) [154].  Given the multidimensional 
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nature of satisfaction, it has been challenging to develop meaningful and robust measures 
of healthcare experience [155].  Very few validated measures of healthcare experience 
exist [156] and in particular, no validated experiential measure exists for women 
undergoing IOL.  Therefore an instrument was developed de novo for this study [157] 
attentive  to the multidimensional nature of satisfaction and with specific  attention  paid  to 
the psychometric properties that maintain high validity  and  reliability.  The   EXperiences  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Maternal satisfaction tool  
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of Induction Tool (EXIT) comprised 10 items as well as a single-Item measure of global 
satisfaction with the birth experience, and two Items to assess validity of the 10-Item scale.  
The EXIT also contained 4 process evaluation Items: 2 quantitative measures and 2 
qualitative measures. A discriminatory 5-point Likert-like scale was chosen as a 
measurement scale. Participants responded to questions about the outcome of their IOL 
and birth experience (eg how long process took, would you be induced this way again, 
would you recommend this to a friend or relative) and questions about the extent to which 
their expectations were met (perception of discomfort and duration of labour, whether 
frequency/intensity of contractions were manageable).   
 
The validity of the satisfaction tool has been tested.  An attempt has been made to 
maintain content validity through the drafting of questions that are specifically focussed on 
IOL and the various steps involved in this process (rather than the birth experience more 
generally).  As no valid gold standard test exists, it has not been possible to demonstrate 
criterion validity.   Face and content validity from the perspective of subject matter experts 
was assessed by seeking feedback on the EXIT and additional items from a group of 8 
senior obstetricians and midwives, and also from a team of 4 research midwives who are 
actively involved in clinical trials and administration of written surveys. Face validity from 
the perspective of women undergoing IOL was inferred from their willingness to participate 
in data collection and rates of missing data.    Exploratory (principal components) factor 
analysis was used to assess construct validity of the questionnaire. Reliability was tested 
using the Cronbach’s alpha coefficient of internal consistency of the included items.  
Internal convergent validity was tested by Pearson’s correlations between respondents’ 
mean responses (to the included items) and their articulated likelihood of choosing the 
same method of IOL again and recommending the method of IOL to a friend or relative.  
The discriminative ability of the final factor solution was then tested (as detailed in Chapter 
6).   
 
Total healthcare costs can be measured using a bottom- up or top-down methodology.  
A bottom-up (or activity-based) costing methodology measures use of resource at the 
individual patient level.  Top-down methodologies, which estimate cost based on pre-
determined average national costs or “weights”, take total expenditure for a given 
diagnosis-related-group (DRG) and divide this by the number of patients to generate an 
average cost per patient.  Dividing total expenditure by number of days can also be used 
to produce a less commonly used “per day” cost [158].  Top-down costing are criticised as 
they may not accurately reflect medical and nursing staffing and intervention duration 
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[159].  They also do not allow further analysis to determine what element of care is driving 
the cost.  Whilst it is recognised that both top-down and bottom-up costing methodologies 
are widely used, bottom-up costing is generally considered to be more accurate and 
relevant [160-162], albeit that it is more time consuming and expensive to perform.  Given 
the interoperability of Mater Health Services clinical and finance systems, some bottom-up 
costing has been possible.  Bottom-up costing comprises a detailed, granular assessment 
of the cost of all resources used by an individual woman throughout all aspects of the 
labour and birth episode of care.  Whilst some of these costs (eg pharmacy, pathology) 
were measured at the patient level, nursing / midwifery, medical, allied health and other 
salaries & wages as well as business overheads were estimated in each grouping as an 
apportioned percentage of total costs.  Chapter 7 builds upon the analysis of total 
healthcare costs and test the robustness of the findings using a Markov costing model. 
 
The concept of an “in-hours” birth has been used as one measure of timeliness and 
safety, and has been defined as birth occurring between 08:00am and 5:00pm.  The time 
from 08:00am to 5:00pm represents the day-time period of maximal midwifery and medical 
staffing in birth suite.  It is also reflects a time when there is direct Consultant presence in 
most birth suites [34].  The majority of maternity services are able to meet the RCOG 
minimum standard of 40-hours of obstetrician presence in birth suite [42] through in-hours 
specialist coverage only.  Following an induced birth, a greater proportion of babies are 
born using vacuum extraction or forceps or by caesarean section when compared with 
women in spontaneous labour.  Several authors have reported the association between 
evening / night-time births following IOL and the risk of adverse perinatal outcomes [37-
39].  It is therefore plausible that safer outcomes would be expected if these sometimes 
complex operative births were to happen during the day when more experienced clinicians 
are able to provide care and/or supervise more junior clinicians.   
 
3.7 Recruitment of participants 
Information regarding the trial was included as part of the welcome information for all 
women booking at the hospital.  Potential participants were identified by clinicians in the 
antenatal clinic at antenatal visits ≥37 weeks.  All women booked for IOL using PGE2 
vaginal gel ≥37 weeks 0 days were provided with written information regarding the trial by 
clinicians and given the opportunity to discuss the details of the study with the research 
midwife.  When the woman presented to the hospital to be induced, the treating clinician 
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asked the woman if she desired to be involved, she was then invited to sign a consent 
form, and a study information sheet for clinical staff was filed in the medical record.  The 
research midwife kept a log of all potentially eligible participants and the reasons for 
participation or not, as per CONSORT guidelines [163].   
 
A $30,000 Mater Research seeding grant funded 18 months of a part-time research 
midwife.  Once these funds were exhausted and enrolment had not yet been completed, 
the process for recruitment of participants was changed.  Whilst women were still provided 
with written information regarding the trial at the time of booking for IOL, consenting and 
enrolment happened when the woman arrived to hospital in the evening to commence her 
IOL.  An automatic alert was scheduled to alarm on the evening Registrar’s pager, 
reminding them to review women booked for IOL and discuss the IOL trial.  Registrars 
were provided with trial material, orientated to the process at the start of each clinical term, 
and a recruitment progress chart in the Registrar room in birth suite provided regular visual 
feedback regarding recruitment numbers.   
 
 
3.8 Randomisation  
Randomisation occurred according to a computer-generated random allocation list into 2 
study arms.  Sequentially numbered sealed opaque envelopes were prepared by Mater 
Research and stored by the research midwife securely in the birth suite.  The envelope 
was opened by the midwife in birth suite at the time of the woman’s morning review (and 
after sighting written consent, and affirming verbal consent).  Delaying randomisation until 
the minutes just before the first post-PGE2 review has helped reduce the number of 
women enrolled into the trial who did not receive care according to the random allocation. 
If randomisation was to occur at the time of written consent or arrival in hospital, there 
would be the potential for women to labour prior to the time of the first post-PGE2 review, 
and yet would still be included in the results despite there being no exposure to the 
protocols being tested.   
 
3.9 Study procedure 
Verbal reaffirmation of consent was obtained prior to IOL and a note recorded in the 
medical record reflecting this.  IOL was commenced in the usual fashion.  All women 
received an initial dose (1mg or 2mg as clinically indicated) of PGE2 vaginal gel in the 
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evening.   A vaginal examination was performed and the MBS documented.  A post-PGE2 
CTG was applied and continuous electronic fetal monitoring continued for at least 60 
minutes.  In the absence of ruptured membranes, need for pain relief and/or onset of 
regular painful contractions, staff endeavoured to review all women the following morning 
at 0530 in birth suites.  The following morning, the woman was assessed by an 
experienced midwife (credentialed to perform ARM).  The midwife performed a cervical 
assessment and documented the MBS.   
 
Women randomised to the amniotomy group underwent ARM, regardless of the MBS.  
Once the membranes were ruptured then, in the absence of uterine activity, clinicians 
recommended that an oxytocin infusion be commenced as soon as possible.  In the event 
that the midwife was unable to rupture the membranes, the woman was reviewed by the 
Registrar and a further attempt made to rupture the membranes.  If the Registrar was 
unable to rupture the membranes, a further dose of PGE2 (1mg) vaginal gel was 
administered.  The following review in 6 hours was performed by the Registrar.  In the 
situation where the membranes still could not be ruptured, the woman was examined by 
the Consultant before concluding that a 3rd dose of 1mg PGE2 vaginal gel was indicated.  
The subsequent review was again performed by the Registrar and, if necessary, the 
Consultant.  If the membranes still could not be ruptured, and there remained a clear 
indication for delivery, then caesarean section was indicated. 
 
Women randomised to the repeat-PGE2 group with a MBS ≥7 underwent an ARM.  In the 
event that the midwife was unable to rupture the membranes, the woman was reviewed by 
the Registrar who then performed the ARM.  Once the membranes were ruptured then, in 
the absence of uterine activity, clinicians recommended that an oxytocin infusion be 
commenced as soon as possible.  Women randomised to the repeat-PGE2 group with a 
MBS less than 7 received a further 1mg dose of PGE2 vaginal gel.   These women were 
reviewed 6 hours later.  Those women now with a MBS greater than or equal to 7 
underwent an ARM whilst those women with a MBS less than 7 received a 3rd dose of 
1mg PGE2 vaginal gel.  Following 3 doses of PGE2 vaginal gel, an attempt was made to 
perform an ARM by the midwife, Registrar or (if necessary) Consultant.  If the membranes 
still could not be ruptured, and there remained a clear indication for delivery, then 
caesarean section was indicated.   
 
At the time of recruitment, the research midwife extracted data (items 1-5 listed above) 
from the medical record.  The research midwife placed the relevant study documentation  
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Figure 3.2: Trial protocol 
Initial dose of PGE2 vaginal gel in the evening
Randomise 0530 next morning
Amniotomy group
Unable to ARM
2nd dose PGE2
Review in 6 hours
Unable to ARM 
3rd dose PGE2
Review in 6 hours
Regardless of Modified Bishops               
If able to ARM 
ARM
Commence Syntocinon
Regardless of Modified Bishops               
If able to ARM 
ARM
Commence Syntocinon
Repeat-PGE2 group
Modified Bishop's score ≥7
ARM
Commence Syntocinon
Modified Bishop's  <7                       
2nd dose PGE2
Review in 6 hours
Modified Bishop's score ≥7
ARM
Commence Syntocinon
Modified Bishop's  <7    
3rd dose PGE2
Review in 6 hours
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pack (PGE2 arm/ARM arm) in the medical record.  When the woman presented for IOL, 
the attending practitioner referred to the study documentation pack for details regarding 
the allocated induction process.  On day 2 or as soon as practical thereafter, the research 
midwife obtained data (see 3.6 Measurements) from the electronic maternity record 
system and, if necessary, perused the Birthing Suite and postnatal ward documentation.   
Healthcare experience was determined by using the previously described questionnaire, 
administered by a different research officer (blinded to treatment allocation) by phone at 
approximately 7 days post-birth. 
 
3.10 Patient safety 
A Data Safety Monitoring Committee was established to provide safety data monitoring.  
Mater Research convened this Committee comprising a clinical advisor, a statistician and 
an epidemiologist. The DSMC met prior to commencement of recruitment to decide the 
measures of maternal/neonatal morbidity to be reviewed at the time of interim analysis and 
the criteria for stopping.  The DSMC defined the adverse events (AE) and serious adverse 
events (SAE) to be reported, the procedures for reporting, reporting timeframes and follow-
up.  The DSMC determined that all SAEs and AEs would be assessed for seriousness, 
expectedness and causality.  
 
A SAE was defined as any adverse event occurring during the study that resulted in:  
• Death 
• A life-threatening adverse event 
• Inpatient hospitalisation or prolongation of existing hospitalisation     
 
An AE was defined as any unfavourable and unintended sign, symptom, syndrome or 
illness that develops or worsens during the period of observation in the study. The 
following were considered adverse events:  
• Postpartum haemorrhage requiring blood transfusion 
• Admission of baby to neonatal critical care unit 
• Cord prolapse 
• Uterine hyperstimulation with fetal heart rate changes, requiring removal of PGE2 
vaginal gel and/or administration of acute tocolysis 
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The DSMC undertook a planned interim analysis (after 125 women had been enrolled). At 
the time of the analysis, the incidences of significant maternal / neonatal morbidity 
comprising SAEs and/or AEs were critically reviewed and a decision made to continue the 
trial.   
 
3.11 Sample size 
Based on the Primary Outcome Measure (time from IOL-to-birth) a sample size of 250 was 
calculated as sufficient to detect a difference of 5 hours (20.5 hours to 15.5 hours) in the 
time from 1st dose PGE2 vaginal gel until birth, with a power of 80% and a type 1 error of 
0.05.   
 
Whilst not Primary Outcome Measures, additional sample size calculations were 
performed, concluding that a sample of 250 women would also be able to detect  
• a 19% increase in proportion of in-hours births (from 25% to 44%; with a power of 
80% and a type 1 error of 0.05)  
• as small as a 14% difference in the overall satisfaction with healthcare experience 
(69% versus 84%; with a power of 80% and a type 1 error of 0.05),  
• at least a $285 difference in total healthcare costs associated with the labour and 
birth episode of care (with a power of 80% and a type 1 error of 0.05). 
 
These assumptions are based on the observed outcomes following the introduction of a 
policy change at Mater Health Services and Bundaberg Base Hospital.  The policy change  
from giving repeat doses of PGE2 vaginal gel, to one of performing an amniotomy once 
technically possible was associated with a 5-6 hour reduction in the time from IOL-to-birth 
[164-166].  The baseline maternal satisfaction data were derived from an analysis of 1438 
women’s experience of IOL in Queensland in “The Having a baby in Queensland Survey 
2009” [167].  The baseline costing assumptions are based on an analysis of ward bed-day 
costs from the Mater patient costing system, which has ascribed a monetary value of $624 
to each saved OBD in an antenatal ward [168].   
 
Over the period 2010-2013, an average of 5420 publically funded women gave birth at 
Mater Mothers Hospital annually, and of these 24% underwent an IOL.  PGE2 vaginal gel 
was used for IOL for women with singleton pregnancies at ≥37 weeks 0 days accounted 
for just under 70% of IOLs during this time [169].  Therefore approximately 2400 publically-
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funded women underwent a PGE2 vaginal IOL at term at Mater Mothers Hospital during 
the period of the study.  Of these, approximately 2000 women were eligible for recruitment, 
267 were approached and 250 women consented to being involved in the trial, 
representing approximately 12% of all eligible women.  Whilst this limits the generalizability 
of the findings, the study has compared two commonly practiced protocols of PGE2 
vaginal gel IOL; care has been provided by a team of midwives, junior and senior doctors 
which is similar to the model of care in many maternity services around the world; the 
primary and secondary outcome measures are meaningful to clinicians, women and 
policy-makers.     
  
3.12 Statistical methods 
Descriptive analyses have initially been undertaken to report on the study participant 
groups, ensuring comparability of the groups following randomisation.  In this analysis 
demographic and other baseline characteristics were compared, to identify any important 
baseline differences needing to be controlled for, using multivariate analysis.  Analysis of 
primary and secondary outcomes has been by intention-to-treat (ITT), comparing the two 
study groups, but also reported as as-per-protocol.  Data from women who withdrew their 
consent has not been included in the analysis.   
 
The Chi squared tests, Fisher exact, independent samples t-tests and Mann-Whitney U 
tests have been used to compare categorical, categorical (small cell numbers), normally 
distributed, and non-normally distributed continuous outcomes, respectively.  There were 
no imbalances in baseline characteristics or demographics that required adjustment.    The 
level of significance for the primary outcome measures is set at 0.05 and Bonferroni 
adjustment for multiple comparisons has been used for secondary outcome measures. 
 
Specific details of the statistical methods used for each of the analyses addressing 
prediction, healthcare experiences and costs have been included in the Methods 
paragraphs in each relevant Chapter 
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3.13 Ethical aspects 
The study was conducted in full conformance with principles of the “Declaration of 
Helsinki”.  Informed consent was obtained in a non-acute setting, days to weeks prior to 
the birth.  The protocol and accompanying material was submitted to the Mater Human 
Research Ethics Committee, and Mater Research Governance Office, and approval 
obtained and documented in a letter to the Lead Investigator.    
 
A protocol modification pertaining to recruitment of participants was made after 
consultation between the investigators and was submitted to the Mater HREC.   
 
The investigators maintained all patients’ anonymity and their identities have been 
protected. On the case report forms, patients were de-identified by being assigned a study 
number and the record of only the first two letters of their first name and last two letters of 
their surname.  All decisions regarding presentations and manuscripts have been made by 
the Candidate and his supervisory team.  Authorship of all abstracts and manuscripts has 
been determined by mutual agreement. 
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Chapter 4 Clinical outcomes 
 
 
 
The material detailed in this Chapter has been:  
 
a) Presented at the 2015 RCOG World Congress, Brisbane 
b) Published in the American Journal of Obstetrics and Gynecology [170] 
 
4.1 Background 
In Australia, more than 25% of women undergo IOL.  The most common method of IOL is 
cervical priming with vaginal Prostaglandin (PGE2), then artificial rupture of membranes 
(ARM) followed by an oxytocin infusion [61].  It is well established that in commencing an 
IOL, cervical priming of an unripe cervix is of value [62].  However clinical practice 
guidelines [47, 79-82] provide no evidence-based recommendations regarding subsequent 
dosage and frequency of PGE2 vaginal gel for women undergoing the commonest method 
of cervical priming.   There is very little objective data of the value of repeated dosing of 
PGE2 vaginal gel.  The single randomised controlled trial that addressed this question 
[78], reported no difference in any outcomes, however no attempt was made to commence 
labour with an ARM and oxytocin infusion until 14-20 hours after the first dose of PGE2 
vaginal gel, irrespective of how many doses were administered.    
 
This Chapter investigates two different policies for IOL using PGE2 vaginal gel.  Using the 
results of a randomised controlled trial comparing the two policies, this Chapter aims to 
determine which policy of PGE2 vaginal gel IOL results in the shorter IOL-to-birth 
time and is associated with lower rates of obstetric intervention and morbidity.  The 
outcomes for women undergoing PGE2 vaginal gel IOL following a policy of amniotomy 
once technically possible (regardless of MBS), or a policy of giving more PGE2 vaginal gel 
(repeat administration and amniotomy only when MBS ≥7) have been compared.     
 
Determining which of the two IOL policies results in the shorter IOL-to-birth time has 
been assessed by measuring and comparing the time intervals  
• Between 1st dose PGE2 and ARM 
• Between ARM and birth 
• Between 1st dose PGE2 and birth 
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The rate of obstetric intervention and morbidity associated with the two IOL policies 
has been assessed by recording maternal outcomes such as: 
• Mode of birth  
• Need for broad-spectrum antibiotics in labour (as a surrogate marker of 
chorioamnionitis)  
• Post-partum haemorrhage (defined as estimated blood loss >500ml)  
 
The relevant perinatal outcomes comprised: 
• Uterine hyperstimulation with fetal heart rate changes, requiring removal of PGE2 
vaginal gel and/or administration of acute tocolysis  
• Admission to Special Care or Intensive Care Nurseries  
• Duration of nursery admission 
 
The concept of an “in-hours” birth has been used as one measure of both duration of IOL 
and safety, and is defined as birth occurring between 08:00am and 5:00pm.   
 
The Chapter tests the following research hypothesis for women undergoing IOL using 
PGE2 vaginal gel:  A policy of amniotomy once technically possible compared with a policy 
of giving more PGE2 vaginal gel will result in a reduction in the IOL-to-birth time, and a 
greater number of “in hours” births. 
 
In addition, the Chapter addresses the following secondary aim: To explore if a policy of 
amniotomy once technically possible compared with a policy of giving more PGE2 vaginal 
gel is associated with differences in the rates of obstetric intervention (operative delivery, 
epidural), or adverse maternal / perinatal outcomes (including estimated blood loss > 
500ml, use of antibiotics in labour, admission to nursery, uterine hyperstimulation). 
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4.2 Methods 
A randomised controlled trial comparing two policies of PGE2 vaginal gel IOL was 
undertaken between March 2010 and August 2013.  Over the 41 months of the trial, 2057 
women were eligible for inclusion, and 267 women were approached by the medical officer 
on the evening of their IOL.    Sealed opaque envelopes were prepared and 250 were 
opened however data is only available for 245 eligible women who consented and were 
randomised the morning following commencement of their IOL using PGE2 vaginal gel.   It 
is not known why these 5 additional envelopes were opened and this was not recognized 
until recruitment was ceased.  Of the 245 women who were randomised, 124 were 
allocated to the repeat-PGE2 group and 121 to the amniotomy group.   The flow of 
participants is presented in the CONSORT diagram below (Figure 4.1).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 CONSORT diagram 
Eligible (n=2057) 
Excluded  (n=1834) 
   Declined to participate (n=22) 
   Not approached (n=1812) 
Analysed  (n=124) 
 Excluded from analysis (n=0) 
Did not complete questionnaire (n=38) 
Discontinued intervention (n=0) 
 
Allocated to repeat-PGE2 group (n=124) 
 Received allocated intervention (n=120) 
 Did not receive allocated intervention (n=4) 
(spontaneous labour after randomisation) 
Did not complete questionnaire (n=37) 
Discontinued intervention (n=0) 
 
Allocated to amniotomy group (n=121) 
 Received allocated intervention (n=120) 
 Did not receive allocated intervention (n=1) 
(spontaneous labour after randomisation) 
Analysed  (n=121) 
 Excluded from analysis (n=0) 
 
Allocation 
Analysis 
Follow-Up 
Randomized (n=245) 
Enrolment 
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Complete baseline demographic and clinical information as well as clinical outcome data 
are available for all 245 participants.  A small number of women in each group (4 in repeat-
PGE2 group and 1 in amniotomy group) went into spontaneous labour after randomisation 
but prior to administering the first dose of PGE2.  Data have been analysed and presented 
by ‘intention-to-treat’ (ITT), however it is also presented ‘as-per-protocol’.  Overall, a 
protocol violation was identified in 39% of cases, with more protocol violations occurring in 
the repeat-PGE2 group than in the amniotomy group (65 versus 36).  Many protocol 
violations represent a delay to undertake a review, or delay to commence an oxytocin 
infusion.  Whilst these women were part of a randomised controlled trial, the clinical 
activity in the birth suites, and the need to bring women back and forth to birth suite for 
multiple IOL reviews, added delays to the patient journey and prevented staff from being 
always able to provide care according to study protocol.  In the absence of an agreed 
standard, “>4 hour delay” was chosen as the discriminator as to whether a protocol 
violation had occurred.  This represents the consensus view of an unacceptable delay 
from a group of senior obstetricians and midwives. 
 
More specifically, the criteria applied to determine a protocol violation are: 
 
a) Repeat-PGE2 group (n=61 protocol violations) 
1) Following initial PGE2 dose, >4 hour delay to undertake first review (n=29) 
Study protocol and hospital policy states PGE2 is administered between 1700 - 1900 
and review at approximately 0530 the following morning (~12 hours later).  Review at 
16 hours or more was therefore considered a protocol violation 
 
2) Following subsequent doses of PGE2, >4 hour delay to undertake next review 
(n=11) 
Study protocol and hospital policy states subsequent review will occur 6 hours later.  
Review at 10 hours or more was therefore considered a protocol violation 
 
3) Following ARM, >4 hour delay to commence an oxytocin infusion (n=10) 
Study protocol and hospital policy states an oxytocin infusion is recommended to 
commence as soon as possible after ARM 
 
4) Failure to perform ARM at any review when the MBS ≥ 7 (n=0) 
Study protocol was for ARM to be performed in repeat-PGE2 group once MBS ≥ 7    
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5) Performing ARM at 2nd or 3rd review when the MBS < 7 (n=32) 
Study protocol was for more PGE2 to be administered in repeat-PGE2 group until MBS 
≥ 7    
 
 
b) Amniotomy group (n=35 protocol violations) 
1) Following initial PGE2 dose, >4 hour delay to undertake first review (n=25) 
Study protocol and hospital policy states PGE2 is administered between 1700-1900 and 
review at approximately 0530 the following morning (~12 hours later).  Review at 16 
hours or more was therefore considered a protocol violation 
 
2) Following subsequent doses of PGE2 (if indicated), >4 hour delay to undertake 
next reviews (n=4) 
Study protocol and hospital policy states subsequent review will occur 6 hours later.  
Review at 10 hours or more was therefore considered a protocol violation 
 
3) Following ARM, >4 hour delay to commence an oxytocin infusion (n=2) 
Study protocol and hospital policy states an oxytocin infusion is recommended to 
commence as soon as possible after ARM 
 
4) Administering more PGE2 vaginal gel at 2nd or 3rd review when the MBS ≥5 
(n=4) 
Study protocol was for ARM to be performed in amniotomy group once technically 
possible.  Based on both the South Australian [80] and Victorian Guidelines [81] and a 
consensus view of senior Mater Obstetricians and Midwives, it is assumed that an 
experienced midwife or doctor attempting to perform ARM would be able to perform an 
ARM once MBS ≥5    
 
 
 
4.3 Results  
 
The baseline characteristics of women randomised to the repeat-PGE2 group and 
amniotomy group did not differ with respect to age, BMI, gestation at IOL, ethnicity, or 
indication for IOL, either overall or in the sub-group of those treated as-per-protocol.  Most 
women were Caucasian with a mean booking BMI in the overweight range.  The 
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commonest induction for PGE2 IOL was “post-term”, and more than 80% of IOLs were 
performed for an identifiable clinical indication.  (Table 4.1).  In addition, the baseline 
characteristics of the 1812 eligible women who were not approached was analysed and 
confirmed to be similar to the study participants.  (Table 4.2).   
 
 
Table 4.1 Baseline characteristics: intention-to-treat and as-per-protocol  
 
a presented as mean (standard deviation) 
 
  
Baseline 
Characteristic 
Intention-to-treat  
n (%) 
As-per-protocol 
n (%) 
Amniotomy 
group 
Repeat-
PGE2 
group 
p-
value 
Amniotomy 
group 
Repeat-
PGE2 
group 
p-
value 
Age (years) a 29.3 (5.2) 29.8 (4.8) 0.391 28.8 (5.0) 29.2 (4.4) 0.673 
BMI (kg/m2) a 26.6 (5.9) 26.9 (6.2) 0.735 26.8 (6.5) 26.3 (5.9) 0.657 
Nulliparity 92 (76.0%) 93 (75.0%) 0.149 61(70.9%) 47 (74.6%) 0.246 
Gestation (weeks) a 40.1 (1.5) 40.3 (1.4) 0.351 40.1 (1.5) 40.5 (1.4) 0.058 
Ethnicity 
  Caucasian 
  Asian 
  ATSI 
  Pacific Island/Maori 
  Other 
 
93 (76.8%) 
10 (8.3%) 
2 (1.7%) 
4 (3.3%) 
12 (9.9%) 
 
86 (69.4%) 
14 (11.3%) 
3 (2.4%) 
4 (3.2%) 
17 (13.7%) 
 
 
 
 
 
0.854 
 
69(80.2%) 
6 (7.0%) 
2 (2.3%) 
1 (1.2%) 
8 (9.3%) 
 
43 (68.3%) 
9 (14.3%) 
1 (1.6%) 
0 (0%) 
10 (15.8%) 
 
 
 
 
 
0.313 
Indication for IOL 
  Post-term 
  Diabetes  
  Hypertension 
  Isoimmunisation 
  Suspected SGA/FGR 
  Cholestasis 
  APH 
  Social 
  Other  
 
64 (52.9%) 
20 (17.0%) 
6 (5.0%) 
0 (0%) 
4 (3.3%) 
5 (4.1%) 
0 (0%) 
3 (2.5%) 
19 (15.7%) 
 
68 (54.8%) 
20 (16.1%) 
10 (8.1%) 
1 (0.8%) 
1 (0.8%) 
5 (4.0%) 
0 (0%) 
2 (1.6%) 
17 (13.7%) 
 
 
 
 
 
 
 
 
 
0.757 
 
43(50.0%) 
16(18.6%) 
4 (4.7%) 
0 (0%) 
5 (5.8%) 
4 (4.7%) 
0 (0%) 
3 (3.5%) 
12(14.0%) 
 
39 (61.9%) 
9 (14.3%) 
4 (6.3%) 
1 (1.6%) 
1 (1.6%) 
3 (4.8%) 
0 (0%) 
2 (3.2%) 
4 (6.4%) 
 
 
 
 
 
 
 
 
 
0.553 
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Table 4.2 Baseline characteristics: eligible women who were recruited and not recruited 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a presented as mean (standard deviation) 
 
The morning after an initial dose of PGE2 vaginal gel, 10.0% of those randomized to the 
amniotomy group, and 12.8% of those randomized to repeat-PGE2 group had a 
favourable cervix (MBS ≥7).  Of the women randomized to the amniotomy group, most 
(80.8%) received just a single dose of PGE2 vaginal gel, 15.0% received 2 doses, 4.2% 
received 3 doses, and 89% were administered an oxytocin infusion.  Of the women 
randomized to the repeat-PGE2 group, only 36.7% received a single dose of PGE2 
vaginal gel, 47.5% received 2 doses, 15.8% received 3 doses, and a similar proportion 
(87%) were administered an oxytocin infusion.  The infusion was commenced immediately 
(within 30 minutes of ROM) for a similar proportion of women in the amniotomy and repeat 
PGE2 groups (20.4% versus 21.4%), and the mean time from ROM until commencement 
of oxytocin was also similar (1.3 versus 1.7 hours).   
 
Baseline 
Characteristic 
Eligible for recruitment 
n (%) 
Recruited 
n=245 
Not recruited 
n=1812 
p-value 
Age (years)a 29.5 (4.9) 29.7 (5.8) 0.477 
BMI (kg/m2)a 26.7 (6.3) 26.0 (7.0) 0.178b 
Nulliparity 185 (75.5%) 1268 (70.0%) 0.087 
Gestation (weeks)a 40.1 (1.4) 39.9 (1.4) 0.314b 
Ethnicity 
  Caucasian 
  Asian 
  ATSI 
  Pacific Islander/Maori 
  Other 
 
179 (73.1%) 
24 (9.8%) 
5 (2.0%) 
8 (3.3%) 
29 (11.9%) 
 
1168 (64.5%) 
344 (19.0%) 
41 (2.3%) 
48 (2.7%) 
211 (11.6%) 
 
 
 
 
 
0.217 
Indication for IOL 
  Post-term 
  Diabetes  
  Hypertension 
  Isoimmunisation 
  Suspected SGA/FGR 
  Cholestasis 
  APH 
  Social 
  Other  
 
132 (53.9%) 
40 (16.3%) 
16 (6.5%) 
1 (0.4%) 
5 (2.0%) 
10 (4.1%) 
0 (0%) 
5 (2.0%) 
36 (14.7%) 
 
853 (47.1%) 
215 (11.9%) 
198 (10.9%) 
7 (0.4%) 
67 (3.7%) 
63 (3.4%) 
11 (0.6%) 
167 (9.2%) 
232 (12.8%) 
 
 
 
 
 
 
 
 
 
0.123 
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1st dose 
PGE2
Review 
next 
morning
Membranes 
ruptured
Syntocinon 
infusion Birth
Discharge 
home
Time from 1st dose 
PGE2 to next review 
Time from ruptured 
membranes to birth 
Time from 1st dose PGE2 
to ruptured membranes 
Time from review after     
1st dose until birth 
Time from 1st dose 
PGE2 to birth 
Time from 1st dose 
PGE2 to discharge 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 4.1 illustrates the patient journey and the individual time measures that comprise 
the primary outcome measure, IOL-to-birth time.  The time between 1st dose PGE2 and 
birth represents the total duration of IOL. The analysis includes measuring the time 
between 1st dose PGE2 and ARM, time between the review after 1st dose and birth, and 
between ARM and birth.   
 
Overall, the time for IOL-to-birth was over 5 hours shorter in women randomised to the 
amniotomy group.  (Table 4.3).  This result was significant overall and in the sub-group of 
those treated as-per-protocol.  Following repeat doses of PGE2 there was a trend toward a 
1 hour shorter interval from ARM until birth.  However, a 1 hour shorter interval from 1st 
dose PGE2 to next review, and a 5-6 hour shorter interval between 1st dose PGE2 and 
rupture of membranes, contributed to the overall finding of a shorter IOL-to-birth time in 
women randomised to the amniotomy group.  Despite this shorter duration of IOL, the 
likelihood of an in-hours birth was no different between the groups.  In addition, the shorter 
IOL-to-birth time in the repeat-PGE2 group did not eventuate in a shorter overall length of 
hospital stay compared to women in the amniotomy group.      
 
 
 
 
Figure 4.2: Patient IOL journey 
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Table 4.3 IOL-to-birth time 
a presented as n (%) 
* p<0.05 
 
 
The clinical outcomes are presented in Table 4.4.  Although there were trends toward 
more vaginal births and fewer CS for women in the amniotomy group, there were no 
differences overall in the mode of birth.   Similarly, there were trends toward fewer failed 
IOLs in the amniotomy group, but there were no differences overall in the indications for 
CS.  In both the overall group and in the sub-group of those treated as-per-protocol, there 
were also no differences in the incidence of uterine hyperstimulation requiring removal of 
PGE2 vaginal gel and/or administration of acute tocolysis, use of epidural analgesia, need 
for broad-spectrum antibiotics in labour, postpartum haemorrhage and 3rd stage blood 
loss, or admission of the baby to nursery or days spent in the nursery.   
Time intervals 
Intention-to-treat 
mean (SD) 
As-per-protocol 
mean (SD) 
Amniotomy 
group 
Repeat-
PGE2 
group 
p-
value 
Amniotomy 
group 
Repeat-
PGE2 
group 
p-
value 
Between 1st dose 
PGE2 and birth  
24.8 (8.3) 30.0 (12.0) <0.001* 22.9 (8.3) 26.8 (10.8) 0.017* 
Between 1st dose 
PGE2 and next review 
12.4 (3.6) 13.7 (5.0) 0.015* 11.0 (2.0) 12.0 (3.1) 0.032* 
Between 1st dose 
PGE2 and ARM  
14.2 (5.3) 20.6 (9.6) <0.001* 12.4 (4.5) 17.8 (8.2) <0.001* 
Between review after 
1st dose and birth 
12.3 (7.2) 16.4 (10.1) <0.001* 11.6 (7.3) 17.0 (11.5) <0.001* 
Between ARM and 
birth  
Between oxytocin and 
birth  
 
9.9 (4.9) 
 
9.4 (4.1) 
8.7 (5.2) 
 
8.2 (4.8) 
0.060 
 
0.060 
9.7 (4.8) 
 
9.7 (4.1) 
8.0 (4.8) 
 
8.0 (4.4) 
0.025* 
 
0.015* 
Between 1st dose 
PGE2 and discharge 
home 
100.6 (32.4) 103.2 (32.6) 0.530 95.7 (33.4) 94.6 (30.1) 0.845 
In-hours birth a 
(0800-1700) 
51 (42.2%) 46 (37.1%) 0.419 41(47.7%) 30 (47.6%) 0.995 
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Table 4.4 Clinical outcomes 
a presented as mean (standard deviation) 
* p<0.05 
  
Clinical outcomes 
Intention-to-treat 
n (%) 
As-per-protocol 
n (%) 
Amniotomy 
group 
Repeat-
PGE2 
group 
p-
value 
Amniotomy 
group 
Repeat-
PGE2 
group 
p-
value 
Unassisted vaginal 
birth 
56 (46.3%) 55 (44.4%) 0.762 48(55.8%) 33 (52.4%) 0.678 
Instrumental birth 21 (17.4%) 23 (18.5%) 0.808 12(14.0%) 8 (12.7%) 0.824 
Caesarean section 
  CS for failed IOL 
  CS for fetal distress 
  CS for slow progress 
  CS for other reasons 
44 (36.4%) 
5 (4.1%) 
18 (14.9%) 
19 (15.7%) 
2 (1.7%) 
46 (37.1%) 
11 (8.9%) 
14 (11.3%) 
15 (12.1%) 
6 (4.8%) 
0.905 
 
 
 
0.384 
26(30.3%) 
4 (4.7%) 
9 (10.5%) 
12(14.0%) 
1 (1.2%) 
22 (34.9%) 
4 (6.4%) 
6 (9.5%) 
8 (12.7%) 
3 (4.8%) 
0.545 
 
 
 
0.787 
Use of epidural 
analgesia 
85 (70.8%) 81 (66.4%) 0.457 57(67.1%) 36 (59.0%) 0.319 
Broad-spectrum 
antibiotics  
17 (14.0%) 10 (8.1%) 0.135 12(14.0%) 4 (6.4%) 0.139 
Uterine 
hyperstimulation  
0 (0%) 0 (0%) n/a 0 (0%) 0 (0%) n/a 
3rd stage labour 
  Mean EBL (mls) a 
  EBL ≥ 500ml 
  EBL ≥ 1000ml 
 
423 (260) 
46 (38.0%) 
4 (3.3%) 
 
460 (348) 
46 (36.3%) 
10 (8.1%) 
 
0.490 
0.882 
0.167 
 
421 (253) 
32(37.2%) 
2 (2.3%) 
 
427 (251) 
22 (34.9%) 
4 (6.4%) 
 
0.892 
0.774 
0.242 
Admission to Special 
Care or Intensive 
Care Nurseries 
11 (9.1%) 10 (8.1%) 0.822 5 (5.8%) 3 (4.8%) 0.541 
Days in nursery a 4.8 (3.8) 4.3 (1.5) 0.698 5.2 (4.1) 3.3 (1.3) 0.478 
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4.4 Conclusions 
After an initial dose of PGE2 vaginal gel, most women do not have a favourable cervix.  
Administering more PGE2 is associated with an IOL-to-birth time that is more than 5 hours 
longer than performing an amniotomy, if at all possible.  Rupturing the membranes when 
the MBS was less than 7 was usually possible, it did not increase the need for an oxytocin 
infusion, it did not change the likelihood of a vaginal birth and it was not associated with 
more failed IOLs.  Whilst an earlier ARM resulted in a quicker induced labour and a greater 
chance of delivery within 24 hours, the likelihood of an in-hours birth was no different, and 
the overall duration of hospital stay was the same.  
 
There were no statistically significant differences in any of the clinical outcome measures.  
The trends generally favoured the amniotomy group with fewer instrumental births, fewer 
CS, fewer failed IOL, less blood loss and less PPH, but there were also trends towards 
more epidurals, more antibiotics in labour and more admissions of baby to nursery.  The 
trial was underpowered to detect these differences.  Based on the as-per-protocol 
analyses, a sample size of 6742 would be required to detect a 3.4% difference in the 
likelihood of an unassisted vaginal birth (55.8% versus 52.4%), or 3258 to detect a 4.6% 
difference in the likelihood of birth by CS (30.3% versus 34.9%).     
 
The primary action of PGE2 vaginal gel is on the ground substance of the cervix.  It 
increases the activity of colleganases and disperse collagen fibres and increase the water 
content of the cervix [100, 171].  In addition PG do increase intracellular calcium and so 
can sometimes cause myometrial contractions [172].  Both mechanical and hormonal 
methods for inducing labour are commonly used.  Mechanical methods can cause 
myometrial contractions too [45].  However, a mechanical method has been effective 
because it has become possible to rupture the membranes, and it is not deemed 
ineffective if the woman is not in labour.  Mechanical methods are therefore recognised as 
a strategy to ripen the cervix.  But there are differing opinions as to whether PGE2 vaginal 
gel is an induction agent or a cervical ripening agent.  Assuming PGE2 to be a drug that 
induces labour, the  RCOG-endorsed NICE guideline [47] recommends a second dose of 
PGE2 vaginal gel after 6 hours “if labour is not established”. Assuming PGE2 to be a drug 
that predominantly ripens the cervix, the ACOG IOL Guideline [147] recommends a 
second dose be administered if there is “inadequate cervical change.”   In broad terms, 
this study has compared the performance of PGE2 as an induction agent (i.e. giving up to 
3 PGE2 doses before rupturing the membranes) and as a cervical priming agent (i.e. 
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aiming to give a single dose of PGE2 and rupture the membranes as soon as possible).  
As an induction agent, PGE2 performed poorly.  The research protocol described that 
oxytocin be recommended to women following ruptured membranes “in the absence of 
uterine activity”.  However, only 7 out of 124 women who received repeated PGE2 dosing 
spontaneously ruptured their membranes and laboured without oxytocin.  Furthermore, 
women in the repeat-PGE2 group had a 5 hour longer IOL-to-birth time, and without any 
difference in maternal or perinatal morbidity, uterine hyperstimulation, or the likelihood of 
birth by CS.  The findings would support the argument that PGE2 vaginal gel is most 
effective as a cervical ripening agent where, like mechanical methods of IOL, priming of 
the cervix should be followed by an ARM (and oxytocin infusion) once it is technically 
possible to do so.    
 
In exploring further the differences in IOL-to-birth time, it is interesting to observe that the 
time from ARM to birth, and also oxytocin to birth, was not appreciably different between 
the two groups (mean difference 1.3 hours).  The differences in IOL-to-birth time did not 
reflect differences in when the oxytocin infusion was commenced either.  Administering 
more PGE2 did not make the ensuing labour significantly quicker nor did it alter the 
likelihood of birth by CS.  The shorter IOL-to-birth time in the amniotomy group, chiefly 
reflects differences during the period prior to ARM.  Whilst it is acknowledged that the 
primary outcome measure (IOL-to-birth time) is a measurement that begins prior to 
randomization, the alternative outcome measure, “time from randomization until birth”, also 
strongly favoured the amniotomy group.  Randomization occurred immediately prior to the 
morning cervical assessment, as a strategy to limit the number of participants who might 
have ruptured their membranes, laboured or birthed prior to their treatment allocation.  
There was some variation in the time of this morning review and it was observed that 
fewer women in the amniotomy group had a favourable cervix (10.0% versus 12.8%) at 
this time.  Had this morning review happened at the same time in both groups, it is 
plausible that more women in the amniotomy group would have had a favourable cervix 
and the shorter duration of time from randomization-to-birth (and also IOL-to-birth) for 
women in the amniotomy group may have been even more exaggerated. 
 
Whilst the labour is quicker when induced with a single dose of PGE2 then ARM, the 
likelihood of an in-hours birth is no different, and the overall duration of hospital stay is the 
same.  Hospitals only rarely discharge patients outside of normal business hours [173].    
Postnatal length-of-stay is counted in “days” not hours since birth, and clinical pathways 
direct a woman’s postnatal course based on a set of expected outcomes achieved on each 
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day post-birth.  Considering that more than 50% of women being induced gave birth 
outside of normal business hours, it is unlikely that the 5 hours “saving” in duration of 
labour would directly translate into a 5-hour shorter length of hospital stay.  But had more 
births following IOL happened during the daytime, it is likely that a reduction in total length-
of-stay of much more than 5 hours would be demonstrated.  To explore this further, the 
IOL-to-birth time, time of birth, and total length-of-stay data were examined more closely. 
 
The mean total length of hospital stay for all women participating in the study and 
undergoing PGE2 IOL was 101.9 hours.  Compared to those women who delivered in-
hours, those who were induced and gave birth out-of-hours had a similar IOL-to-birth time 
(28.8 versus 25.2 hours) however their length of hospital stay that was almost 11 hours 
longer (106.2 versus 95.4 hours).   A cohort of women who gave birth in-hours were then 
matched 1:1 with a cohort who gave birth after-hours.  The records of 90 women were able 
to be matched for parity, mode of birth and IOL-to-birth time.  (Table 4.5).  In this post-hoc 
analysis, despite having a similar duration of labour, an in-hours birth was associated with 
a hospital length-of-stay that was 20 hours shorter (89.9 versus 110.6 hours) than an after-
hours birth.   
 
 
Table 4.5 In-hours versus after-hour births and differences in length of hospital stay (post-hoc 
analysis) 
 
 
a presented as n (%) 
* p<0.05 
 
The time of birth may directly impact how clinicians apply the postnatal clinical pathway.  
An in-hours “afternoon birth” is likely to be considered the first post-natal day.  Following a 
Measurement 
In hours birth 
mean (SD) 
After hours birth 
mean (SD) 
p-value 
Birth by CS a 18 (40.0%) 17 (37.8%) 0.829 
Nulliparity  a 37 (82.2%) 37 (82.2%) 0.99 
Between 1st dose PGE2 and birth 
(hours) 
25.4 (10.6) 25.3 (8.6) 0.976 
Between 1st dose PGE2 and 
discharge home (hours) 
89.9 (31.1) 110.6 (24.6) <0.001* 
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vaginal birth, a morning hospital discharge would then be expected / planned after 2 
nights’ accommodation.   An out-of-hours “evening birth” may occur just a few hours later, 
yet it is unlikely to be counted as the first post-natal day.  In this context, hospital discharge 
would still be expected / planned after 2 nights’ accommodation, but this would be counted 
from the first postnatal day.  It is therefore hypothesised that an in-hours birth aligns with 
hospitals’ morning discharge practices and maximises the chances of a shorter hospital 
length-of-stay.  Whilst there may be several other explanations for the post-hoc analysis 
finding of a significantly shortened length-of-stay, it is not explained by differences in 
parity, mode of birth, or duration of labour.   
 
An in-hours birth may have significant benefits in terms of the total length-of-hospital–stay.  
However, birth between 08:00 am and 5:00 pm was an uncommon outcome in this study.  
Women randomised to the amniotomy group experienced, on average, a 5-hour shorter 
labour than those in the repeat-PGE2 group, but fewer than half of women actually gave 
birth in-hours.  Examining the protocol violation data, the single largest contributor to 
protocol violations (in both the amniotomy and repeat-PGE2 groups) was the delay to 
undertake the first review post PGE2 administration.  More than 20% of the time the 
morning review was delayed for more than 4 hours.  The reasons for the delay may 
include a lack of recognition by clinical staff of the value of achieving an in-hours birth, 
reluctance of staff to take on new work prior to shift-change, or a lack of available clinical 
rooms, reflecting the busyness of the birth suite at the appointed time of the PGE2 review.  
In the birth suite there is both scheduled and unscheduled clinical work.  It is not possible 
to always utilise every room, and there is a need to maintain an overall lower utilisation 
rate of rooms in order to accommodate the unscheduled work [174].  As there are peaks 
and troughs in birth suite activity, there are corresponding peaks and troughs in availability 
of clinical rooms to proceed with IOLs.  It is also plausible that the running of the RCT 
itself, impeded the ability of staff to undertake the PGE2 review at the desired time.  The 
RCT necessitated the running of two simultaneous protocols of care for women 
undergoing PGE2 IOL, it increased clinical variability, and so likely reduced efficiency.  For 
example, larger numbers of women required more PGE2 and therefore a clinical room in 
which to be examined and CTG monitoring undertaken.  Unexpectedly, a 1-hour difference 
in the time from 1st dose PGE2 until next review was observed between the two groups 
(12.4h versus 13.7h; p=0.015).  Documented hospital policy at the time recommended an 
ARM be attempted at the next review.  Therefore, this shorter time from 1st dose PGE2 
until next review may reflect the preferential treatment given to women in the amniotomy 
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group by the senior clinicians in birth suite, complying with hospital policy and 
endeavouring to manage an effective and efficient clinical unit.  Irrespective of the reason 
for delay, when women in the amniotomy group were reviewed before 06:00 am (as 
outlined in the trial protocol and hospital policy) they had a much higher likelihood of an in-
hours birth compared to those who were reviewed after 06:00 am (63.0% versus 38.4%) 
and a correspondingly shorter length of hospital stay (91.0 versus 103.6 hours).   This 
underscores the pivotal role of the first PGE2 review in achieving a timely and efficient 
induction process.   
 
The risk of bias associated with this trial protocol is low.  Random sequence generation 
was utilised, and allocation concealment was maintained through the use of sequentially 
numbered opaque envelopes.  This was an un-blinded trial and compared two approaches 
to PGE2 vaginal gel IOL in a hospital where one of these approaches was hospital policy. 
This raises the question of a performance bias, however several pre-trial clinical audits 
demonstrated poor compliance with policy, and a high degree of variation in practice.      
The primary outcome measure was unambiguous minimising the risk of ascertainment 
bias.  Outcome assessment was completed by a research midwife not involved in clinical 
care, blinded to the treatment allocation; there was minimal attrition.  Although 92% of 
women who were approached consented to be involved in the trial, only 12% of potentially 
eligible women were approached.  With only a small seeding grant, it was necessary for 
recruitment and consent to be undertaken by the birth suite Registrar, and frequently their 
clinical workload precluded timely review of women prior to commencement of their IOL.  
Having analysed and confirmed the similarity in baseline characteristics of those who were 
and were not approached, it is considered that the risk of selection bias is nevertheless 
small.  This assumption is further supported by the observation that the CS rate amongst 
those who were not approached was similar to trial participants (37.0% versus 36.7%).           
 
The high numbers of protocol violations do bring into question the internal validity of the 
findings, albeit that in many clinical trials an ‘ideal’ intention to treat analysis is not possible 
[175, 176].  ITT analyses are considered the methodological gold-standard, however in the 
setting of large numbers of protocol violations, the analysis tends to weaken any observed 
treatment effect size, as it inadequately demonstrates the effect of treatment received.  
The per protocol analyses introduce selection bias [177] yet they provide a ‘real life’ insight 
into the effectiveness and efficacy of the protocols [178].  Ideally, studies should report 
results following both analyses to enable robust assessment of the intervention in a 
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‘controlled’ and a ‘practical’ setting [179].  By both analyses, the study findings are 
consistent and the effect size is similar hence the observation that a policy of amniotomy 
once technically possible leads to a shorter induced labour is likely to be credible   Both 
the low percentage of women who were approached and the high numbers of protocol 
violations likely reflect the challenges facing maternity services in performing clinical trials 
and in trying to undertake IOLs in a timely manner.     
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4.5 Chapter Summary 
PGE2 vaginal gel is an effective agent to ripen the cervix.  When the intention is to use a 
single dose (prior to an ARM and oxytocin infusion), it is associated with a significantly 
shorter IOL-to-birth time compared with using multiple doses of PGE2.  Repeat dosing of 
PGE2 in the hope of starting contractions and/or making the cervix “very favourable” has 
no demonstrable clinical benefits over a single dose.   
 
Large numbers of women were unable to be reviewed after their first dose PGE2 within an 
acceptable timeframe.  Although the undertaking of a RCT may have negatively impacted 
the efficiency of birth suites, there remains a significant challenge for hospitals and health 
services to conduct IOLs in a timely manner, and maximise the likelihood of in-hours birth.  
Nevertheless, there is the potential for significant cost savings if this goal could be 
consistently achieved. 
 
Following an analysis of the clinical outcomes of this RCT, there are a number of 
unanswered questions:  
 
1. Do women prefer a shorter IOL-to-birth time, oxytocin immediately after ARM, an in-
hours birth, earlier ARM?  Is the examination following repeat PGE2 vaginal gel 
dosing more unpleasant / uncomfortable than attempting to rupture the membranes 
when the cervix is less favourable? 
 
2. Is a policy of amniotomy once technically possible (regardless of MBS), associated 
with cost savings?  Are there demonstrable cost savings associated with a shorter 
IOL-to-birth time, or are the savings only realised if there is a reduction in total 
hospital length-of-stay? 
 
3. Are there some women who would benefit from repeat PGE2 dosing?  Are these 
results likely to be influenced by parity, age, BMI, MBS, indication for IOL? 
 
4. What are the barriers to timely review following first dose PGE2 vaginal gel? 
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Chapter 5 Prediction  
 
The material detailed in this Chapter has been has been:  
a) Presented at 2016 RCOG World Congress, Birmingham (and awarded best 
presentation in stream) 
b) Published in the Australian New Zealand Journal of Obstetrics and Gynaecology 
[180] 
 
5.1 Background 
There are both non-modifiable and potentially-modifiable factors that may influence the 
outcomes following IOL.  IOL is more likely to be successful in multiparous women [87-90], 
in taller women [90, 91], in younger women [89], and in women with a lower BMI [13, 90, 
92-94], and less likely to be successful where baby has a higher birth weight [13, 93] or is 
in a persistent occipito-posterior position [87, 95].  The degree of cervical ripeness has 
been consistently recognized as one of the most important predictors of induction success 
and mode of birth outcomes [83, 92, 99].    Whilst there is nil or limited capacity to modify 
these factors at the time when the decision is made to commence an IOL, there is the 
potential that the outcomes following IOL using different methods, may be different in 
different patient cohorts.  In other words, certain methods or protocols of IOL in specific 
patient groups may be associated with fewer failed IOLs, more in-hours births and shorter 
IOL-to-birth times.   
 
According to the NICE Guideline on Induction of Labour [47],  Prostaglandin E2 (PGE2) 
vaginal gel is the preferred method of IOL.  In Australia [79-82], the United States [147] 
and the United Kingdom [47], clinical practice guidelines provide no evidence-based 
recommendations regarding dosage and frequency of PGE2 vaginal gel for cervical 
priming.  A standard approach is taken where the woman’s parity dictates the initial dose 
of PGE2 vaginal gel that is administered.  However, neither the MBS nor any other clinical 
characteristic is considered when prescribing the initial or subsequent doses of PGE2 
vaginal gel.  It is likely that a more tailored approach to the use of PGE2 vaginal gel may 
result in superior outcomes for some women being induced.    
 
This Chapter builds upon the previous Clinical Outcomes Chapter, using the data from a 
randomised controlled trial comparing two policies of PGE2 vaginal gel IOL.  The objective 
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is to determine if factors such as parity, age, BMI, MBS, and gestation predict clinical 
outcomes following PGE2 vaginal gel IOL.  In doing so, it may then be possible to identify 
the clinical characteristic(s) of women who would benefit from a amniotomy once 
technically possible (and regardless of the MBS) as opposed to giving more PGE2 vaginal 
gel (and performing an amniotomy only when MBS is greater than or equal to 7).   
 
The Chapter tests the following research hypothesis for women undergoing IOL using 
PGE2 vaginal gel:  Parity, age, BMI, MBS, and gestation are predictive of IOL-to-birth-
time, likelihood of “in-hours birth”, and mode of birth 
 
In addition, the Chapter addresses the secondary aim: To define the indications for 
adopting a policy of amniotomy once technically possible versus a policy of giving more 
PGE2 vaginal gel, by identifying the clinical characteristics (parity, age, BMI, MBS, and 
gestation) that predict superior IOL outcomes (shorter IOL-to-birth-time, an “in-hours birth”, 
and vaginal birth) with each policy.   
 
5.2 Methods 
A randomised controlled trial comparing two common approaches to PGE2 vaginal gel IOL 
was undertaken between March 2010 and August 2013.  The data from all 245 
participants were used to develop the multivariate prediction models.  The data were 
complete with the exception of MBS at first review.  This variable was incomplete for 11 
women who spontaneously laboured before first review, 1 woman who was delivered by 
CS soon after administration of the first dose of PGE2 vaginal gel, and 5 other women 
where this was not recorded.  Missing data for MBS at first review were similar in 
amniotomy group (6.6%) and repeat PGE2 group (7.3%); women who did (6.6%) and did 
not (7.1%) have a CS; and those who did (7.6%) and did not (6.6%) experience a vaginal 
delivery within 24 hours (VD < 24h).        
 
The primary outcome measure for this analysis was a vaginal delivery within 24 hours 
of commencement of IOL.  A clinically important measure of the effectiveness of IOL, VD 
< 24h was the primary outcome measures reported in each of nine published Cochrane 
reviews on methods of IOL.  In addition, separate analyses using the outcomes of 
caesarean section, in-hours delivery (08:00-17:00), and IOL-to-birth time have been 
reported as secondary outcome measures.   
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Bivariate analyses were carried out initially to compare demographic and clinical 
characteristics and outcomes for those who did and did not experience the outcomes of 
interest, in order to identify potential confounders and predictors for inclusion in the 
multivariate analyses. Proportional data were compared using the chi-squared and 
Fisher’s-exact test, and continuous data were compared using Student’s t-test (normal 
distribution) and Mann Whitney U test (non-normal distribution).  Continuous data was 
tested for normality by graphical interpretation (histogram). 
 
To determine the factors associated with each of the outcome measures, multivariate 
logistic and linear regression models were constructed including the predictors of interest 
identified from the literature review (parity, age, BMI, gestation, MBS at start of IOL, MBS 
at first review), as well as the PGE2 vaginal gel policy to which the woman was allocated.  
To meet the assumptions of logistic regression, the non-normal distribution of BMI was 
addressed by using its inverse, and normal distribution subsequently confirmed by 
graphical interpretation (histogram).  Using a discriminatory p-value < 0.25 [181], no 
additional potential confounder variables were identified from the bivariate analyses.  
Assumptions of logistic regression were tested and met.   Goodness-of-fit was assessed 
by the Hosmer–Lemeshow test (logistic regression) and adjusted R2 (linear regression).  
The discriminatory ability of the model was determined by area under the receiver–
operating characteristics curve (AUROC). Adjusted odds ratios (aOR) and 95% confidence 
intervals (CI) are presented. 
 
The robustness of the model predictive of a VD < 24h was then tested by comparing 
AUROC across multiple sub-groups, stratifying by PGE2 vaginal gel policy, parity, 
ethnicity, IOL indication, and MBS.  Finally, using the regression equations, a modelling 
exercise was undertaken to explore the relationship between the independent predictor 
variables and the primary and secondary outcome measures.  
 
        
5.3 Results  
Data were available for 245 women who were enrolled in a randomised controlled trial 
comparing two policies of PGE2 vaginal gel IOL.   Of these, 90 women gave birth by CS, 
155 delivered vaginally, 79 had a VD < 24h, and 97 women experienced an in-hours-
delivery.   Those who experienced a VD < 24h compared  to  those women  who  did   not,  
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Table 5.1 Demographic and clinical characteristics of participants who did and did not experience a 
vaginal delivery within 24 hours  
 
 
a presented as mean (standard deviation)      
b ≥41+0 weeks compared with <41+0 weeks 
c Aboriginal and/or Torres Strait Islander      
d Fetal growth restriction and/or small for gestational age      
e Modified Bishop’s score      
Characteristic 
Vaginal delivery within 24 hours 
p-value 
YES  n (%) NO  n (%) 
Age (years) a 30.1 (4.8) 29.3 (5.1) 0.224 
BMI 
     <18.5 kg/m2 
     18.5-24.9 kg/m2 
     25.0-29.9 kg/m2 
     30.0-34.9 kg/m2 
     ≥35.0 kg/m2 
     Median (IQR) 
 
4 (5.1%) 
35 (44.3%) 
18 (22.8%) 
10 (12.7%) 
12 (15.2%) 
25.0 (21.0, 30.9) 
 
8 (4.8%) 
65 (39.1%) 
40 (24.1%) 
35 (21.1%) 
18 (10.9%) 
25.9 (22.0, 31.0) 
 
 
 
 
 
0.511 
0.391  
Gestation  
     37 weeks 
     38 weeks 
     39 weeks 
     40 weeks 
     41 weeks 
     42 weeks 
     ≥41 weeks 
 
4 (5.1%) 
13 (16.5%) 
9 (11.4%) 
8 (10.1%) 
34 (43.0%) 
11 (13.9%) 
45 (50.0%) 
 
7 (4.2%) 
24 (14.5%) 
16 (9.6%) 
24 (14.5%) 
65 (39.2%) 
30 (18.1%) 
95 (61.3%) 
 
 
 
 
 
 
0.862 
0.112 b 
Nulliparity 37 (46.9%) 148 (89.2%) <0.001* 
Ethnicity  
     Caucasian 
     Asian 
     ATSI c 
     Pacific Islander/Maori 
     Other  
 
61 (77.2%) 
9 (11.4%) 
6 (7.6%) 
2 (2.5%) 
1 (1.3%) 
 
118 (71.1%) 
20 (12.1%) 
18 (10.8%) 
3 (1.8%) 
7 (4.2%) 
 
 
 
 
 
0.656 
Indication for IOL 
     Post-term 
     Diabetes in pregnancy 
     Hypertensive disorder 
     Suspicion FGR/SGA d 
     Cholestasis 
     Social/elective 
     Other       
 
44 (55.7%) 
14 (17.7%) 
5.(6.3%) 
3 (3.8%) 
0 (0%) 
3 (3.8%) 
10 (12.6%) 
 
88 (53.1%) 
26 (15.7%) 
11 (6.6%) 
2 (1.2%) 
10 (6.0%) 
2 (1.2%) 
26 (15.7%) 
 
 
 
 
 
 
 
0.231 
MBS e at start of IOL 
     Mean score a 
     ≤3     
 
3.8 (1.4) 
32 (40.5%) 
 
3.3 (1.4) 
94 (56.6%) 
 
0.009* 
0.018* 
MBS e at first review 
     Mean score a 
     ≤3      
     Data missing 
 
6.1 (1.9) 
5 (6.9%) 
6 (7.6%) 
 
4.5 (2.0) 
47 (30.1%) 
11 (6.6%) 
 
<0.001* 
<0.001* 
0.992 
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were more likely to be multiparous, to have a more favourable cervix (as assessed by the 
MBS) at the start of the IOL and at the time of the morning review, and a greater change in 
MBS between these two examinations.  Women who had a VD<24h were also more likely 
to have had an amniotomy performed at 1st review (78.8% vs 47.0%; p<0.001), and less 
likely to have required a Syntocinon infusion.  There were no differences in the groups with 
respect to maternal age, BMI, ethnicity, gestation, indication for IOL, or MBS at the start of 
the IOL.  (Table 5.1).   
 
Additional bivariate analyses were undertaken for each of the three secondary outcomes.  
For the outcomes of CS, nulliparity and favourability of the cervix at both the start of the 
IOL and at the time of the morning review were the three statistically significant variables 
identified.  (Table 5.2).  Similarly, for the outcome of a prolonged (i.e. greater than 
average) IOL-to-birth time, nulliparity and favourability of the cervix at both the start of the 
IOL and at the time of the morning review were the three statistically significant variables 
identified.  (Table 5.4).  For the outcome of in-hours delivery, nulliparity and age were the 
two statistically significant variables identified.   (Table 5.3).  
 
Examining the primary outcome, the statistically significant variables from the bivariate 
analysis (nulliparity and MBS at 1st review) along with variables identified from the 
literature review (maternal age, BMI (inverse), gestation and MBS at the start of the IOL), 
were included in a multivariate logistic regression analysis.  Nulliparity (aOR=0.06 [0.02, 
0.15]; p<0.001), MBS at first review (aOR=1.66 [1.35, 2.05]; p<0.001) and a policy of early 
amniotomy (aOR=2.28 [1.10, 4.74]; p=0.026) were independently associated with VD < 
24h. The model had excellent discriminatory ability (AUROC=0.85 [0.80, 0.91]; p<0.001) 
and the Hosmer–Lemeshow test (p=0.803) showed a good fit to data.  (Table 5.5).   
 
For the secondary outcomes, the same variables (nulliparity, MBS at the start of the IOL 
and at 1st review, maternal age, BMI (inverse), gestation), were included in the logistic and 
linear regression models,  The models were predictive of an  in-hours delivery 
(AUROC=0.68 (0.61, 0.76); p<0.0001; Hosmer-Lemeshow p=0.369), caesarean section 
(AUROC=0.72 (0.65, 0.79); p<0.0001; Hosmer-Lemeshow p=0.307), and the IOL-to-birth 
time (p<0.0001; adjusted R2=0.318).  Nulliparity was an independent predictor of all three 
secondary outcomes, and MBS at 1st review was predictive of caesarean section and the 
IOL-to-birth time.   (Table 5.6).   
 
The model to predict a VD < 24h (generated based on the whole dataset) was tested for 
robustness by undertaking multiple sub-group analyses.  The AUROC between nulliparous  
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Table 5.2 Demographic and clinical characteristics of participants who did and did not give birth by 
caesarean section 
 
Characteristic 
Caesarean section 
p-value 
YES  n (%) NO  n (%) 
Age (years) d 29.8 (5.2) 29.5 (4.9)  0.656 
BMI 
     <18.5 kg/m2 
     18.5-24.9 kg/m2 
     25.0-29.9 kg/m2 
     30.0-34.9 kg/m2 
     ≥35.0 kg/m2 
 
5 (5.6%) 
37 (41.1%) 
22 (24.4%) 
20 (20.2%) 
6 (6.7%) 
 
7 (4.5%) 
63 (40.7%) 
36 (23.3%) 
25 (16.1%) 
24 (15.5%) 
 
 
 
 
 
0.295 
Gestation  
     37 weeks 
     38 weeks 
     39 weeks 
     40 weeks 
     41 weeks 
     42 weeks 
    ≥41weeks 
 
3 (3.3%) 
12 (13.3%) 
4 (4.4%) 
13 (14.4%) 
39 (43.3%) 
19 (21.1%) 
48 (53.3%) 
 
8 (5.2%) 
25 (16.1%) 
21 (13.6%) 
19 (12.3%) 
60 (38.7%) 
22 (14.2%) 
82 (52.9%) 
 
 
 
 
 
 
0.187 
0.903 
Nulliparity 81 (90.0%) 104 (67.1%) <0.001* 
Ethnicity  
     Caucasian 
     Asian 
     ATSI b 
     Pacific Islander/Maori 
     Other  
 
60 (60.7%) 
9 (10.0%) 
13 (15.6%) 
3 (3.3%) 
4 (4.4%) 
 
119 (76.8%) 
20 (12.9%) 
10 (6.5%) 
2 (1.3%) 
4 (2.6%) 
 
 
 
 
 
0.300 
Indication for IOL 
     Post-term 
     Diabetes in pregnancy 
     Hypertensive disorder 
     Suspicion FGR/SGA c 
     Cholestasis 
     Social/elective 
     Other       
 
53 (58.9%) 
13 (14.4%) 
4 (4.4%) 
0 (0%) 
2 (2.2%) 
4 (4.4%) 
14 (15.5%) 
 
79 (51.0%) 
27 (17.4%) 
12 (7.7%) 
1 (0.7%) 
3 (1.9%) 
6 (3.9%) 
27 (17.4%) 
 
 
 
 
 
 
 
0.905 
MBS a at start of IOL 
     Mean score d 
     ≤3 
 
3.0 (1.5) 
53 (68.9%) 
 
3.6 (1.3) 
62 (45.3%) 
 
0.003* 
0.007* 
MBS a at 1st review 
     Mean score d 
     ≤3      
     Data missing 
 
4.3 (2.1) 
31 (36.5%) 
6 (6.6%) 
 
5.5 (1.9) 
21 (14.7%) 
11 (7.1%) 
 
<0.001* 
<0.001* 
0.894 
 
a Modified Bishop’s score      
b Aboriginal and/or Torres Strait Islander      
c Fetal growth restriction and/or small for gestational age      
d presented as mean (standard deviation)      
* p <0.05 
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Table 5.3 Demographic and clinical characteristics of participants who did and did not deliver in-
hours (08:00-17:00) 
 
Characteristic 
In-hours delivery 
p-value 
YES  n (%) NO  n (%) 
Age (years) d 30.5 (4.6)  29.0 (5.2)  0.017* 
BMI 
     <18.5 kg/m2 
     18.5-24.9 kg/m2 
     25.0-29.9 kg/m2 
     30.0-34.9 kg/m2 
     ≥35.0 kg/m2 
 
3 (3.1%) 
45 (46.4%) 
22 (22.7%) 
13 (13.4%) 
14 (14.4%) 
 
9 (6.1%) 
55 (37.2%) 
36 (24.3%) 
32 (21.6%) 
16 (10.8%) 
 
 
 
 
 
0.273 
Gestation  
     37 weeks 
     38 weeks 
     39 weeks 
     40 weeks 
     41 weeks 
     42 weeks 
    ≥41weeks 
 
5 (5.2%) 
18 (18.6%) 
9 (9.3%) 
12 (12.4%) 
41 (42.3%) 
12 (12.4%) 
53 (54.6%) 
 
6 (4.1%) 
19 (12.8%) 
16 (10.8%) 
20 (13.5%) 
58 (39.2%) 
29 (19.6%) 
87 (58.8%) 
 
 
 
 
 
 
0.611 
0.610 
Nulliparity 63 (65.0%) 122 (82.4%) 0.002* 
Ethnicity  
     Caucasian 
     Asian 
     ATSI b 
     Pacific Islander/Maori 
     Other  
 
68 (70.1%) 
13 (14.4%) 
7 (7.2%) 
3 (3.1%) 
5 (5.2%) 
 
111 (75.0%) 
15 (10.1%) 
17 (11.5%) 
2 (1.4%) 
3 (2.0%) 
 
 
 
 
 
0.306 
Indication for IOL 
     Post-term 
     Diabetes in pregnancy 
     Hypertensive disorder 
     Suspicion FGR/SGA c 
     Cholestasis 
     Social/elective 
     Other       
 
50 (51.6%) 
18 (18.6%) 
5 (5.2%) 
0 (0%) 
3 (3.1%) 
2 (2.1%) 
19 (19.6%) 
 
82 (55.4%) 
22 (14.9%) 
11 (7.4%) 
1 (0.7%) 
2 (1.4%) 
8 (5.4%) 
22 (14.9%) 
 
 
 
 
 
 
 
0.602 
MBS a at start of IOL 
     Mean score d 
     ≤3      
 
3.39 (1.4) 
48 (53.3%) 
 
3.39 (1.4) 
67 (51.5%) 
 
0.986 
0.793 
MBS a at 1st review 
     Mean score d 
     ≤3 
     Data missing 
 
5.2 (2.1) 
18 (19.8%) 
6 (6.2%) 
 
4.9 (2.1) 
34 (24.8%) 
11 (7.4%) 
 
0.236 
0.375 
0.906 
 
a Modified Bishop’s score           
b Aboriginal and/or Torres Strait Islander      
c Fetal growth restriction and/or small for gestational age      
d presented as mean (standard deviation)      
* p <0.05 
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Table 5.4 Demographic and clinical characteristics of participants who did and did not have a 
prolonged (i.ie greater than average) IOL-to-birth time  
 
Characteristic 
Prolonged IOL-to-birth time (≥27 hours) 
p-value 
YES  n (%) NO  n (%) 
Age (years) d 29.6 (5.0) 29.7 (5.0) 0.815 
BMI 
     <18.5 kg/m2 
     18.5-24.9 kg/m2 
     25.0-29.9 kg/m2 
     30.0-34.9 kg/m2 
     ≥35.0 kg/m2 
 
4 (3.8%) 
43 (50.0%) 
25 (23.8%) 
21 (20.0%) 
12 (11.4%) 
 
8 (6.2%) 
51 (39.2%) 
30 (23.1%) 
24 (18.5%) 
17 (13.1%) 
 
 
 
 
 
0.927 
Gestation  
     37 weeks 
     38 weeks 
     39 weeks 
     40 weeks 
     41 weeks 
     42 weeks 
    ≥41weeks 
 
2 (1.9%) 
17 (16.2%) 
12 (11.4%) 
13 (12.4%) 
39 (37.1%) 
22 (30.0%) 
51 (48.6%) 
 
9 (6.2%) 
19 (14.6%) 
13 (10.0%) 
19 (14.6%) 
53 (40.8%) 
18 (13.9%) 
71 (54.6%) 
 
 
 
 
 
 
0.441 
0.429 
Nulliparity 96 (91.4%) 81 (62.3%) <0.001* 
Ethnicity  
     Caucasian 
     Asian 
     ATSI b 
     Pacific Islander/Maori 
     Other  
 
73 (69.5%) 
14 (13.3%) 
10 (9.5%) 
3 (2.9%) 
5 (4.8%) 
 
99 (76.2%) 
13 (10.0%) 
13 (10.0%) 
2 (1.5%) 
3 (2.3%) 
 
 
 
 
 
0.658 
Indication for IOL 
     Post-term 
     Diabetes in pregnancy 
     Hypertensive disorder 
     Suspicion FGR/SGA c 
     Cholestasis 
     Social/elective 
     Other       
 
58 (55.2%) 
19 (18.1%) 
6.(5.7%) 
1 (1.0%) 
1 (1.0%) 
7 (6.7%) 
13 (12.4%) 
 
67 (51.5%) 
20 (15.4%) 
10 (7.7%) 
0 (0%) 
4 (3.1%) 
3 (2.3%) 
26 (20.0%) 
 
 
 
 
 
 
 
0.298 
MBS a at start of IOL 
     Mean score d 
     ≤3 
 
3.2 (1.4) 
56 (57.7%) 
 
3.6 (1.4) 
55 (46.6%) 
 
0.019* 
0.104 
MBS a at 1st review 
     Mean score d 
     ≤3 
     Data missing 
 
4.2 (2.0) 
40 (37.4%) 
4 (4.4%) 
 
5.8 (1.8) 
11 (9.5%) 
7 (6.7%) 
 
<0.001* 
<0.001* 
0.680 
 
a Modified Bishop’s score           
b Aboriginal and/or Torres Strait Islander      
c Fetal growth restriction and/or small for gestational age      
d presented as mean (standard deviation)      
* p <0.05 
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Table 5.5 Primary outcome: Multivariate analysis of factors associated with a vaginal delivery 
within 24 hours  
Predictor variables 
Vaginal delivery within 24 hours c 
aOR (95% CI) Adj  p-value  
Age 1.03 [0.96, 1.11] 0.423 
BMI a 24.37 [-17.14, 65.88] 0.250 
Gestation <40+0 weeks 1.10 [0.85, 1.43] 0.469 
Nulliparity 0.06 [0.02, 0.15] <0.001* 
MBS b at start of IOL 0.83 [0.62, 1.12] 0.223 
MBS b at 1st review 1.66 [1.35, 2.05] <0.001* 
Early amniotomy policy  2.28 [1.10, 4.74] 0.026* 
 
a Inverse of BMI; coefficient reported      
b Modified Bishop’s score 
c n=228; logistic regression model p<0.0001; goodness-of-fit test (Hosmer–Lemeshow) 
p=0.803; AUROC=0.85 (0.80, 0.91) 
* p <0.05 
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Table 5.6 Secondary outcomes: Multivariate analyses of predictors of in-hours delivery, predictors of caesarean section, and predictors of the IOL-
to-birth time 
 
Predictor variables 
In-hours delivery b Caesarean Section c IOL-to-birth time d 
aOR (95% CI) 
Adj       
p-value  
aOR (95% CI) 
Adj           
p-value  
Coefficient (95% CI) 
Adj           
p-value  
Age 1.05 (0.99, 1.12) 0.086 1.01 [0.96, 1.08] 0.599 -0.03 (-0.27, 0.22) 0.836 
BMI e  25.15 (-8.81, 59.11) 0.147 7.98 [-27.73, 43.68] 0.661 -5.04 (-146.16, 136.07) 0.944 
Gestation 0.94 (0.77, 1.15) 0.563 1.18 [0.95, 1.47] 0.124 0.01 (-0.84, 0.85) 0.991 
Nulliparity 0.34 (0.17, 0.68) 0.002* 3.71 [1.55, 8.88] 0.003* 6.74 (3.80, 9.69) <0.001* 
MBS a at start of IOL 0.84 (0.66, 1.06) 0.142 0.92 [0.72, 1.17] 0.493 -0.02 (-0.96, 0.99) 0.973 
MBS a at 1st review 1.12 (0.96, 1.30) 0.159 0.78 [0.66, 0.92] 0.003* -1.93 (-2.56, -1.29) <0.001* 
Early amniotomy policy 1.31 (0.75, 2.31) 0.342 1.00 [0.56, 1.81] 0.986 -4.84 (-7.20,-2.49) <0.001* 
 
a Modified Bishop’s score         
b n=228; logistic regression model  p<0.0001; goodness-of-fit test (Hosmer–Lemeshow) p=0.369; AUROC=0.68 (0.61, 0.76) 
c n=228; logistic regression model  p<0.0001; goodness-of-fit test (Hosmer–Lemeshow) p=0.307; AUROC=0.72 (0.65, 0.79) 
d n=228; linear regression model  p<0.0001; adjusted R2=0.318 
e Inverse of MBS; coefficient reported   
* adjusted p <0.05 
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Figure 5.1 AUROC of model predicting a vaginal delivery with 24 hours: sub-group analyses by parity, ethnicity, indication, gestation, and MBS  
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and multiparous women, caucasian and non-caucasian women, induction before or after 
40+0 weeks gestation, IOL undertaken because of a post-term pregnancy or another 
indication, or where the cervix was less favourable (MBS ≤ 3) or more favourable (MBS > 
3) at either the initial or subsequent examination, were compared, including stratification 
by PGE2 vaginal gel policy.  The point-estimates of the AUROCs were all similar, and the 
95% CI for the AUROCs were overlapping, supporting the conclusion that the model was 
applicable across multiple clinical scenarios.  (Figure 5.1).   
 
Next, using the regression equations, a modelling exercise using available data was 
undertaken to predict the likelihood of a VD < 24h.  The significant independent variables 
identified from the multivariate analysis (parity and MBS at first review) were varied in an 
attempt to establish the clinical scenarios where a policy of amniotomy as soon as 
technically possible, versus repeat PGE2 administration would be indicated.   For both 
nulliparous and multiparous women, a policy of amniotomy once technically possible was 
associated with a greater likelihood of a VD < 24h.  There was no combination of parity or 
MBS value where the model clearly favoured a policy of repeat-PGE2 administration.  
(Figure 5.2) 
 
Similarly, the likelihood of caesarean section, in-hours delivery and the IOL-to-birth time 
were predicted using the regression equations.   Varying the parity and MBS at first review 
did not identify a scenario where a policy of repeat-PGE2 administration would clearly be 
favoured.  For both nulliparous and multiparous women, the modelling exercise predicted 
a greater chance of in-hours delivery, a shorter IOL-to-birth time, and a reduced likelihood 
of CS with a policy of amniotomy once technically possible.  (Figure 5.3, 5.4, 5.5). 
 
Further exploratory analyses were undertaken amongst other sub-groups.  Again, the 
outcomes of VD < 24h, caesarean section, in-hours delivery and the IOL-to-birth time were 
predicted using the regression equations.  Multiple sub-group analyses were performed: 
gestation ≥40+0 weeks versus <40+0 weeks; caucasian versus non-caucasian; post-term 
versus other indications.  Parity and MBS at first review were once again varied in an 
attempt to establish the clinical scenarios where one policy would be preferred over the 
other.   Across all sub-groups, varying the parity and MBS at first review, did not predict a 
scenario where the repeat-PGE2 policy would be favoured.  
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Figure 5.2 Prediction of a vaginal delivery within 24 hours using regression equation (varying the 
parity and MBS at 1st review)  
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Figure 5.3 Prediction of birth of by caesarean section using regression equation (varying parity 
and MBS at 1st review) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4 Prediction of an in-hours delivery using regression equation (varying parity and MBS 
at 1st review) 
 
 
 
 
 
 
 
 
Figure 5.5 Prediction of time (hours) from commencement of IOL to birth using regression equation 
(varying parity and MBS at 1st review) 
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5.4 Conclusions  
Amongst women being induced using PGE2 vaginal gel, parity and the MBS at the time of 
1st review are the two factors that are most predictive of the mode, duration and time of 
birth.  But regardless of both parity and favourability of the cervix, a policy of amniotomy 
once technically possible is modelled to predict a greater chance of a vaginal delivery 
within 24 hours, an in-hours delivery, a shorter labour and a vaginal birth.  The prediction 
modelling did not identify a scenario where a policy of repeat-PGE2 administration would 
be preferred.   
 
Several potential predictive factors were considered in the analyses.   Cohort studies [182]   
support the perception of many clinicians that IOL prior to 40 weeks may be associated 
with a longer labour or greater likelihood of birth by CS.  Yet similar to the findings in 
prospective trials [3], the gestation at time of IOL in this analysis was not an independent 
predictor of the primary or secondary outcomes.  Maternal age and BMI have been 
reported to be factors associated with labour outcomes following IOL [13, 94], but neither 
were shown in this analysis to be associated with the primary or secondary outcomes.  
The MBS has been clearly and consistently demonstrated to be predictive of labour 
outcomes following IOL [109] and clinicians pay much credence to the favourability of 
cervix at the commencement of the IOL.  However, when this factor was included in the 
predictive model as well as the MBS prior to 1st review, the first vaginal examination 
findings were not associated with any of the outcomes.   
 
Despite the common perception that an unfavourable cervix at the commencement of IOL 
might foretell a long and difficult labour, this analysis would suggest that it is the MBS at 
the time of the next examination that is the most informative.   For example in Figure 5.3, 
the model predicts the chance of a CS in nulliparous women varying by almost 50% when 
the cervix at time of the 1st review is very favourable (MBS > 7) versus very unfavourable 
(MBS ≤ 3) (Figure 5.3).  Similarly there is more than a 10-fold difference in the likelihood of 
VD < 24h amongst nulliparous women with and without a favourable cervix at the time of 
first review (Figure 5.2).   
 
Exploring this observation further, a post-hoc analysis was undertaken to compare the 
likelihood of a VD < 24h amongst nulliparous women, based on the favourability of the 
cervix at the initial vaginal examination, and at the time of the next review.  A VD < 24h 
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was just as likely amongst nulliparous women with both a more favourable cervix (MBS > 
3) and a less favourable cervix (MBS ≤ 3) prior to PGE2 administration (23.4% versus 
17.6%; p=0.398).  But after 1 dose of PGE2 vaginal gel, there were no nulliparous women 
with a less favourable cervix who went on to have a vaginal delivery within 24 hours, 
compared with over one third of those who had a more favourable cervix at this 
examination (Table 5.7).   
  
Table 5.7 Likelihood of a vaginal delivery within 24 hours in nulliparous women, stratified by 
favourability of the cervix at the initial and subsequent vaginal examination (post-hoc analysis) 
a Modified Bishop’s score    
* p<0.05 
 
In a similar way, the data were examined to compare the likelihood of birth by CS amongst 
nulliparous women, based on the favourability of the cervix at these two examinations.  
Although there was a trend towards more CS if the initial vaginal examination determined 
the cervix to be unfavourable, again it was the next examination that best foretold the likely 
mode of birth.  In this post-hoc sub-group analysis, those with a MBS of 3 or less after one 
dose of PGE2 vaginal gel, were almost twice as likely to give birth by CS.  (Table 5.8).   
  
 
Table 5.8 Likelihood of caesarean section in nulliparous women, stratified by favourability of the 
cervix at the initial and subsequent vaginal examination (post-hoc analysis) 
a Modified Bishops score    
* p<0.05 
 
Vaginal Examination 
Vaginal delivery within 24 hours n (%) 
 
Less favourable cervix 
MBS a ≤ 3   
 
More favourable cervix 
MBS a > 3   
p-value 
Initial vaginal examination 19 (17.6%) 18 (23.4%) 0.398 
Following 1st dose PGE2  0 (0%) 33 (24.8%) <0.001* 
Vaginal Examination 
Caesarean Section n (%) 
 
Less favourable cervix 
MBS a ≤ 3   
 
More favourable cervix   
MBS a > 3   
p-value 
Initial vaginal examination 51 (44.0%) 27 (35.0%) 0.278 
Following 1st dose PGE2   28 (66.6%) 49 (36.8%) 0.001* 
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The MBS at the commencement of IOL is widely accepted as the most robust predictor of 
labour outcomes [183].  The predictive value of this score when assessed following the 
administration of the first dose of PGE2 vaginal gel has, however, not previously been 
reported.  Assessing the favourability of the cervix the morning after administration of an 
initial dose of PGE2 vaginal gel, measures the same “readiness for labour” as is observed 
at the first examination.  But in contrast to the first examination, this next assessment also 
provides information about the response of the cervix to pharmacological priming.  The 
enhanced predictive ability of the MBS at this examination may be because an 
unfavourable cervix reflects both an unpreparedness to labour and a lack of response to 
PGE2.       
 
There are numerous, varied and complex reasons for the increasing trend in CS, [184] 
with maternal request being one of the most commonly cited [185].  Qualitative studies that 
have explored these reasons identify women’s fear of long labour as one of their primary 
concerns [186].  With an unfavourable cervix and the expectation of a long labour and 
possible CS, women are sometimes counselled and then elect not to commence an IOL, 
and instead choose to give birth by planned CS.  Yet, of the 126 women in this analysis 
with an unfavourable cervix (MBS ≤ 3) at the commencement of the IOL, more than half 
(n=76) did not have an unfavourable cervix at next review, and they went on to experience 
not dissimilar rates of CS (35.5%) and VD < 24h (34.2%) compared to the entire cohort.  
These data challenge the perceptions that commencing an IOL with an unfavourable 
cervix is always going to be prolonged and may often fail.  Mindful that the initial MBS was 
not predictive of either mode of birth or duration of labour, this data may enable both 
clinicians and women to have some optimism in commencing a PGE2 vaginal gel IOL, 
even when the cervix is perceived to be very unfavourable at the outset.  And recognising 
that the majority of women who have one planned CS will subsequently elect to have a 
repeat CS, strategies to reduce the incidence of primary CS are likely to have cumulative 
benefits in reducing the overall CS rate.   
 
The results presented in this chapter support the conclusion that the repeat dosing 
protocol of PGE2 vaginal gel has no demonstrable clinical benefits over the single dose 
protocol.   It is acknowledged that these are modelling data and the RCT was not powered 
to address the specific question of IOL and mode of birth, or IOL in women with 
unfavourable cervixes. Variables that have been reported in the literature and those 
identified in the bivariate analyses have been included in the predictive model, however 
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the model is limited in its ability to address all known and unknown confounders.  
Causation cannot be inferred from these analyses, and the wide confidence-intervals for 
some predictor variables (especially early amniotomy policy) is noted.  A number of 
models have been presented, and the inferior predictive ability of the models in the 
secondary analyses is acknowledged.  These models are supporting evidence as to the 
importance of the key variables that predict IOL outcomes (parity and MBS at 1st review).  
Although there is a possibility of data entry and classification error, this is unlikely as the 
data were prospectively collected by a single research assistant, using a specific data 
collection tool and with the primary intention of analysis.  This is in contrast to many other 
studies developing predictive models that have drawn routinely collected clinical 
information from data-systems.  Missing data are acknowledged, specifically MBS at first 
review, however this did not differ between women who did and not have a CS or in-hours 
birth, or between the treatment and allocation groups.  
 
The predictive ability of MBS at first review is a unique finding, but the clinical application is 
not yet defined.  It is important that this observation is confirmed in larger analyses, 
especially its association with CS (AUROC =0.72).  It is acknowledged that MBS is a 
composite score comprising five individual measures assessed by digital examination, 
hence it is plausible that it is not the MBS but rather one component of the score that best 
explains the association between the examination at time of first review, and the primary 
and secondary outcomes. The component assessments were not collected in this study 
unfortunately, and only the total MBS values are available for analysis.  The length, 
dilatation, consistency, position and station are subjective assessments; all of which are 
determined by feel, and none of which can be confirmed objectively.  The scores were 
derived from vaginal examinations performed by both experienced and less experienced 
clinicians.      Cervical length can be assessed objectively on ultrasound scan, however 
there is as yet no robust data to suggest this predicts clinical outcomes better than the 
MBS [111, 187].  Perhaps ultrasound assessment of cervical length 6-12 hours after the 
first dose of PGE2 vaginal gel may be predictive of clinical outcomes, in the same way as 
there appears to be an association between the digital findings at this examination and 
clinical outcomes.   
    
  
99 
 
5.5 Chapter Summary 
These analyses confirm that the MBS after the 1st dose of PGE2 vaginal gel (and not the 
initial examination) is an independent predictor of the mode, duration and time of birth.  
Using regression equations to model outcomes, varying both the parity and the MBS at 1st 
review, there were no clinical scenarios where a policy of repeat PGE2 administration was 
predicted to be superior to a policy of amniotomy once technically possible. 
 
Following an examination of the clinical outcomes of the RCT (Chapter 4) and an analysis 
in this Chapter of the factors independently associated with a vaginal delivery within 24 
hours, caesarean section, in-hours delivery and the IOL-to-birth time, there are a number 
of unanswered questions:  
 
1. At the 1st review, is it the MBS per se, or rather one component of the score that is 
most significantly associated with the outcomes of VD < 24h, caesarean section, in-
hours delivery and IOL-to-birth time? 
 
2. Do women prefer a shorter IOL-to-birth time, oxytocin immediately after ARM, an in-
hours birth, earlier ARM?  Is the examination following repeat PGE2 vaginal gel 
dosing more unpleasant / uncomfortable than attempting to rupture the membranes 
when the cervix is less favourable? 
 
3. Is a policy of amniotomy once technically possible associated with cost savings?  
Are there demonstrable cost savings associated with a shorter IOL-to-birth time, or 
are the savings only realised if there is a reduction in total hospital length-of-stay? 
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Chapter 6 Healthcare Experience 
 
The material detailed in this Chapter has been: 
a)  Presented at the 2016 World Congress on Controversies in Obstetrics, Gynecology 
and Infertility, Melbourne 
b) Published in the European Journal of Obstetric Gynecology and Reproductive 
Biology [188] 
 
6.1 Background 
The 21st century healthcare consumer expects excellent health outcomes [117].  In 
maternity, more than any other area of healthcare, the psychological and emotional 
experience of the healthcare encounter has risen to be one of the most important 
indicators that consumers use to judge the quality of their care [189, 190].  This underpins 
the imperative to explore women’s wishes for care during pregnancy, labour and birth, and 
for including women in decisions regarding their care.  Healthcare experience outcomes 
have been reported in various trials comparing different IOL methods and protocols [30, 
31, 53, 55, 123-125] but were not reported in the sole trial that compared single versus 
repeat PGE2 vaginal gel policies.  These trials all used different surveys, and no 
consistent instrument was used.  Given the multidimensional nature of satisfaction [154], it 
has been challenging to develop meaningful and robust measures of healthcare 
experience [155].  Very few validated measures of maternal satisfaction exist [156] and in 
particular, no validated patient satisfaction measure exists for women undergoing IOL.   
 
This Chapter builds upon the Clinical Outcomes Chapter, using the data from a 
randomised controlled trial of two common approaches to PGE2 vaginal gel IOL.  In the 
absence of a validated metric, the EXperiences of Induction Tool (EXIT) was developed de 
novo for this study.  The objective of the research described in this Chapter was to validate 
this tool, and then report the experiential outcomes of women undergoing IOL following a 
policy of amniotomy once technically possible, compared with a policy of repeat PGE2 
administration.   
 
The Chapter tests the following research hypothesis for women undergoing IOL using 
PGE2 vaginal gel: A policy of amniotomy once technically possible compared with a policy 
of giving more PGE2 vaginal gel will result in a more positive healthcare experience for 
women    
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6.2 Methods 
A randomised controlled trial comparing two common approaches to PGE2 vaginal gel IOL 
was undertaken between March 2010 and August 2013.  The primary outcome was the 
time from commencement of IOL until birth.  Women’s experience and satisfaction with 
IOL was a secondary outcome measure assessed using the EXIT.  The EXIT was 
administered by a research midwife who was not involved in the woman’s intrapartum or 
postpartum care and who was also blinded to the woman’s treatment allocation.  The EXIT 
was administered by phone at 7-9 days post-partum.  For non-English speaking woman, 
this was undertaken with the assistance of a phone interpreter.    An attempt was made to 
call women on 3 separate occasions before concluding that the data were unobtainable 
 
The EXIT was developed de novo in collaboration with three psychologist-researchers with 
expertise in patient-reported measurement.  Following a review of the existing literature on 
women’s experience of IOL and consultation with women, 10 items were developed to 
capture meaningful aspects of women’s experience of IOL. Items were then refined 
through collaborative review with four clinician-researchers (one nurse, one midwife, two 
obstetricians). The final 10-item scale included 5 reverse-scored items.  In addition, 3 
single-item measures (global satisfaction with the birth experience, likelihood of choosing 
the same method of IOL again, and likelihood of recommending the method of IOL to a 
friend or relative; see Table 1) were administered alongside the EXIT to enable the 
assessment of concurrent validity.  Women were also invited to respond to four process 
evaluation items comprising two quantitative items (perceived adequate preparation for 
induction and perceived necessity of medical procedures), and two qualitative items 
(exploring women’s experience of IOL, and their views on ways to improve the experience 
of other women undergoing IOL). Responses to all quantitative items were recorded on a 
5-point Likert scale either from 1 (‘strongly disagree’) to 5 (‘strongly agree’) or from 1 
(‘definitely not’) to 5 (‘definitely’). Responses to the qualitative questions were coded as 
“positive” or negative” and example statements are presented for illustrative purposes.   
 
Face and content validity were assessed by seeking feedback on the EXIT from a group of 
8 senior obstetricians and midwives, and also from a team of 4 research midwives who are 
actively involved in clinical trials and administration of written surveys.  Face validity from 
the perspective of women undergoing IOL was inferred from their willingness to participate 
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in data collection and rates of missing data.  Principal components analysis with 
orthogonal varimax rotation was undertaken to examine the structure of the 10-item EXIT.   
 
Table 6.1 Items of satisfaction questionnaire  
 
* item was reverse-scored 
 
 
The internal convergent validity of the instrument was tested by measuring the correlation 
between respondents’ mean satisfaction scores (based on the included Items) and both 
Item 14 and Item 15.  The discriminative ability of the EXIT was assessed by comparing 
mean subscale scores among different subgroups of women.  Specifically, three   
hypotheses were tested: 
 
A) Women with a longer IOL-to-birth time would report lower scores for the factor 
satisfaction with time taken to give birth  
B) Women receiving more doses of PGE2 vaginal gel  would report lower scores for 
the factor satisfaction with cervical ripening 
C) Women with lower scores for the factor satisfaction with subsequent contractions 
would be more likely to have received epidural analgesia 
Satisfaction with IOL 
10-item scale 
 
(time taken to give 
birth; cervical ripening, 
subsequent 
contractions) 
1.  I was happy with how long it took for my labour to start after I  first had 
the vaginal gel  
2.  I was happy with how long it took for my baby to be born after I first 
had the vaginal gel  
3. I was unhappy about the number of internal vaginal examinations I 
had* 
4.  Being induced was painful* 
5.  I could move around as freely as I wanted to after being induced 
6.  Having my waters broken was unpleasant* 
7.  I experienced unpleasant side effects after being induced* 
8.  The frequency of my contractions was manageable 
9.  The intensity of my contractions was manageable 
10. I was unhappy with the procedures that followed being induced* 
Global satisfaction 11. Overall I was happy with my birth experience 
Mediators of 
relationship between 
IOL experience and 
satisfaction 
12. Looking back, do you feel you were adequately prepared for being 
induced  
13. Looking back, do you feel that everything that happened during your 
birth was necessary? 
 
Assess validity of   
10-item scale 
 
14. Given you experience, would you choose to be induced in this way 
again? 
15. Would you recommend being induced in this way to a friend or 
relative? 
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For the individual items in the EXIT, satisfaction outcomes have been presented as the 
median score on a 5-point Likert-scale, stratified by PGE2 vaginal gel policy.  Composite 
scores have been created for each of the factors by summing the responses to individual 
items that loaded to the factors and dividing by the number of responses (i.e. presented as 
a mean score).  There is significant disagreement in the literature as to whether Likert-
scales are ordinal or interval levels of measurement and whether medians or means, and 
parametric or non-parametric tests should be employed [191-193].  For individual 
questionnaire items, median scores have been presented as they more precisely measure 
central tendency.  For composite scores, summing the responses is likely to improve the 
interval scale property of the composite and is generally considered to be appropriate 
[192].  The Mann Whitney U test for non-normally distributed continuous variables has 
been used throughout.   
 
 
6.3 Results 
6.3.1 EXIT (EXperiences of Induction Tool) validation 
The item correlation matrix indicated that all but one (item 5) of the 10 items correlated 
with at least one other item at = 0.4, suggesting adequate factorability1.  In addition, the 
Kaiser-Meyer-Olkin measure of sampling adequacy was adequate (0.67) and Bartlett’s test 
of sphericity was significant (p<0.001) [194] .  Sample size was considered adequate 
being almost 10 times the number of variables included in the analysis [195] 
 
Principal components analysis identified 3 components with Eigen-values greater than 1.0 
(Kaiser test).  This was supported by a levelling off in the scree-plot after 3 components 
had been extracted. This initial solution explained 64.1% of the variance.  Items with a 
primary-factor loading <0.5 were then sequentially removed [196] and the analysis 
repeated.  The final 3-factor solution comprised 8 of the 10 items in the EXIT, explained 
76.1% of the variance and had a good fit to model (p<0.001).   
 
The communalities2 for items loading to each component were all above 0.5 indicating a 
high degree of shared common variance with the other items (see Table 2).  The resulting 
components appeared to reflect experiential aspects of the time taken to give birth, 
discomfort with IOL and experience of subsequent contractions. The interclass correlations 
within each sub-scale were examined using Cronbach’s alpha and showed good internal  
1 Factorability: the degree of collinearity among the variables 
2 Communality: indicates the variance in each item explained by the chosen Factor 
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Table 6.2 Final loading, communalities and alphas following principal components analysis with orthogonal rotation of 8 of 10 Items in questionnaire 
Factor Item 
Factor 
loadings 
Communality 
Cronbach’s 
alpha 
Time taken to 
give birth 
1. I was happy with how long it took for my labour to start after I first had 
the vaginal gel  
2. I was happy with how long it took for my baby to be born after I first 
had the vaginal gel  
0.94 
 
0.94 
 
0.90 
 
0.91 
 
 
0.88 
Cervical 
ripening 
3. I was unhappy about the number of internal vaginal examinations I had  
4. Being induced was painful  
5. I could move around as freely as I wanted to after being induced* 
6. Having my waters broken was unpleasant  
7. I experienced unpleasant side effects after being induced  
0.72 
0.86 
<0.5 
0.81 
0.63 
0.61 
0.76 
 
0.66 
0.54 
 
 
 
 
 
0.78 
Subsequent 
contractions 
8. The frequency of my contractions was manageable  
9. The intensity of my contractions was manageable  
10. I was unhappy with the procedures that followed being induced  
0.93 
0.94 
<0.5 
0.88 
0.90 
 
0.87 
 
* item was reverse-scored 
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consistency for experiences of time taken to give birth (a=0.88), discomfort with IOL 
(a=0.78), and experience of subsequent contractions (a=0.87).  The final factor loadings, 
communalities and alphas based on the principal components analysis are reported in 
Table 6.2.    
 
The internal consistency of the final 8-item EXIT was acceptable (a=0.77).   In assessing 
the internal convergent validity of the instrument, there was a positive correlation between 
respondents’ mean overall EXIT scores and both item 14 (likelihood of choosing IOL 
method again) (Pearson’s r=0.63; p<0.001) and item 15 (likelihood of recommending IOL 
method to a friend or relative) (Pearson’s r=0.60; p<0.001).  Discriminant validity of the 
EXIT was then tested by comparing mean subscale scores among different subgroups of 
women.  The sub-group of women whose medical records indicated they experienced a 
longer IOL-to-birth interval (mean + 1 SD; >38.0 hours), compared to those whose IOL-to-
birth-interval was shorter (mean – 1 SD; <16.8 hours), responded less positively about the 
time taken to give birth (mean 2.7 versus 4.6; p<0.01). Similarly, the subgroup of women 
receiving 2 or more doses of PGE2 vaginal gel reported higher scores for discomfort with 
IOL compared to those who only received 1 dose (mean 3.1 versus 2.7; p=0.03).   
 
6.3.2 Experiential outcomes 
Questionnaire data were available for 170 (69.4%) of the 245 women who were enrolled in 
the RCT comparing two policies of PGE2 vaginal gel IOL.  EXIT respondents answered 
98.9% of the questionnaire items; there were 19 missing data items in total. The baseline 
characteristics of the responders versus non-responders did not differ with respect to age, 
BMI, parity, gestation, ethnicity or indication for IOL.  (Table 6.3).   
 
Composite scores were created for each sub-scale as the mean of individual items that 
loaded onto that component.  Women in the repeat-PGE2 group were less positive about 
the time taken to give birth (mean (SD): 3.5 (1.4) versus 3.9 (1.2); p=0.04) and reported 
greater discomfort with IOL (2.9 (1.1) versus 2.5 (1.0); p=0.04) compared to women in the 
amniotomy group.  There were no statistically significant group differences in women’s 
experience of subsequent contractions.  (Table 6.4). 
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  Table 6.3 Baseline characteristics of the women who did and did not respond to the questionnaire 
 
 
a presented as mean (standard deviation) 
 
 
  
Characteristic 
Responded to 
questionnaire 
n=170 
Did not respond to  
questionnaire 
n=75 
p-value 
Age (years)a 29.7 (4.8) 29.4 (5.4) 0.64 
BMI (kg/m2)a 27.2 (7.1) 25.8 (5.5) 0.14 
Nulliparity 129 (75.9%) 56 (74.7%) 0.84 
Gestation (weeks)a 40.1 (1.5) 40.3 (1.5) 0.35 
Ethnicity 
  Caucasian 
  Asian 
  ATSI 
  Pacific Islander/Maori 
  Other 
 
127 (74.7%) 
17 (10.0%) 
18 (10.6%) 
4 (2.4%) 
4 (2.4%) 
 
52 (69.3%) 
12 (16.0%) 
6 (8.0%) 
1 (1.3%) 
4 (5.3%) 
 
 
 
 
 
0.43 
Indication for IOL 
  Post-term 
  Diabetes  
  Hypertension 
  Isoimmunisation 
  Suspected SGA/FGR 
  Cholestasis 
  APH 
  Social 
  Other  
 
88 (51.8%) 
30 (17.7%) 
10 (5.9%) 
1 (0.6%) 
4 (2.4%) 
8 (4.7%) 
0 (0%) 
3 (1.8%) 
26 (15.3%) 
 
44 (58.7%) 
10 (13.3%) 
6 (8.0%) 
0 (0%) 
1 (1.3%) 
2 (2.7%) 
0 (0%) 
2 (2.7%) 
10 (13.3%) 
 
 
 
 
 
 
 
 
 
0.89 
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Table 6.4 Responses across three sub-scales of the questionnaire, stratified by PGE2 vaginal gel policy  
 
Factor Item 
Amniotomy group 
Mean (SD) 
Repeat-PGE2 group 
Mean (SD) 
p-value 
Time taken to       
give birth 
1. I was happy with how long it took for my labour to start 
after I first had vaginal gel  
 
2. I was happy with how long it took for my baby to be born 
after I first had vaginal gel  
3.9 (1.2) 3.5 (1.4) 0.04* 
Discomfort           
with IOL 
3. I was unhappy about the number of internal vaginal 
examinations I had*  
 
4. Being induced was painful*  
 
6. Having my waters broken was unpleasant*  
 
7. I experienced unpleasant side effects after being induced*  
2.9 (1.1) 2.5 (1.0) 0.04* 
Experience of 
subsequent 
contractions 
8. The frequency of my contractions was manageable  
 
9. The intensity of my contractions was manageable  3.4 (1.2) 3.3 (1.3) 0.62 
 
* item was reverse-scored 
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Responses were then compared between the groups at the individual item level. An 
analysis stratified by parity was also undertaken.  Women in the amniotomy group were 
more positive about the time taken to have their baby (median (IQR): 4 (3-5) versus 3 (2-
5); p<0.01).  Specifically, it was the responses of nulliparous women in the amniotomy 
group that were more positive, compared to nulliparous women in the repeat-PGE2 group 
(4 (3-5) versus 3 (2-4); p<0.01).  Overall, women in the amniotomy group were also less 
“unhappy” about the number of vaginal examinations they experienced (2 (1-3) versus 2 
(1-4); p=0.05).   Similarly, this finding was only significant for nulliparous women in the 
amniotomy group, compared to nulliparous women in the repeat-PGE2 group (2 (1-3) 
versus 3 (1-4); p=0.01).  Responses to the remaining individual EXIT items did not differ 
between the amniotomy and repeat-PGE2 groups, or between the sub-groups of 
nulliparous and multiparous women. (Table 6.5).   
 
Comparing the responses to the process evaluation items, there were no differences 
between the two groups in women’s perceived necessity of medical procedures.  Women 
in the repeat-PGE2 group, however, reported feeling less “adequately prepared” for IOL 
than women in the amniotomy group (median 4 (IQR 3-5) versus 5 (4-5); p=0.04).  Again, 
there were differences between responses of nulliparous and multiparous women.  
Specifically, it was the sub-group of multiparous women in the repeat-PGE2 group 
(median 4 (IQR 4-5) versus 5 (5-5), p=0.01), not nulliparous women (median 4 (IQR 3-5) 
versus 4 (3-5); p=0.22) where responses differed. 
 
Free text responses were provided by 108 of the 170 questionnaire respondents.  A similar 
proportion of responses from women in amniotomy group and repeat-PGE2 group were 
coded as “positive” statements (49% versus 51%; p=0.93).  The majority of these were an 
expression of gratitude to staff or the hospital for a positive birthing experience. Amongst 
the responses coded as “negative”, the timeliness of the IOL process was the most 
common subject.  One woman responded “horrendous experience waited too long 
between gel ... wasted 24 hours”; another reported “in hospital more than 2 days before 
getting into labour”; and ten women all responded similarly “it took too long”.   Overall, 20% 
of the total free-text responses comprised participants expressing dissatisfaction with how 
long the IOL process took.   
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Table 6.5 Responses to questionnaire items, stratified by PGE2 vaginal gel policy  
Questionnaire Item 
Amniotomy 
group 
Median (IQR) 
Repeat-PGE2 
group 
Median (IQR) 
p-
value 
I was happy with how long it took for my labour to 
start after I first had the vaginal gel 
4 (3-5) 4 (3-5) 0.12 
I was happy with how long it took for my baby to 
be born after I first had the vaginal gel 
4 (3-5) 3 (2-5) 0.01* 
I was unhappy about the number of internal 
vaginal examinations I had 
2 (1-3) 2 (1-4) 0.05* 
Being induced was painful 3 (1-4) 3 (2-4) 0.22 
I could move around as freely as I wanted to after 
being induced 
4 (3-5) 4 (3-5) 0.98 
Having my waters broken was unpleasant 3 (1-4) 3 (3-4) 0.18 
I experienced unpleasant side effects after being 
induced 
2 (1-3) 2 (1-3) 0.44 
The frequency of my contractions was manageable 4 (2-5) 4 (3-5) 0.86 
The intensity of my contractions was manageable 3 (2-4) 4 (2-4) 0.61 
I was unhappy with the procedures that followed 
being induced 
2 (1-3) 2 (1-3) 0.46 
Overall I was happy with my birth experience 4 (4-5) 4 (3-5) 0.32 
Looking back, do you feel you were adequately 
prepared for being induced 
5 (4-5) 4 (3-5) 0.04* 
Looking back, do you feel that everything that 
happened during your birth was necessary? 
5 (4-5) 5 (4-5) 0.18 
Given your experience, would you choose to be 
induced in this way again? 
4 (2-5) 4 (2-5) 0.26 
Would you recommend being induced in this way to 
a friend or relative? 
4 (3-5) 4 (3-5) 0.65 
 
 
* p<0.05 
IQR: inter-quartile range
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6.4 Conclusions  
The analyses in this Chapter validate the EXIT (EXperiences of Induction Tool), and also 
report the experiences of women undergoing IOL in a RCT comparing single and multiple 
dose PGE2 vaginal gel policies.  The analyses demonstrate the internal consistency, face, 
content, construct, and discriminant validity of the EXIT.  The data also supports the 
conclusion that where IOL is undertaken following a policy of amniotomy once technically 
possible, women report a more favourable experience of the duration of their labour and 
with the discomfort of the induction process. 
 
No validated tool currently exists for measuring women’s experience of IOL.  Increasingly 
patient experience and satisfaction is reported by researchers, reflecting the growing 
imperative for clinicians and researchers to consider the psychological / emotional 
experience of the health encounter as well the clinical outcomes.  In the absence of 
validated tools, many researchers have therefore created their own scales, most with poor 
psychometric properties [197].    Specifically, in the area of maternal satisfaction, only a 
handful of valid measures exist [156].  The EXIT shows promise, having demonstrated 
construct validity, and internal consistency comparable to the Six Simple Questions [198], 
Consumer Satisfaction Questionnaire [199] and the Patient Perception Score [200], and 
superior to the Labour and Delivery Satisfaction Index [201], and the Intrapartal-Specific 
QPP Questionnaire [202].   
 
In exploring the structure of the EXIT, principal components analysis identified three 
components that map appropriately to theoretical constructs of the experience of IOL: time 
taken to given birth, discomfort with IOL and experience of subsequent contractions.  Two 
Items with relatively low Eigen-values and high cross-loading were removed from the final 
scale, improving the usability of the tool as a more succinct 8-item instrument.   As the only 
valid measure of patient experience for women undergoing IOL, the 8-item EXIT provides 
researchers with the opportunity to appraise the performance of this instrument for women 
undergoing other protocols of IOL, and also to compare experiential outcomes across IOL 
studies.   
 
The questionnaire also appears to show good discriminative ability, with the exception of 
satisfaction with subsequent contractions.  Unfortunately, outcomes such as timed VAS 
measures, other objective assessments of pain, and frequency / intensity of contractions 
were not collected in the trial.  Therefore the clinical outcome of “epidural analgesia” may 
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simply be too imprecise a measure to be an effective discriminator for this factor.    Whilst 
the baseline clinical characteristics of those who completed the EXIT and those who did 
not were shown to be similar (Table 6.1), it is acknowledged that data is only available for 
70% of the participants in the trial.  Although EXIT respondents appeared willing to 
participate and answered 98.9% of the questionnaire, women were not involved in formal 
testing of face and content validity, and the test-retest reliability of the EXIT was not 
assessed.  Also, the EXIT has also only been applied in one maternity hospital, using one 
method of IOL.  The research protocol recommended immediate commencement of 
oxytocin after ARM and hence women in both arms of the study were not encouraged to 
await spontaneous onset of contractions.  It is unknown the extent to which this early 
recourse to use of exogenous oxytocin may have modulated the experiential outcomes of 
participants. It would therefore be important to analyse this tool in another setting, with 
larger numbers, potentially with a different IOL method, and incorporating a measurement 
of test-retest reliability, to further assess the psychometric properties of the EXIT as a 
measure of women’s experience with IOL.  
 
At the individual item level, responses of women in the amniotomy group were consistently 
more favourable.  For three questions, the differences were statistically significant.  Having 
received more doses of PGE2 and likely experienced a longer labour, it is not a surprising 
finding that women in the repeat-PGE2 group were less happy with the time it took to have 
their baby, and with the number of vaginal examinations they received.  Furthermore, it is 
not unexpected that this result was specific to nulliparous women, who are more like to 
commence IOL with an unfavourable cervix.    Less intuitive, however, was why there were 
differences between the groups in responses to some of the process evaluation Items. 
Whilst responses to the item about perceived necessity of medical procedures did not 
differ between the groups, women in the repeat-PGE2 group (specifically multiparous 
women) did report feeling less “adequately prepared for being induced”.  There are 
marked differences in the rates of IOL between nulliparous and multiparous women [61].   
Less than one quarter of the study population had given birth prior, and many women who 
were induced with their second or third baby had been induced before.  These findings 
may highlight a “blindside” in maternity care, where women who have previously given 
birth are assumed to know “everything” already, and clinicians are insufficiently attentive to 
their queries and concerns [203].  However an alternative explanation would be that this 
item is not actually measuring the degree to which women feel involved in their care 
decisions.  Multiparous women who reported being the least prepared for being induced 
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experienced an IOL-to-birth interval over 7 hours longer than those who reported being the 
most prepared (27.8h versus 20.5h).    It is therefore plausible that the low scores for 
multiparous women in the repeat-PGE2 group may equate to them being under-prepared 
to experience a longer IOL process with repeated pharmacological ripening, rather than 
indicating inadequate involvement of patients in decisions about their care.   
 
Across the three sub-scales, responses of women in the amniotomy group were again 
consistently more favourable.  Women in the repeat-PGE2 group received up to 3 doses of 
PGE2 vaginal gel until labour commenced or the cervix was very favourable.  
Consequently, the time form IOL-to-birth was more than 5 hours longer than those 
managed according to a policy of amniotomy once technically possible, and their mean 
satisfaction scores with length of labour were correspondingly lower.  Vaginal 
examinations can be very uncomfortable for some women.  Use of dinoprostone for IOL is 
associated with vaginal pain [204, 205] thus it is a reasonable assumption that using more 
pharmacological priming may amplify this discomfort.    Similarly attempting to perform an 
ARM when the cervix is less ripe might be perceived by women as more uncomfortable 
[206, 207].  However, both the responses to the items and to the sub-scale measuring 
satisfaction with cervical ripening, are evidence that the activities involved in preparing the 
cervix for labour may be less uncomfortable when a policy of amniotomy once technically 
possible is adopted.  Considered together, the responses of women undergoing IOL in 
these Items and two sub-scales could support a broader hypothesis that short-term 
discomfort is expected, perceived as less intense, and even preferred when there is a 
reasonable expectation of a timely IOL process.  By contrast, women undergoing IOL may 
be less prepared for a long labour (especially a long period of cervical ripening and 
hospital admission), and less receptive to repeated vaginal examinations.  Indeed, to date 
the limited published studies on this topic, would affirm this principle that women being 
induced prefer a quicker labour, and are accepting of the interventions to achieve this 
[118, 119, 208, 209].  Regardless, it is important that women are adequately informed 
about the process of IOL including the possible time taken for labour to commence, the 
success rate of different protocols, and the likelihood of subsequent interventions that may 
be associated with the given method   
 
In previous Chapters, an in-hours birth was specifically promoted as a desired outcome 
following IOL in terms of safety, efficiency, and satisfaction.  In terms of the healthcare 
experience, satisfaction with an “in-hours” as opposed to “out-of-hours” birth has not 
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previously been measured.  Exploring the trial data further, the mean responses to Item 11 
(global satisfaction measure) for women who did and did not have an in-hours birth were 
compared in a post-hoc analysis.  In a bivariate analysis, women giving birth in-hours did 
not report higher mean scores than those who gave birth out-of-hours (4.0 versus 4.0, 
p=0.95).  When controlled for PGE2 vaginal gel policy, birth by CS and IOL-to-birth time in 
a simple linear regression analysis, an in-hours birth was not shown to be associated with 
greater overall satisfaction. However the variables birth by CS (p=0.01) and the IOL-to-
birth time (p<0.01) were identified as independent predictors of overall satisfaction.  
 
Consider first the association observed between birth by CS and overall satisfaction.  In 
broad terms, satisfaction can be determined either by the outcome of the healthcare event 
(so-called fulfilment theory), or by the degree to which the experience meets or does not 
meet expectations (so-called discrepancy theory) [154].  For women being induced and 
anticipating to birth vaginally, an emergency CS is likely to be both an undesired and 
unexpected outcome, and hence a driver of satisfaction.  With reference to these 
satisfaction theories, the association observed between overall satisfaction and IOL-to-
birth time, would support a hypothesis that a longer labour is an undesired and 
unanticipated outcome too.  But despite the logical connection between shorter labours 
and in-hours births, a daytime delivery was not associated with a more positive 
experience. 
 
It is reasonable assumption that women undergoing an IOL prefer a shorter labour.  
Women randomised to the amniotomy group experienced a 5-6 hour shorter duration of 
labour and, when asked of their experience 7 days later, reported being happier with how 
long it took for labour to start.  They reported being more satisfied with the length of labour; 
and women in both the amniotomy and repeat-PGE2 groups who experienced a shorter 
IOL-to-birth time, reported higher overall satisfaction.   The free text responses to the 
questionnaire were also consistent with this observation that the duration of induced labour 
is an important factor influencing women’s birth experience.   
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6.5 Chapter Summary 
The analyses in this Chapter validate the EXIT (EXperiences of Induction Tool) amongst 
women being induced with PGE2 vaginal gel. The experiential outcomes of women in the 
RCT (measured using the EXIT) are that where a policy of amniotomy once technically 
possible is followed, women report a more favourable experience of the duration of their 
labour and with the discomfort of the induction process. 
 
Maximising the chance of a timely commencement of IOL and subsequent reviews, 
performing an ARM as soon as technically possible, and commencing an oxytocin infusion 
immediately after ARM, are strategies that are likely to shorten an induced labour and 
contribute positively to a woman’s experience.  Indeed, the duration of an induced labour 
appears to be the factor most associated with maternal satisfaction.  Shortening an 
induced labour is also likely to result in less discomfort with cervical priming, a shorter 
hospital admission, and potentially it may reduce overall healthcare costs.   
 
Following an examination of the clinical outcomes of the RCT, an analysis of the factors 
associated with the time and mode of birth, and now an examination of women’s 
experiences with IOL, there remain a number of unanswered questions:  
 
1. Is the EXIT a valid tool for measuring the experience of women receiving 
mechanical methods of cervical ripening? 
 
2. What content and what method(s) should be used to share information with women 
to allow them to feel engaged in their healthcare decisions and to feel adequately 
prepared for IOL and their chosen IOL method? 
 
3. Would undertaking cervical ripening as an outpatient positively impact women’s 
experience of the length of induced labour and their overall satisfaction? 
 
4. Is a policy of amniotomy once technically possible associated with cost savings?  
Are there demonstrable cost savings associated with a shorter IOL-to-birth time, or 
are the savings only realised if there is a reduction in total hospital length-of-stay? 
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Chapter 7 Cost 
 
The material detailed in this Chapter has been has been:  
c) Presented at 2016 RCOG World Congress, Birmingham, UK 
d) Published in the European Journal of Obstetric Gynecology and Reproductive 
Biology [210] 
 
7.1 Background 
Having a baby is one of the commonest of all healthcare encounters.  More than 300,000 
babies were born in Australia in 2013 [1].  There is, however, very sparse detailed 
information as to how much this costs, and there have only been a handful of papers 
analysing the specific costs of maternity care in Australia [129-131].  These studies are 
now more than 15 years old.  They are also limited in their ability to describe the cost for 
both mother and baby, to describe costs for vaginal birth versus CS, or spontaneous 
versus induced birth, or to adequately calculate the real cost of the whole episode of 
maternity care (antenatal, intrapartum and postpartum care) [132, 133].  The sole RCT 
[140] that compared single dose versus multiple dose PGE2 vaginal gel regimens did 
report on healthcare costs.  Women receiving the single dose regimen incurred less 
antenatal ward expenses related to a short IOL-birth time, and also less neonatal costs, 
but greater birth suite costs.  Of note, whilst there may have been an opportunity to rupture 
the membranes and commence an oxytocin infusion after 6 hours for women in the 
amniotomy group,  only the women in the repeat dose arm of the trial were reviewed at 
this time, and given more PGE2.  These differences may have impacted the overall 
duration of ward care and birth suite care and therefore the healthcare costs.      
 
This Chapter again builds upon the Clinical Outcomes Chapter, using the data from a 
randomised controlled trial of two PGE2 vaginal gel policies, where the salient clinical 
findings included shorter IOL-to-birth time when following a policy of amniotomy once 
technically possible, rather than repeat PGE2 administration.  The analyses in this chapter 
also draw data from the hospital’s patient costing systems.  Finance has access to payroll, 
pathology, pharmacy, hotel services, the electronic maternity databases as well as the 
patient management index, to enable some computation of resource use at the patient 
level.  The overall cost of IOL and birth for women in the amniotomy group and repeat-
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PGE2 groups will be compared from the perspective of the hospital/health service.  
Considering the inherent uncertainty in the estimates of both cost and likelihoods of 
various clinical outcomes, a decision analytic model will be developed and presented.   
 
The Chapter tests the following research hypothesis for women undergoing IOL using 
PGE2 vaginal gel: A policy of amniotomy once technically possible compared with a policy 
of giving more PGE2 vaginal gel will result in less overall healthcare costs 
 
7.2 Methods 
A randomised controlled trial comparing two policies of PGE2 vaginal gel IOL was 
undertaken between March 2010 and August 2013.  Following an initial dose of PGE2 
vaginal gel in the evening, women were randomized the following morning into either the 
amniotomy or repeat-PGE2 group. Women in the amniotomy group underwent artificial 
rupture of membranes (ARM) regardless of MBS, and only received a further 1mg dose if 
ARM by an experienced clinician was not technically possible.   Women randomized to the 
repeat-PGE2 group received further doses of 1mg PGE2 to a maximum of 3 doses, until 
the MBS was greater than or equal to 7, when an ARM was performed.  The primary 
outcome was the time from commencement of IOL until birth.  Healthcare costs were a 
secondary outcome measure.  The dataset comprised both clinical outcomes and finance 
data during the time from the woman’s hospital admission until hospital discharge of 
mother and baby, for all 245 trial participants.   Finance data comprised information from 
payroll, pathology, pharmacy, hotel services, revenue services and patient management 
index.  Clinical data, that was recorded in the hospital’s electronic maternity record and 
paper health record, were extracted from the hospital’s record systems by a research 
midwife and written onto a proforma before entry into the electronic research database.   
 
The use of healthcare resources during the patient journey was divided and counted in 4 
separate groupings:  
 
1. cervical priming and care in an antenatal ward 
2. labour 
3. birth in birth suite or birth in the operating theatre, and  
4. postnatal care of mother and baby.   
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Hospital Finance provided an estimate of cost for each participant inclusive of nursing / 
midwifery, medical and allied health staff costs, equipment and consumables, hotel 
services and business overheads.  The specific healthcare resources included cost per 
hour of admission (to ward, birth suite, theatre, ICU, neonatal nursery); cost of PGE2, 
Syntocinon and analgesia; costs of amnihook, fetal blood sampling, suturing, IV fluids, 
pathology tests and blood transfusions.  (Table 7.1).  Health records were perused by the 
research midwife to determine time intervals from PGE2 1st dose to 2nd dose (or ARM or 
SROM); from PGE2 2nd dose to 3rd dose (or ARM or SROM); from PGE2 3rd dose to ARM 
or SROM; from  ARM  or  SROM  until  birth  in  birth  suite  or  birth  in theatre; and from  
 
Table 7.1: Itemised costs for women undergoing IOL (2015 $AUD) 
 
 
a per hour of admission, inclusive of midwifery, medical and allied health staff costs, 
equipment, consumables, hotel services and business overheads    
 
 
b per hour in operating theatre complex, inclusive of nursing and anaesthetic staff costs, 
equipment, consumables and business overheads    
 
c per hour of nursery admission, inclusive of nursing, medical and allied health staff costs, 
equipment, consumables and business overheads    
 
admission to postnatal ward until discharge home of mother and baby.   Whilst some of 
these costs (eg pharmacy, pathology) were measured at the patient level, nursing / 
midwifery, medical, allied health and other salaries & wages as well as business 
overheads were estimated in each grouping as an apportioned percentage of total costs.   
Item Unit Unit Cost 
Length of stay in birth suite hour $281 a 
Length of stay in pregnancy assessment unit hour $485 a 
Length of stay in postnatal ward hour $37 a 
Length of stay in antenatal ward hour $33 a 
Length of stay in operating theatre hour $1520 b 
Length of stay in neonatal intensive care nursery  hour $103 c 
Length of stay in neonatal special care nursery hour $72 c 
PGE2 vaginal gel 2mg dose $67.53 
PGE2 vaginal gel 1mg dose $56.10 
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The analyses have taken a hospital perspective of healthcare costs, from hospital 
admission until hospital discharge.  Total mean / median costs, and the cost differences 
between amniotomy and repeat-PGE2 groups have been presented.  Costs have been 
expressed in Australian dollars at 2015 prices, and inflated as per Australia’s CPI over this 
time (mean 2.6% p.a.) [211].  Qquality-adjusted life-years (QALY), a common and 
accepted measure of cost and health benefit [212], have not been reported.  QALY-based 
analyses take a long-term and often life-long view; as such, analyses are rarely 
undertaken in maternity [213].  In the short timeframe from IOL to birth, it is highly unlikely 
that utility scores would differ between women who laboured longer or shorter.  Even for 
the outcome of CS with its longer hospital stay, recovery, and potential complications, 
authors have reported no appreciable difference in utility scores compared to those giving 
birth vaginally [214, 215].   
 
There is a paucity of information about the costs and benefits of IOL both generally, and 
specifically for IOL using PGE2 vaginal gel.  Although QALYs may not be the appropriate 
measure, the reporting of just costs or just clinical outcomes would fail to accurately 
summarise the benefit or cost (harm) of following one policy versus the other.  There is 
also inherent uncertainty in both the cost estimate and the likelihood of the clinical 
outcomes, such that reporting just a point estimate risks misrepresenting the true gamete 
of probable outcomes.  A decision analytic model, specifically a Markov model, was 
therefore developed to further investigate the costs and benefits of adopting a policy of 
amniotomy once technically possible compared with a policy of repeat PGE2 
administration.  Using this methodology, the various points in the IOL journey 
(administration of PGE2 doses, labour, birth in birth suite or theatre), and inpatient journey 
(postnatal care and accommodation for mother and baby) are described as mutually 
exclusive “states” through which women transition.  The likelihood of transition from one 
state to the next (eg from PGE2 dose to labour) has a specific probability, depending on 
the woman’s actual treatment sequence.  And once each of these Markov states are 
ascribed a cost, a hypothetical cohort model can generate a clearer understanding of the 
costs for women receiving one IOL policy versus the other.  When a Markov model applies 
Monte Carlo simulation, the statistical uncertainty of the parameters (here cost and 
transition probabilities) and the heterogeneity of the patient cohort can be analysed.  
Hereby, the model is run thousands of times with each simulation drawing a value from a 
given parameter distribution at random.  The result is a large sample of possible 
outcomes, which can then be summarised and reported [145, 146].
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State A 
Admitted for 
1st dose PGE2   
State B 
Review for   
2nd dose PGE2   
 
State C 
Review for    
3rd dose PGE2   
  State D 
Labour   
  State E 
  Vaginal birth  
State F 
Caesarean 
Section    
Absorbing State H 
Mother & Baby  
discharged home 
State G1 
Postnatal care 
in Ward Day 0                 
 
State G3 
Day 1                 
 
State G4 
Day 2                 
 
State G2 
Day 1                 
 
State G5 
Day 2                 
 
State G6 
Day 3                 
 
Figure 7.1: Markov chain – PGE2 vaginal gel IOL 
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State A 
• Time when woman is admitted to hospital for 1st dose PGE2
• Includes: 2h process of PGE2 administration (CTG, midwifery / medical time), then ward care
• STARTS when: 1st dose PGE2 adminstered in Pregnancy Assessment Unit
• ENDS when: leaves antenatal ward to go to Birth Suite for  next review, or because in labour
State B
• Administration & care after PGE2 (2nd dose)
• Includes: 2h process of PGE2 administration (CTG, midwifery / medical time), then ward care
• STARTS when: leaves antenatal ward to go to Birth Suite for 2nd dose of PGE2
• ENDS when: leaves ward again to go to Birth Suite for next review, or because in labour
State C
• Administration & care after PGE2 (3rd dose)
• Includes: 2h process of PGE2 administration (CTG, midwifery / medical time), then ward care
• STARTS when: leaves antenatal ward to go to Birth Suite for 3rd dose of PGE2
• ENDS when: leaves ward again to go to Birth Suite for next review, or because in labour
State D
• Labour (woman is in Birth Suite)
• Includes: midwifery / medical time, syntocinon, analgesia 
• STARTS when: “admitted” to Birth Suite when in labour, or to have membranes ruptured
• ENDS when: baby is born in Birth Suite or woman goes to theatre
State E
• Vaginal Birth (and first 12 hours)
• Includes:midwifery / medical time, paediatric, anaesthetic, then ward care
• STARTS when: baby is born
• ENDS when: 12 hours after birth, mother and baby are in postnatal ward
State F
• Caesarean Section (and first 12 hours)
• Includes: nursing, midwifery, obstetric, paediatric, anaesthetics, recovery, then ward care 
• STARTS when: “admitted” to theatre to have a baby
• ENDS when: 12 hours after birth, mother and baby are in postnatal ward
State G
• Postnatal care (includes mother and baby)
• Includes: nursing, medical, physio, pharmacy, consumables, drugs, baby care costs (per 12h)
• STARTS when: 12 hours post-birth  
• ENDS when: (a) 12h cycle is up and moving to next State or (b) mother & baby discharged 
State H
• Absorbing State - mother & baby discharged home
Figure 7.2: Markov states defined 
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A decision analytic model for PGE2 vaginal gel IOL was constructed to compare the costs 
of adopting a policy of amniotomy once technically possible versus repeat-PGE2 
administration.   (Figure 7.1).  The analysis was constructed as a Markov chain with 13 
states from hospital admission to commence IOL, until discharge home of mother and 
baby.  Having considered the mean duration from 1st dose PGE2 to next review and from 
ARM to birth, a 12-hour cycle was chosen.  Two states (D, G6) were drawn as a recurring 
State which means women can spend more than one cycle (>12 hours) in this State.  After 
reviewing the statistical distribution of postnatal length of stay (especially for those who 
remained an inpatient beyond 3 days postpartum), the “postnatal care” States (G1 to G55) 
were drawn as tunnel states (only one cycle in each State), and State G6 was drawn as a 
recurring State, prior to moving to the absorbing State H where mother and baby are 
discharged home.  Each State was defined in terms of its start and end points and a list of 
cost components in each State was assembled.  (Figure 7.2).  The probability of 
transitioning from one State to the next was derived from the RCT data.  In each 12-hour 
cycle the likelihood of remaining in the current State or progressing to future States was 
calculated.  These transition probabilities (and 95% CI) were determined for both the 
amniotomy and repeat-PGE2 groups.  (Tables 7.2 and 7.3).   
 
Using the point estimates of the transition probabilities and the median resource use in 
each Markov State, a 1000-patient cohort simulation was performed over 16 cycles, and 
the total cost differences (and cost per participant) between the two PGE2 vaginal gel 
policies have been reported.  To confirm the robustness of these findings, a 104 Monte 
Carlo simulation was performed varying both the transition probabilities and cost estimates 
through a random draw of these values from between the upper and lower 95% 
confidence intervals.  A beta distribution of variance was used for the transition 
probabilities and a gamma distribution was used for costs.  Both mean and median costs 
and cost differences between each PGE2 vaginal gel policy have been reported.  
Modelling was built de novo and analyses undertaken using Microsoft Excel (2010).
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Table 7.2: Transition probabilities (95% CI) – repeat-PGE2 policy 
 
 Transition to 
State 
A 
State 
B 
State 
C 
State 
D 
State 
E 
State 
F 
State 
G1 
State 
G2 
State 
G3 
State 
G4 
State 
G5 
State 
G6 
State 
H 
T
ra
n
s
it
io
n
 f
ro
m
 
State A 0 0.63  
0.54, 0.72 
0 0.34 
0.26, 0.42 
0.03 
0, 0.06 
0 0 0 0 0 0 0 0 
State B 0 0 0.25 
0.15, 0.35 
0.63 
0.52, 0.74 
0.08 
0.02, 0.14 
0.04 
0, 0.08 
0 0 0 0 0 0 0 
State C 0 0 0 0.60 
0.38, 0.82 
0.24 
0.05, 0.43 
0.16 
0, 0.32 
0 0 0 0 0 0 0 
State D 0 0 0 0.32 
0.24, 0.40 
0.50 
0.41, 0.59 
0.18 
0.11, 0.25 
0 0 0 0 0 0 0 
State E 0 0 0 0 0 0 0.99 
0.97, 1 
0 0 0 0 0 0.01 
0, 0.03 
State F 0 0 0 0 0 0 1 0 0 0 0 0 0 
State G1 0 0 0 0 0 0 0 0.99 
0.97, 1 
0 0 0 0 0.01 
0, 0.03 
State G2 0 0 0 0 0 0 0 0 0.84 
0.77, 0.91 
0 0 0 0.16 
0.09, 0.23 
State G3 0 0 0 0 0 0 0 0 0 0.94 
0.89, 0.99 
0 0 0.06 
0.01, 0.11 
State G4 0 0 0 0 0 0 0 0 0 0 0.85 
0.78, 0.92 
0 0.15 
0.08, 0.22 
State G5 0 0 0 0 0 0 0 0 0 0 0 0.78 
0.69, 0.87 
0.22 
0.13, 0.31 
State G6 0 0 0 0 0 0 0 0 0 0 0 0.47 
0.35, 0.59 
0.53 
0.41,0.65 
State H 0 0 0 0 0 0 0 0 0 0 0 0 1 
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Table 7.3 :Transition probabilities (95% CI) – amniotomy policy 
 
 
 Transition to 
State A State 
B 
State 
C 
State 
D 
State 
E 
State 
F 
State 
G1 
State 
G2 
State 
G3 
State 
G4 
State 
G5 
State 
G6 
State H 
T
ra
n
s
it
io
n
 f
ro
m
 
State A  0 0.19 
0.12, 0.26 
0 0.78 
0.71, 0.85 
0.03 
0, 0.06 
0 0 0 0 0 0 0 0 
State B 0 0 0.22 
0.05, 0.39 
0.65 
0.46, 0.84 
0.09 
0, 0.21 
0.04 
0, 0.12 
0 0 0 0 0 0 0 
State C 0 0 0 0.80 
0.52,1 
0 0.20 
0, 0.48 
0 0 0 0 0 0 0 
State D  0 0 0 0.34 
0.26, 0.42 
0.5 
0.41, 0.59 
0.16 
0.09, 0.23 
0 0 0 0 0 0 0 
State E 0 0 0 0 0 0 0.95 
0.91,0.99 
0 0 0 0 0 0.05 
0.01, 0.09 
State F 0 0 0 0 0 0 1 0 0 0 0 0 0 
State G1 0 0 0 0 0 0 0 0.91 
0.86, 0.96 
0 0 0 0 0.09 
0.04, 0.14 
State G2 0 0 0 0 0 0 0 0 0.97 
0.94, 1 
0 0 0 0.03 
0, 0.06 
State G3 0 0 0 0 0 0 0 0 0 0.85 
0.78, 0.92 
0 0 0.15 
0.08, 0.22 
State G4 0 0 0 0 0 0 0 0 0 0 0.75 
0.66, 0.84 
0 0.25 
0.16, 0.34 
State G5 0 0 0 0 0 0 0 0 0 0 0 0.73 
0.62, 0.84 
0.27 
0.16, 0.38 
State G6 0 0 0 0 0 0 0 0 0 0 0 0.48 
0.34, 0.62 
0.52 
0.38, 0.66 
State H 0 0 0 0 0 0 0 0 0 0 0 0 1 
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7.3 Results 
7.3.1. Healthcare costs 
The healthcare costs associated with IOL were available for all 245 trial participants.  
These costs did not differ across the budget groupings of salaries & wages, pharmacy and 
pathology, hotel services or other indirect costs.  Whilst costs were less in every grouping 
in the amniotomy group compared with the repeat-PGE2 group, there were no statistically 
significant differences.  The total mean difference ($374) and median difference ($297) 
also favoured the amniotomy group.  (Table 7.4) 
 
Table 7.4 Total healthcare costs for trial participants, stratified by PGE2 vaginal gel policy  
Cost 
Amniotomy group Repeat-PGE2 group 
p-value* Mean Median   
(IQR) 
Mean Median 
(IQR) 
Nursing / midwifery  
salaries & wages 
$3426 
$3280         
($2630-$4022) 
$3532 
$3349        
($2601-$4110) 
0.580 
Medical  
salaries & wages 
$741 
$630         
($360-$1074) 
$860 
$657        
($431-$1083) 
0.783 
Other  
salaries & wages 
$1426 
$1308     
($1001-$1736) 
$1450 
$1362      
($979-$1826) 
0.627 
Pharmacy and 
Pathology 
$370 
$335        
($184-$502) 
$448 
$375        
($185-$511) 
0.834 
Hotel services $339 
$318        
($223-$426) 
$357 
$324        
($239-$416) 
0.829 
Other indirect costs $1077 
$1057       
($830-$1372) 
$1147 
$1069   
($734-$1347) 
0.640 
Total $7541 
$7121 
($5510-$9198) 
$7915 
$7418 
($5115-$9366) 
0.669 
 
 
* Mann-Whitney-U test 
IQR: inter-quartile range  
 
7.3.2. Cohort simulation 
Using the constructed Markov chain (Figure 7.1) and transition probabilities (Tables 7.2 
and 7.3), a 1000-patient cohort simulation was performed over 16 cycles.  This number of 
cycles (192 hours) reflected the time from admission to hospital discharge for all but one of 
the 245 trial participants.  The results of the Markov trace detail the proportion of patients 
in each state for each12-hour cycle and are presented for both the amniotomy and repeat-
PGE2 groups. (Tables 7.5 and 7.6).   
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Table 7.5 Results of Markov trace for amniotomy group: cohort simulation of 1000  
 
 
 
 
 
 
Cycle State A State B State C State D State E State F State G1 State G2 State G3 State G4 State G5 State G6 State H Total 
1 0 190 0 780 30 0 0 0 0 0 0 0 0 1000 
2 0 0 42 389 407 132 29 0 0 0 0 0 2 1000 
3 0 0 0 166 194 71 519 26 0 0 0 0 24 1000 
4 0 0 0 56 83 26 255 472 25 0 0 0 82 1000 
5 0 0 0 19 28 9 105 232 458 21 0 0 127 1000 
6 0 0 0 7 10 3 36 96 225 390 16 0 219 1000 
7 0 0 0 2 3 1 12 33 93 191 292 12 361 1000 
8 0 0 0 1 1 0 4 11 32 79 144 219 510 1000 
9 0 0 0 0 0 0 1 4 11 27 59 210 687 1000 
10 0 0 0 0 0 0 0 1 4 9 20 144 821 1000 
11 0 0 0 0 0 0 0 0 1 3 7 84 904 1000 
12 0 0 0 0 0 0 0 0 0 1 2 45 951 1000 
13 0 0 0 0 0 0 0 0 0 0 1 23 975 1000 
14 0 0 0 0 0 0 0 0 0 0 0 12 988 1000 
15 0 0 0 0 0 0 0 0 0 0 0 6 994 1000 
16 0 0 0 0 0 0 0 0 0 0 0 3 997 1000 
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Table 7.6 Results of Markov trace for repeat-PGE2 group: cohort simulation of 1000  
 
 
 
Cycle State A State B State C State D State E State F State G1 State G2 State G3 State G4 State G5 State G6 State H Total 
1 0 630 0 340 30 0 0 0 0 0 0 0 0 1000 
2 0 0 158 506 220 86 30 0 0 0 0 0 0 1000 
3 0 0 0 256 291 116 305 29 0 0 0 0 3 1000 
4 0 0 0 82 128 46 404 302 25 0 0 0 13 1000 
5 0 0 0 26 41 15 173 400 253 23 0 0 69 1000 
6 0 0 0 8 13 5 55 171 336 238 20 0 153 1000 
7 0 0 0 3 4 2 18 55 144 316 202 15 242 1000 
8 0 0 0 1 1 0 6 18 46 135 268 165 359 1000 
9 0 0 0 0 0 0 2 6 15 43 115 287 532 1000 
10 0 0 0 0 0 0 1 2 5 14 37 225 717 1000 
11 0 0 0 0 0 0 0 1 2 4 12 134 847 1000 
12 0 0 0 0 0 0 0 0 0 1 4 72 922 1000 
13 0 0 0 0 0 0 0 0 0 0 1 37 961 1000 
14 0 0 0 0 0 0 0 0 0 0 0 18 981 1000 
15 0 0 0 0 0 0 0 0 0 0 0 9 991 1000 
16 0 0 0 0 0 0 0 0 0 0 0 4 996 1000 
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Using the RCT data, and the healthcare costs for each participant, the mean and median 
costs for each Markov state were then calculated.  The tunnel states (G1-G6) were 
ascribed the same cost per 12-hour cycle.  (Table 7.7).    
 
Table 7.7 Mean and median costs associated with each Markov State 
State Mean cost (SD) Median cost (IQR) 
A $1525 ($145) $1485 ($1443 - $1576) 
B $981 ($118) $950 ($916 - $1015) 
C $829 ($105) $783 ($772 – 859) 
D $2593 ($1402) $2389 ($1570 - $3543) 
E $1356 ($838) $1123 ($1038 - $1326) 
F $2360 ($579) $2260 ($1927 - $2599) 
G1-6 $476 ($189) $444 ($444 - $444) 
 
 
Then by multiplying the proportion of participants in each state by the median cost of being 
in that state over the 16 cycles, the healthcare costs for two hypothetical cohorts of 1000 
women undergoing PGE2 IOL following either of the two policies were determined.  In this 
simulation, the cost per participant in the amniotomy group was $289.32 less than in the 
repeat-PGE2 group.  (Table 7.8).   
 
Table 7.8 Costs of amniotomy once technically possible, and repeat-PGE2 policies: cohort 
simulation of 1000 using probabilistic modelling 
 
Amniotomy group Repeat-PGE2 group Cost difference Per participant 
$7,094,270 $7,383,587 $289,317 $289.32 
 
 
 
7.3.2. Markov chain Monte Carlo simulation 
Propagating the uncertainty through the model 10,000 times, a policy of amniotomy once 
technically possible was associated with a median cost that was $487.11 less than a policy 
of repeat PGE2 administration.  (Table 7.9).  A box plot (Figure 7.3) and histogram derived 
from the cumulative probability distribution (Figure 7.4) demonstrate the distribution of 
costs.    
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Figure 7.3 Box plot of costs of amniotomy once technically possible, and repeat-PGE2 policies: 104 
Markov chain Monte Carlo Simulation 
 
 
 
 
Figure 7.4 Cumulative histogram of costs of amniotomy once technically possible, and repeat-
PGE2 policies: 104 Markov chain Monte Carlo Simulation 
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Table 7.9 Mean and median costs, and cost differences comparing amniotomy and repeat-PGE2 groups: 104 Markov chain Monte Carlo Simulation 
 
 
 
 
 
 
 
 
 
 
 
  
 
Table 7.10 Sensitivity analyses of median costs based on 104 Markov chain Monte Carlo Simulation 
 
Sensitivity Analyses 
Amniotomy group 
Median cost (IQR) 
Repeat-PGE2 group 
Median cost (IQR) 
Median cost difference 
(IQR) 
0. Base case 
$7414.17 
($6677.00, $8285.65) 
$7891.77 
($7286.64, $8596.00) 
$487.11 
(-$573.08, +$1497.80) 
1. Nullipara 
$8426.81 
($7690.72, $9306.55) 
$8590.64 
($7950.85, $9325.19) 
$158.33 
(-$963.48,+$1228.40) 
2. Multipara 
$5958.78 
($5330.03, $6745.11) 
$6090.12 
($5567.26, $6694.68) 
$146.04 
(-$791.28, +$997.62) 
3. Unfavourable cervix a 
$8137.83 
($7488.04, $8960.66) 
$8332.55 
($7743.02, $9033.82) 
$180.66 
(-$831.75, +$1140.83) 
4. Favourable cervix b 
$6940.96 
($6232.70, $7833.61) 
$7163.84 
($6592.41, $7817.03) 
$203.83 
(-$837.16, +$1189.50) 
 
a MBS at initial vaginal examination ≤3   
b MBS at initial vaginal examination >3     
Group 
Mean cost 
(95% CI) 
Median cost 
(IQR) 
Mean cost difference 
(95% CI) 
Median cost difference 
(IQR) 
Amniotomy  
$7603.38 
($7577.27, $7629.41) 
$7414.17 
($6677.00, $8285.65) 
ref ref 
Repeat-PGE2  
$8023.98 
($8003.73, $8044.82) 
$7891.77 
($7286.64, $8596.00) 
+$420.61 
(+$387.52, +$454.35) 
+$487.11 
(-$573.08, +$1497.80) 
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Sensitivity analyses were then undertaken by generating transition probabilities (and 95% 
CI) from the RCT data for the subgroups of nulliparas, multiparas, unfavourable (MBS at 
initial vaginal examination less than or equal to 3) and favourable cervix (MBS at initial 
vaginal examination greater than 3).  Four 104 Monte Carlo simulations were performed.  
Across every sub-group, the median costs of PGE2 vaginal gel IOL favoured a policy of 
amniotomy once technically possible.  The simulations did not identify a scenario where a 
policy of repeat-PGE2 administration would clearly be favoured.  (Table 7.10).    
       
 
7.4 Conclusions 
After an initial dose of PGE2 vaginal gel, administering more PGE2 when the MBS is less 
than 7 was associated with increased healthcare costs compared with performing an 
amniotomy, if technically possible.  A decision analytic model constructed from the RCT 
data, demonstrated that in a hypothetical cohort of 1000 participants, median cost savings 
of almost $300 per participant would be expected if a policy of amniotomy once technically 
possible was adopted rather than a policy of repeat-PGE2 administration.  And by varying 
all of the input parameters simultaneously in a 104 Monte Carlo simulation, the model 
demonstrated median cost savings closer to $500, when a policy of early amniotomy was 
followed rather than one of giving more PGE2.  Whilst the RCT demonstrated no overall 
difference in length of hospital stay, a policy of early amniotomy (rather than repeat-PGE2 
administration) reduced the IOL-to-birth time, and would appear to be cost-saving.      
 
The healthcare costs of the 245 participants in the amniotomy and repeat-PGE2 groups 
were not statistically significantly different.  Although median costs were $297 less in the 
amniotomy group, the estimates of costs were imprecise (comprising a mix of both patient-
level costings and apportioned percentages of total costs), and the trial was under-
powered to demonstrate this difference.  Decision analytic modelling is a framework that 
embraces uncertainty, and accepts the imprecision of the assumptions and of the input 
cost parameters.  Statistical significance is of lesser importance; rather the focus is on 
quantifying uncertainty for each variable in order to best represent the direction and 
magnitude of an effect.  Decision-analytic models commonly use QALYs, measures 
reflective of both cost and health (utility) scores.  One study has reported utility scores for 
women undergoing IOL [216], and health utility scores have also been reported for 
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significant life-altering birth outcomes like hysterectomy and neurological disability [217].   
But generally in the short interval from onset of labour to birth of the baby, utility scores are 
too blunt a discriminator of quality of life.  Furthermore, in maternity there is the additional 
challenge of simultaneously considering the outcomes for both mother and child, and there 
is no accepted way to do this.  Five economic evaluations of RCTs of IOL protocols have 
been published in the last 6 years [137, 139, 218-220], but only one has reported QALYs.   
 
The primary outcome of the RCT was the time from IOL-to-birth.  Not only is the timeliness 
a key factor in the woman’s healthcare experience, the costs associated with IOL are also 
a function of the time taken to provide this care.  As an alternative, the costs associated 
with IOL could have been analysed using a decision-tree.  However decision-tree models 
are unable to incorporate a time variable, and all events are assumed to happen at the 
same time.  Markov analyses, on the other hand, are ideally suited to represent complex 
processes that change over time, like IOL.  All models are imperfect.  The limitation of a 
Markov analysis is the lack of “memory”.  The transition probabilities from one State to the 
next are dependent upon just the prior state, and significant events from earlier in the 
patient journey are unable to influence these probabilities.  In addressing this, the Markov 
chain used in these analyses has been constructed in some detail, using the RCT data to 
describe time-dependent transition probabilities between each of the named PGE2 doses 
(1, 2, 3), rather than providing an average transition probability.  Furthermore, a relatively 
short cycle length of 12 hours has been chosen, after considering the duration of active 
labour and the common intervals between PGE2 doses.  A Markov decision processes is a 
more flexible type of Markov analysis which is able to take into account the decision-
maker, rather than just random transition probabilities [221].   In Markov decision 
processes there are a number of possible events that can cause a transition and therefore 
usually require thousands of data points in order to generate the multiple transition 
probabilities for each decision-point.  Given the trial protocol dictated the care for women 
in the amniotomy and repeat-PGE2 groups, the IOL patient journey did not comprise 
complex decision-making, and was able to be described using a relatively simple Markov 
chain inclusive of time-dependent probabilities. 
 
The analyses of healthcare costs demonstrate that some aspects of the patient journey 
were much more expensive than others.  State F (birth by caesarean section and the first 
12 hours in a postnatal ward), was just as expensive as State D (12 hours in birth suite), 
but both states were three times the cost of States B & C (review in birth suite for 
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subsequent doses of PGE2 vaginal gel, then transfer to antenatal ward).  Administering 
more PGE2 did not make the ensuing labour significantly quicker nor did it alter the 
likelihood of birth by CS.   Therefore the cost savings associated with earlier amniotomy 
likely reflect savings in salaries & wages, pharmacy, hotel services and indirect costs by 
avoiding additional doses of PGE2 vaginal gel.  Even when modelled for multiparous 
women and those with a favourable cervix (where it might be assumed that women are 
more “primed” for labour and that giving more PG might shorten the duration of 
contractions and the expensive stay in birth suite), earlier amniotomy was still cost-saving.    
 
These findings are in contrast to the analysis of cost for the only other RCT that has 
compared amniotomy and repeat-PGE2 PGE2 vaginal gel protocols of IOL [140].   In their 
cost analysis, Mackenzie reported that antenatal ward costs were also lower when a single 
dose of PGE2 gel was used.   Birth suite costs were however higher, and the overall costs 
slightly more in the amniotomy group.  It is noteworthy that in this trial, it was only the 
women randomised to the repeat dose group who were reviewed 6 hours later.  Unless the 
woman laboured, an ARM was not attempted until 14-20 hours following the first dose of 
PGE2 vaginal gel.   Had the review for women in the single dose arm occurred at the 
same time as women in the repeat dose arm, it is plausible that an ARM would have been 
performed, an oxytocin infusion commenced earlier, IOL-to-birth time and length-of-stay 
may have been shorter, and therefore birth suite and postnatal costs reduced in the single 
dose group.  Regardless, both of these cost analyses are a clear reminder that differences 
in healthcare costs are dominated by the duration of care more than any other cost.  Given 
that we observed no difference in the hospital length of stay, it would appear that IOL 
policies that specifically reduce the duration from IOL to birth may be associated with the 
lowest costs. 
 
There are many examples of how duration of care is the driver of cost.    Van Baaren 
[218], in a comparison of Foley catheters with PGE2 vaginal gel, reported that cost 
differences in the two groups predominantly originated from differences in the duration of 
labour ward stay.  Eddama [219], in a placebo controlled RCT of outpatient isosorbide 
mononitrate prior to IOL, identified that the largest cost difference between groups was 
due to time spent in the antenatal ward.  And Petrou [220], in a RCT of IOL using PGE2 
vaginal gel versus tablet, reported cost savings associated with a reduction in the time 
from IOL-to-birth.  Outside of maternity care, examples include the use of emergency 
department observation units [222], clinical pathways [223, 224], and fast-track surgery / 
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advanced recovery programs [225, 226].  Reducing the length of stay not only reduces 
workforce costs, it also enables the fixed costs associated with the delivery of healthcare 
to be reallocated to the treatment of more patients with additional benefit.  So despite the 
capital costs involved in building observation units and the additional workforce costs 
associated with advanced recovery programs, these strategies are cost-effective because 
they successfully reduce the biggest driver of healthcare costs: length of stay. 
 
The costing analyses presented have a number of limitations.  Whilst the risk of bias 
associated with the trial protocol is considered low, it is recognised that the clinical 
outcome data used for the models has been derived from a single trial of only 245 women.  
The numbers in each Markov state, particularly in the sub-groups used for the sensitivity 
analyses, are very small, and the uncertainty around some probability estimates is high.  
Rare adverse clinical outcomes following IOL were not modelled.  Additionally, the 
estimates of costs are, with few exceptions, representative of a cost per hour, rather than a 
precise estimate of cost for the individual woman.  The analyses are also considering the 
impacts on the healthcare system alone, and not the broader context of costs to the 
woman or community.   It is acknowledged that alternative costing methods, or applied in a 
different hospital setting, may have resulted in different conclusions.  However it is 
because of this uncertainty in both costs and clinical outcomes that Monte Carlo 
simulations and sensitivity analyses were undertaken.  The policy of amniotomy once 
technically possible was associated with reduced healthcare costs compared with the 
policy of repeat-PGE2 administration through 10,000 patient cohort simulations, both 
overall and in the subgroups of nulliparous and multiparous women, and in those with and 
without a favourable cervix.  There were no scenarios where the policy of repeat PGE2 
administration was favoured.  Considered in the context of the Clinical Outcomes Chapter, 
giving more PGE2 when it is technically possible to perform an ARM, would seem merely 
to postpone labour and birth, and lead to greater use of healthcare resources.  A median 
cost difference of $487 may seem a relatively small amount.  However, when considering 
that almost 80,000 inductions of labour will be undertaken in Australian this year [5], the 
nationwide adoption of a policy of amniotomy once technically possible would be 
associated with cost-savings of more than $AUD 38,000,000 per annum. 
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7.5 Chapter Summary 
The analyses in this Chapter support the conclusion that amongst women being induced 
using PGE2 vaginal gel, a policy of earlier amniotomy is associated with less healthcare 
costs than a policy of repeat-PGE2 administration.  The duration of care is the key variable 
driving cost.  Administering more PGE2 vaginal gel when it is technically possible to 
perform an ARM, has no demonstrable clinical advantage, it leads to an overall longer time 
from IOL-to-birth and therefore increased healthcare costs.  Costs were explored using a 
hypothetical cohort of 1000 patients, and a 104 Markov chain Monte Carlo simulation plus 
sensitivity analyses across four sub-groups. In each analysis the policy of amniotomy once 
technically possible was shown to cost less.   
 
Following an examination of the clinical outcomes of the RCT, an investigation into the 
factors associated with the time and mode of birth, an exploration of women’s experiences, 
and now an analysis of healthcare costs associated with two common approaches to 
PGE2 vaginal gel IOL, there remain a number of unanswered questions:  
 
1. Would outpatient cervical ripening be as efficacious and safe, as acceptable to 
women, and associated with cost savings compared with cervical ripening as an 
inpatient? 
 
2. Similarly, would mechanical methods of cervical ripening (eg balloon catheters) be 
associated with more or less cost, and similar clinical and satisfaction outcomes, 
when compared with pharmacological cervical ripening? 
 
3. Given the premium costs associated with care in birth suite, would establishing 
alternative models of care clinic units for the care of women in early labour (eg early 
labour wards) be associated with cost savings compared to current models of care? 
 
4. Would a more liberal / routine use of IOL near term, be associated with more or 
fewer CS, increased or decreased maternal satisfaction, shorter or longer labours 
(and therefore differences in healthcare costs), when compared with the current 
practice of undertaking IOL only for defined maternal  and fetal indications? 
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Chapter 8 Conclusions 
 
In most developed countries, more than one in four women will have their labour induced.   
In Australia and around the world, PGE2 vaginal gel is the most commonly used agent to 
prepare the cervix for labour.  Yet the policies and guidelines that direct the use of this 
product provide scarce detail and there is almost no evidence-base to the 
recommendations of how to use this.  Clinicians’ experience of IOL is dominated by 
exposure to a select group of women with usually complicated or post-term pregnancies.  
They observe a prolonged process, women experiencing discomfort, and seemingly 
disproportionate rates of obstetric intervention.  Drawn to minimise what clinicians perceive 
to be a negative experience for women, some will delay administration of oxytocin once 
the membranes are ruptured in the hope of ‘spontaneous’ onset of contractions, or they 
may administer more PGE2 when it is technically possibly but presumably more painful to 
rupture the membranes.  Others (and for similar motivations), endeavour to accelerate the 
process as much as possible, presuming that a longer process is associated with a 
negative experience, is more uncomfortable overall and more likely to lead to failure and 
need for CS.  To date, we have not known the best way to undertake IOL using PGE2 
vaginal gel.   This thesis, therefore, sought to explore the clinical outcomes, healthcare 
experiences and costs associated with two specific protocols of PGE2 vaginal gel IOL.   
 
 
 
8.1 The research questions 
This aim of this thesis was to compare two policies of PGE2 vaginal gel for IOL at term: a 
policy of amniotomy once technically possible (regardless of MBS), versus a policy of 
giving more PGE2 vaginal gel (repeat administration and amniotomy only when MBS ≥ 7).  
Under both protocols, in the absence of uterine activity, clinicians recommended that an 
oxytocin infusion be commenced as soon as possible.  Four key objectives were 
addressed.  Across the domains of clinical outcomes, healthcare experience and costs, a 
policy of amniotomy once technically possible was consistently associated with superior 
outcomes: 
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1) Determine which policy of PGE2 vaginal gel IOL results in the shorter IOL-to-birth time 
and is associated with lower rates of obstetric intervention and morbidity 
 
A randomised controlled trial was devised and undertaken to compare the two policies of 
PGE2 vaginal gel IOL.  The primary outcome was the time from IOL-to-birth.  The use of a 
single dose (prior to an ARM and oxytocin infusion), was associated with a significantly 
shorter IOL-to-birth time compared with using multiple doses of PGE2.  Whilst under-
powered to determine differences in mode of birth, use of epidural analgesia and adverse 
maternal / perinatal outcomes, no differences were observed between the two groups.  
Repeat dosing of PGE2 in the hope of starting contractions and/or making the cervix “very 
favourable” had no demonstrable clinical benefits over a single dose.     
 
2) Determine the clinical characteristics of women who might experience the shortest 
labours and lowest rates of CS with each policy of PGE2 vaginal gel IOL 
 
Using the data from the RCT this analysis determined that parity and the MBS at the time 
of 1st review were the two factors that were most predictive of the mode, duration and time 
of birth.  But regardless of both parity and favourability of the cervix, a policy of amniotomy 
once technically possible was associated with a greater chance of a VD < 24h, an in-hours 
delivery, a shorter labour and a vaginal birth.  The multiple analyses did not identify any 
clinical scenario where a policy of repeat-PGE2 administration would be preferred, hence 
there is no rationale to consider specific clinical factors (like parity, age, BMI, MBS, 
gestation) when deciding how best to commence a PGE2 vaginal gel IOL.  A policy of 
amniotomy once technically possible was consistently associated with superior outcomes.   
 
3) Determine which policy of PGE2 vaginal gel IOL is more appealing to women 
 
As part of the RCT, a questionnaire measuring the patient experience was developed de 
novo.  Items were developed around the experiences of women undergoing IOL such as 
time taken to give birth, discomfort with IOL, and experience of subsequent contractions.  
Women were surveyed by phone at approximately 7 days post-birth.  This analysis found 
that where IOL was undertaken following a policy of amniotomy once technically possible, 
women reported higher satisfaction with the time taken to give birth and with the 
discomfort of IOL, compared to women being induced following a policy of repeat-PGE2 
administration. 
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4) Determine which policy of PGE2 vaginal gel IOL is associated with lower healthcare 
costs 
 
This analysis compared the healthcare costs associated with the two PGE2 vaginal gel 
IOL policies, from the hospital perspective, from hospital admission to discharge.  The 
analysis found that administering more PGE2 was associated with increased healthcare 
costs.  A decision analytic model constructed from the RCT data, demonstrated that in a 
hypothetical cohort of 1000 participants, median cost savings of almost $AUD300 per 
participant would be expected if a policy of amniotomy once technically possible was 
adopted.  And by varying all of the input parameters simultaneously in a 104 Monte Carlo 
simulation, the model demonstrated median cost savings closer to $AUD500.  Multiple 
sensitivity analyses were also undertaken and did not identify a scenario where a policy of 
repeat-PGE2 administration would clearly be favoured.    
 
 
8.2 Other findings and impact of this research 
This work helps to fill a substantial void in the literature about IOL methods.    For women 
being induced at term using PGE2 vaginal gel, performing an amniotomy once technically 
possible is quicker, more satisfying and less costly than administering more PGE2 (to 
make the cervix more favourable).  Despite the worldwide use of this product and the lack 
of evidence guiding its use, there has only been one other RCT appraising protocols of 
PGE2 vaginal gel administration for IOL.  There is no evidence basis for clinical practice 
guidelines about the use of PGE2 vaginal gel and they are inconsistent in their 
recommendations.  The 124-page RCOG-endorsed NICE guideline on Induction of Labour 
[47] comments that the optimal frequency of use and the maximum dose are not clear from 
the evidence.  “Despite extensive studies carried out over the past 30 years to determine 
the most effective ways of inducing labour with vaginal PGE2, uncertainties remain about 
how best to apply these agents in terms of their dosage and timing.”   When considering 
the literature on methods of IOL more broadly, there is a general dearth of information 
regarding the healthcare experience and healthcare costs associated with such a common 
obstetric intervention, and this body of work adds important new knowledge to this topic.   
Aside from addressing the four research objectives, this thesis of clinical outcomes, 
prediction, healthcare experience and healthcare costs has generated several unique 
findings.    
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Overall, no difference was observed in the length of hospital stay for women being induced 
under either policy.  Exploring the association between hospital length-of-stay and time of 
birth, the RCT findings suggested, however, that there is a 20 hour shorter stay for women 
who give birth in-hours versus out-of-hours.  In maternity, more than many other areas of 
healthcare in Australia, clinical pathways have been embraced as a key tool to (somewhat 
rigidly) define normal care and recognise variation in the journey from admission to 
hospital discharge.  When clinical pathways are then adopted by  a similarly inflexible 
business and workforce model (where days are staffed differently to nights and hospital 
discharge only occurs at certain hours), it becomes apparent how the failing to meet a 
given clinical milestone by a given hour can add much time to the length of stay.  When 
considering that birth can occur at any hour, yet hospital discharge can only occur at 
prescribed times, large variation in length-of-stay results.  But because the defined clinical 
journey focus is on achieving discharge by a certain day of hospital stay post-partum, large 
variations in length-of-stay from time-of-birth to time-of-discharge can go otherwise 
undetected.  Prolonged and unnecessary hospitalisation will be associated with additional 
cost, it is likely to have a negative effect on the patient experience, and it risks iatrogenic 
harm.  In other areas of healthcare where clinical presentations are more heterogeneous 
and/or where there is more unwarranted clinical variation, the costs, the risks of a negative 
healthcare experience and the potential for patient harm, may be very significant.  These 
findings should challenge clinician leaders to define the elements of the patient journey, 
the barriers and enablers to patients reaching that clinical milestone at the expected time, 
and the real-time metrics that will help to identify variation. 
 
The multivariate analyses undertaken in the Prediction Chapter of the thesis, affirmed the 
well-known association between parity and labour / birth outcomes.  The association 
between the favourability of the cervix, as measured by the MBS, and mode and duration 
of birth has also been demonstrated in these analyses and by others.  But it is the 
favourability of the cervix 6-12 hours after the administration of an initial dose of PGE2 
vaginal gel that best predicts the clinical outcomes for women being induced.  Surprisingly 
there was no association between the favourability of the cervix prior to the 1st PGE2 dose 
and birth outcomes, once controlled for the MBS at 1st review.  Assuming these results are 
able to be replicated by others, then these findings have the potential to alter clinicians’ 
decision-making process about commencing IOL, and influence how they talk to women 
about this.  There is limited data to assist the decision as to when an IOL has failed, 
amongst women receiving oxytocin.  There is even less data to assist the decision about 
139 
 
whether to commence an IOL or opt for an elective CS when the MBS is very low.  But if it 
is not this score that matters, but rather the one in 6-12 hours, then these findings have the 
potential to open a window of opportunity for many women every year who are counselled 
that their likelihood of a vaginal birth is very low.  At a population level, if fewer women 
were to then choose to have a primary CS, then the incidences of repeat CS (as well as 
rarer outcomes like placenta praevia, placenta accreta and uterine rupture) would also be 
reduced.  There are also women whose IOL may be very prolonged or end in a failed IOL.  
These findings have the potential to better inform clinicians and women of the likely 
outcomes of an induced labour, when the cervix is felt to be very unfavourable 6-12 hours 
after an initial PGE2 dose. 
 
The work described in the Healthcare Experience Chapter of the thesis, includes the 
validation of the EXIT (EXperiences of Induction Tool), as a measure of the healthcare 
experience of women being induced.  There are no other validated tools of patient 
experience for women undergoing IOL; hence this is an important contribution to the 
literature for future research into methods of induction of labour.  To date, the literature has 
taken a clinician-centric view of outcomes following IOL, presuming measures such as 
mode of birth and obstetric intervention would be similarly valued by healthcare 
consumers.  The analyses found that it is the length of an induced labour and not the time 
of day or night that birth occurs, that most influences the healthcare experience.   In 
clinical practice, it would be usual to schedule the time of cervical ripening and/or the time 
of next review in order to minimise the chance of an after-hours birth; with little 
consideration to the fact that this may increase the overall time from IOL-to-birth. The 
findings are, therefore, an important reminder that how patients experience a healthcare 
encounter cannot be supposed, and that experience outcomes need to be considered as 
part of an overall assessment of the pros and cons of healthcare choices.  The findings in 
this Chapter also shed light on the “band-aid removal theory”: whether a shorter more 
intense discomfort is preferable to a more prolonged and less intense discomfort.  In the 
setting of PGE2 vaginal gel IOL, the early amniotomy group had a less favourable cervix 
and presumably more difficult ARM, yet reported an experience of less discomfort with 
IOL.  But there was some inconsistency in these findings, with some women in the repeat-
PGE2 group expressing satisfaction with their experience despite the long duration.  In the 
same way as clinical decision-making is maturing to present patients with tailored 
information about their specific risks and expected outcomes, perhaps understanding an 
individual healthcare consumer’s psychological and emotional hallmarks might allow a 
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similar presentation of tailored healthcare choices, to maximise the chances of positive 
healthcare experiences. 
 
Finally the cost analyses presented in Chapter 7 builds upon the theme of “duration of 
care”.  Despite there being no difference in the length of hospital stay, a policy of early 
amniotomy, rather than repeat-PGE2 administration, reduces the IOL-to-birth time.  These 
findings highlight an important observation that there are significant differences in the 
hourly cost of care in different parts of the patient journey.  The drive to influence clinician 
behaviour and improve systems / processes to reduce length-of-stay and so reduce cost, 
may be ill-informed.  In the specific example of maternity care, postnatal care is the least 
expensive part of the patient journey.  Yet because women spend the majority of their time 
during a maternity hospital admission as a postnatal patient in a postnatal ward, this is the 
area most targeted for reductions.   The last 20 years have seen significant reductions in 
postnatal length of stay.  At the same time, early discharge programs, domiciliary 
midwifery, and caseload midwifery, have evolved as maternity models of care that provide 
ongoing clinical care and support to a new mother and baby outside of the hospital.  When 
considering that the hourly cost of undergoing cervical ripening was twice that of the hourly 
cost of postnatal care, and that each hour in labour ward cost six times that of the 
postnatal ward, strategies that reduce the time it takes to have a baby will deliver the 
greatest cost-savings.  Feasibly, a reinvestment of these savings into the area of postnatal 
care might help address issues like languishing breast-feeding rates [227] and the growing 
prevalence of postpartum psychological morbidity [228, 229].  More broadly, dividing 
healthcare costs into its components and/or into States, should will help better inform 
policy decisions about healthcare expenditure, especially for large-volume low-variation 
DRGs like those in maternity care. 
 
 
8.3 Limitations 
As an isolated finding, reducing the duration of time from IOL to birth is of little apparent 
consequence.   However in reducing this time, women report more positively about their 
healthcare experience, and there are cost savings.  Indeed, this thesis concludes that 
there is no apparent benefit to any women undergoing IOL in being administered repeat 
does of PGE2 vaginal gel when it is technically possible to perform an amniotomy.  The 
limitations of this body of work are however recognised.  This thesis is based on a single 
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RCT, conducted in a single institution, comparing two specific protocols of PGE2 vaginal 
gel, where clinicians recommended “earlier” administration of oxytocin to women in both 
arms.  The findings need to be considered in this context, cognisant that the specific 
timing, dosing, and duration of oxytocin (although similar between the two groups) may 
have impacted the overall duration of labour, the likelihood of VD < 24h, the costs, and 
women’s healthcare experience.   Trends towards differences in key clinical outcomes 
have been observed (e.g. fewer instrumental births, fewer CS, fewer failed IOL, less blood 
loss and less PPH in the amniotomy group), and the intention is that these data will be 
used to updated the relevant Cochrane review [62].  However it is acknowledged that the 
RCT was neither powered to detect these differences, nor designed appropriately as a 
non-inferiority experiment to demonstrate that there were no differences.    The absence of 
a trial budget meant that trial recruitment was dependent on clinicians and that recruitment 
extended over several years.  The prediction modelling analyses are based upon a 
relatively small dataset and include small sub-group analyses.  It is further acknowledged 
that in attempting to validate the EXIT, women were not involved in testing face and 
content validity, and a test-retest for reliability was not performed.  And similar to the 
prediction modelling, the numbers in each Markov state in the costing analysis (particularly 
in the sub-groups used for the sensitivity analyses) are again small, and the uncertainty 
around some probability estimates is high.  Nevertheless, the research objectives have 
been met, and this thesis has generated a number of additional and unique findings, that 
contribute to the body of knowledge.   
 
 
 
8.4 Future research 
The thesis has taken a holistic view of the research question as to which policy of PGE2 
vaginal gel IOL is superior.  In so doing, it has comprised a breadth of research designs, 
methodologies, analytical techniques and scientific writing styles, and so has functioned as 
an excellent research learning framework for my PhD.  It has necessitated building 
collaborations across disciplines, and across Universities.  Now on reflection, had funding 
been secured, enrolment accelerated (perhaps by including other centres), then a larger 
sample size may have been feasible and the trial powered to detect differences (or non-
inferiority) in a clinically relevant primary outcome measure.  A larger sample size may 
have strengthened the robustness of the findings especially with respect to the sub-group 
142 
 
and sensitivity analyses.   The thesis has generated a number of important research 
questions, only some of which have been answered thus far.  
 
Recognising the pivotal role of the first PGE2 review in achieving a timely and 
efficient induction process, then what are the barriers to timely review 
following first dose PGE2 vaginal gel? 
 
It is noteworthy that the MBS 6-12 hours after administration of the initial PGE2 
dose appears to be predictive of outcomes, but is it the modified Bishop’s 
score per se, or rather one component of the score that is most 
significantly associated with the outcomes of a vaginal delivery within 24 
hours, caesarean section, in-hours delivery and IOL-to-birth time? 
 
Recognising the increasing use of mechanical methods of cervical priming, and 
the potential for commencing the IOL process at home, then  
• Is the EXIT a valid tool for measuring the experience of women receiving 
mechanical methods? 
 
• Would undertaking cervical ripening as an outpatient positively impact 
women’s experience of the length of induced labour and their overall 
healthcare experience?    
• Would mechanical methods of cervical ripening be associated with more 
or less cost (and similar clinical and experiential outcomes) when 
compared with pharmacological cervical ripening? 
 
• Would outpatient cervical ripening be as efficacious and safe, as 
acceptable to women, and associated with cost savings compared with 
cervical ripening as an inpatient? 
 
And acknowledging the consistent findings of systematic reviews of randomised 
controlled trials are consistent in their findings, that women undergoing IOL are 
less likely to give birth by CS than women managed expectantly, would a more 
liberal / routine use of IOL near term, be associated with more or fewer CS, 
positive or negative healthcare experiences, shorter or longer labours (and 
therefore differences in healthcare costs), when compared with the current 
practice of undertaking IOL only for defined maternal  and fetal indications? 
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The generation of these research questions and the “lessons learnt” from the undertaking 
of my PhD, have helped inform the research design of a new RCT that again addresses 
methods of IOL.  This trial will compare PGE2 vaginal gel IOL as an inpatient (following a 
policy of early amniotomy as described in this thesis) with balloon catheter IOL as an 
outpatient.  Funding has been secured, and the investigators comprise my PhD 
supervisors and three other researchers with whom I have co-authored papers arising 
from this thesis.  The primary outcome measure is a composite clinical measure of 
maternal and perinatal outcomes.  The trial is powered to also detect differences in 
healthcare experiences (with a plan to validate and again use the EXIT) and costs.  
Recruiting 2500 women across 9 participating centres, this will be the largest investigation 
of IOL ever undertaken. 
 
8.5 Conclusion 
IOL is the most common childbirth intervention.  Each year more women are induced than 
have an elective CS.  Over 80,000 Australian women will undergo an IOL this year.  In the 
United States, the number of women induced annually is almost 1,000,000.  Worldwide, 
the majority of these inductions will involve cervical ripening, and most commonly with the 
use of PGE2 vaginal gel.  Yet there is scant evidence as to how best to use this product, 
and almost nothing is known about women’s experiences of their IOL.  This thesis finds 
that in women being induced with PGE2 vaginal gel, performing an earlier amniotomy 
(even if the cervix is deemed unfavourable) is likely to result  in similar clinical outcomes, 
but a shorter labour, a more positive healthcare experience, and lower healthcare costs, 
when compared to giving more PGE2.  The widespread adoption of a policy of performing 
an amniotomy once technically possible is likely to be associated with significant benefits 
to both women and to the healthcare system.   
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